diff --git a/code/bibtex.bib b/code/bibtex.bib
index 9ff8d535685451e7c2a7e60151a59d143b1a2f09..f5e5323eccebf88558933f8abda69a4fe049c956 100644
--- a/code/bibtex.bib
+++ b/code/bibtex.bib
@@ -1,25 +1,40 @@
-@article{
-
-doi:10.1073/pnas.1213273110,
-
-author = {Baruch Fischhoff },
-
-title = {The sciences of science communication},
-
-journal = {Proceedings of the National Academy of Sciences},
-
-volume = {110},
-
-number = {supplement\_3},
-
-pages = {14033-14039},
-
-year = {2013},
-
-doi = {10.1073/pnas.1213273110},
-
-URL = {https://www.pnas.org/doi/abs/10.1073/pnas.1213273110},
-
-eprint = {https://www.pnas.org/doi/pdf/10.1073/pnas.1213273110},
-
-abstract = {The May 2012 Sackler Colloquium on “The Science of Science Communication†brought together scientists with research to communicate and scientists whose research could facilitate that communication. The latter include decision scientists who can identify the scientific results that an audience needs to know, from among all of the scientific results that it would be nice to know; behavioral scientists who can design ways to convey those results and then evaluate the success of those attempts; and social scientists who can create the channels needed for trustworthy communications. This overview offers an introduction to these communication sciences and their roles in science-based communication programs.}}
\ No newline at end of file
+@article{Cloarec-Ung_Beaulieu_Suthananthan_Lehnertz_Sauvageau_Sheppard_Knapp_2024,
+ title = {
+ Near-perfect precise on-target editing of human hematopoietic stem and
+ progenitor cells
+ },
+ author = {
+ Cloarec-Ung, Fanny-Mei and Beaulieu, Jamie and Suthananthan, Arunan and
+ Lehnertz, Bernhard and Sauvageau, Guy and Sheppard, Hilary M. and Knapp,
+ David J. H. F.
+ },
+ year = 2024,
+ month = jun,
+ journal = {eLife},
+ volume = 12,
+ pages = {RP91288},
+ doi = {10.7554/eLife.91288},
+ issn = {2050-084X},
+ abstractnote = {
+ Precision gene editing in primary hematopoietic stem and progenitor cells
+ (HSPCs) would facilitate both curative treatments for monogenic disorders as
+ well as disease modelling. Precise efficiencies even with the CRISPR/Cas
+ system, however, remain limited. Through an optimization of guide RNA
+ delivery, donor design, and additives, we have now obtained mean precise
+ editing efficiencies >90% on primary cord blood HSCPs with minimal toxicity
+ and without observed off-target editing. The main protocol modifications
+ needed to achieve such high efficiencies were the addition of the DNA-PK
+ inhibitor AZD7648, and the inclusion of spacer-breaking silent mutations in
+ the donor in addition to mutations disrupting the PAM sequence. Critically,
+ editing was even across the progenitor hierarchy, did not substantially
+ distort the hierarchy or affect lineage outputs in colony-forming cell assays
+ or the frequency of high self-renewal potential long-term culture initiating
+ cells. As modelling of many diseases requires heterozygosity, we also
+ demonstrated that the overall editing and zygosity can be tuned by adding in
+ defined mixtures of mutant and wild-type donors. With these optimizations,
+ editing at near-perfect efficiency can now be accomplished directly in human
+ HSPCs. This will open new avenues in both therapeutic strategies and disease
+ modelling.
+ },
+ language = {eng}
+}
\ No newline at end of file
diff --git a/code/cit.py b/code/cit.py
index 39221c659aee688d22146b95868c0e08c7537742..5b3f9224e026001956c18ad202baca2f93fd1444 100644
--- a/code/cit.py
+++ b/code/cit.py
@@ -2,7 +2,7 @@
#- Python 3.x
#- bibtexparser (Installieren Sie es mit `pip install bibtexparser`)
# use like: python3 cit.py -i bibtex.bib -s 1
-
+import re
problemlist = []
def main():
@@ -64,27 +64,29 @@ def main():
en_x = library.entries[x]
print("Filling dictionary for entry "+ str(startnum+count) + "")
- # Direkt auf die Einträge zugreifen, da es sich um ein Dictionary handelt
+
for key, value in en_x.items():
key_low = key.lower()
dictio[key_low] = value
- # Überprüfung auf den Typ des Eintrags über 'ENTRYTYPE'
+ print("Checking Entry type of "+ str(startnum+count) + "")
if en_x['ENTRYTYPE'] == "article":
articleHTML(dictio, (startnum+count), out)
elif en_x['ENTRYTYPE'] == "misc":
miscHTML(dictio, (startnum+count), out)
elif en_x['ENTRYTYPE'] == "book":
bookHTML(dictio, (startnum+count), out)
+ elif en_x['ENTRYTYPE'] == "inbook":
+ bookHTML(dictio, (startnum+count), out)
count += 1;
except Exception as e:
- print(f"An unexpected error occurred: {e}")
+ print(f"An unexpected error occurred: {e} in line 85")
except Exception as e:
- print(f"An unexpected error occurred: {e}")
+ print(f"An unexpected error occurred: {e} in line 87")
except FileNotFoundError:
- print(f"Error: The file '{args.input}' was not found.")
+ print(f"Error: The file '{args.input}' was not found. line 89")
if len(problemlist)>0:
print("- - - - - - - - - - - - - - - - - ")
print("REMAINING ERRORS:")
@@ -94,86 +96,88 @@ def main():
else:
print("DONE")
-
-
+def makeauthors(authors, out):
+ authors = authors.replace("\n", " ").replace(" and ", "|").strip() # "and" durch "|" ersetzen und Whitespace entfernen
+ autlist = authors.split("|")
-def articleHTML(dictio, x, out):
- print("Writing html code for entry "+ str(x) + "...")
- out.write("{/*<!-- Citation num " + str(x) + "--> */}" + "\n")
- out.write("<li typeof=\"schema:ScolarlyArticle\" role=\"doc-biblioentry\" property=\"schema:citation\" id=\"desc-" + str(x) + "\">"+ "\n")
- out.write("\t" + "<span property=\"schema:author\" typeof=\"schema:Person\">"+ "\n")
+ # Maximale Anzahl der anzuzeigenden Autoren
+ max_authors = 7
- print("Just a sec, seperating authors...")
- authors = dictio['author']
- authors = authors.replace(" and ", "|")
- liste = authors.split("|")
- for a in liste:
- try:
- #print("processing " + a)
- first = None
- last = None
- name = None
+ out.write("\t<span property=\"schema:author\" typeof=\"schema:Person\">\n") # Tag für Autoren öffnen
+ #print(autlist)
+ for i, a in enumerate(autlist):
+ try:
+ a = a.strip() # Whitespace entfernen
+
+ # Nachnamen und Vornamen aufteilen
if ',' in a:
s = a.split(", ")
- first = s[1]
- first_sh = first[0]
- last = s[0]
- name = last + ", " + first_sh + "."
+ last = s[0].strip() # Nachname
+ first_names = s[1].strip() if len(s) > 1 else ''
+
+ # Initialen für Vornamen erstellen
+ initials = '. '.join([n[0] for n in first_names.split()]) + '.' if first_names else ''
+ name = f"{last}, {initials}" if initials else f"{last}, "
else:
s = a.split()
- if len(s) == 2:
- first = s[0]
- first_sh = first[0]
- last = s[1]
- name = last + ", " + first_sh + "."
- else:
- leng = len(s)
- last = s[leng-1]
- first = ''
- for n in s:
- if n != s[-1]:
- first = first + n[0] + '.'
- name = last + ", " + first
-
- if a == liste[-1]:
- out.write("\t" + "\t" +"<span property=\"schema:Name\"> " +name + "</span>"+ "\n")
- else:
- out.write("\t" +"\t" +"<span property=\"schema:Name\"> " +name + "</span>;"+ "\n")
+ last = s[-1].strip() # Nachname
+ first = '. '.join([n[0] for n in s[:-1]]) + '.' # Initialen der Vornamen
+ name = f"{last}, {first}"
+
+ # Schreibe den Namen in die Ausgabedatei
+ if i < max_authors:
+ out.write(f"\t\t<span property=\"schema:Name\"> {name}</span>\n")
+ # Wenn wir den 6. Autor erreicht haben, schreibe "et al." nach dem 6. Autor
+ if i == max_authors:
+ out.write("\t\t<span property=\"schema:Name\"> et al.</span>\n")
+ break # Stoppe die Schleife, nachdem "et al." hinzugefügt wurde
+
except Exception as e:
print(f"An unexpected error occurred: {e} see " + a)
- out.write("\t" +"</span>"+ "\n")
- out.write("\t" + "<span property=\"schema:name\"> "+dictio['title']+ ". </span>"+ "\n")
+
+ out.write("\t</span>\n") # Tag für Autoren schließen
+
+
+
+def articleHTML(dictio, x, out):
+ print("Writing html code for article "+ str(x) + "...")
+ out.write("{/*<!-- Citation num " + str(x) + "--> */}" + "\n")
+ out.write("<li typeof=\"schema:ScolarlyArticle\" role=\"doc-biblioentry\" property=\"schema:citation\" id=\"desc-" + str(x) + "\">"+ "\n")
+# out.write("\t" + "<span property=\"schema:author\" typeof=\"schema:Person\">"+ "\n")
+
+ print("Just a sec, separating authors...")
+ authors = dictio['author']
+ makeauthors(authors, out)
+
+# out.write("\t" +"</span>"+ "\n")
+ title = dictio['title'].replace('{', '').replace('}', '')
+ out.write("\t" + "<span property=\"schema:name\"> "+ title + "</span>. "+ "\n")
out.write("\t" +"<i property=\"schema:publisher\" typeof=\"schema:Organization\"> "+ dictio['journal'] +"</i>"+ "\n")
- out.write("\t" +"<b property=\"issueNumber\" typeof=\"PublicationIssue\"> "+dictio['volume']+"</b>, "+ "\n")
+ out.write("\t" +"<b property=\"issueNumber\" typeof=\"PublicationIssue\"> "+dictio['volume']+"</b>"+ "\n")
print("Getting pages...")
try:
pages = dictio['pages']
- if pages is not None:
- if len(pages) > 0:
- if '--' in pages:
- pag = pages.split("--")
+ if pages is not None and len(pages) > 0:
+ # Überprüfen, ob die Seitenangabe nur aus Zahlen und Bindestrichen besteht
+ if '-' in pages or '–' in pages or '--' in pages:
+ pag = re.split('--|-|–', pages)
begin = pag[0].strip()
end = pag[1].strip()
- out.write("\t" + "<span property=\"schema:pageBegin\"> "+ begin +"</span>-<span property=\"schema:pageEnd\">"+ end + "</span>"+ "\n")
- elif '-' in pages:
- pag = pages.split("-")
- begin = pag[0].strip()
- end = pag[1].strip()
- out.write("\t" + "<span property=\"schema:pageBegin\"> "+ begin +"</span>-<span property=\"schema:pageEnd\">"+ end + "</span>"+ "\n")
- elif len(pages) > 0:
- out.write("\t" + "<span property=\"schema:pageBegin\">"+ pages +"</span>"+ "\n")
+ out.write("\t" + ", <span property=\"schema:pageBegin\"> "+ begin +"</span>-<span property=\"schema:pageEnd\">"+ end + "</span> "+ "\n")
else:
- print("Sorry, no readable page information")
- problemlist.append("Check for missing page info at " + str (x))
- else:
- print("Sorry, no page information")
- problemlist.append("Check for missing page info at " + str (x))
+ if re.match(r'^\d+(-\d+)?$', pages): # Check for typical numeric page ranges
+ out.write("\t" + "<span property=\"schema:pageBegin\">"+ pages +"</span> "+ "\n")
+ else:
+ # Seitenangabe ist nicht numerisch, als fehlend behandeln
+ print(f"Non-numeric page information detected ('{pages}'). Treating as missing.")
+ problemlist.append(f"Non-numeric page info at entry {x}")
else:
print("Sorry, no page information")
- problemlist.append("Check for missing page info at " + str (x))
- except KeyError as e:
+ problemlist.append("Check for missing page info at " + str(x))
+ except KeyError:
print("Sorry, no page information")
- problemlist.append("Check for missing page info at " + str (x))
+ problemlist.append("Check for missing page info at " + str(x))
+
year = dictio['year']
out.write("\t" +"(<time property=\"schema:datePublished\" datatype=\"xsd:gYear\" dateTime=\" " + year + "\">"+year+"</time>)."+ "\n")
@@ -199,22 +203,32 @@ def miscHTML(dictio, x, out):
out.write("\t" + "<span property=\"schema:name\">"+dictio['title']+ ".</span>"+ "\n")
out.write("\t" +"<i property=\"schema:publisher\" typeof=\"schema:Organization\">"+ dictio['howpublished'] +"</i>"+ "\n")
year = dictio['year']
- out.write("\t" +" (<time property=\"schema:datePublished\" datatype=\"xsd:gYear\" dateTime=\"" + year + "\">"+year+"</time>)."+ "\n")
+ out.write("\t" +" (<time property=\"schema:datePublished\" datatype=\"xsd:gYear\" dateTime=\"" + year + "\">"+year+"</time>)."+ "\n")
out.write("</li>" + "\n"+ "\n")
def bookHTML(dictio, x, out):
print("Writing html code for entry "+ str(x) + "...")
out.write("{/*<!-- Citation num " + str(x) + "--> */}" + "\n")
- out.write("<li typeof=\"schema:WebPage\" role=\"doc-biblioentry\" property=\"schema:citation\" id=\"desc-" + str(x) + "\">"+ "\n")
- out.write("\t" + "<span property=\"schema:author\" typeof=\"schema:Organisation\">"+ "\n")
- aut = dictio['author']
- out.write("\t" + "\t" +"<span property=\"schema:Name\"> " + aut + "</span>."+ "\n")
- out.write("\t" +"</span>"+ "\n")
- out.write("\t" + "<span property=\"schema:name\">"+dictio['title']+ ".</span>"+ "\n")
- out.write("\t" +"<i property=\"schema:publisher\" typeof=\"schema:Organization\">"+ dictio['publisher'] +"</i>"+ "\n")
+ out.write("<li typeof=\"schema:Book\" role=\"doc-biblioentry\" property=\"schema:citation\" id=\"desc-" + str(x) + "\">"+ "\n")
+ # out.write("\t" + "<span property=\"schema:author\" typeof=\"schema:Organisation\">"+ "\n")
+ print("Just a sec, separating authors...")
+ authors = dictio['author']
+ makeauthors(authors, out)
+ # out.write("\t" + "\t" +"<span property=\"schema:Name\"> " + aut + "</span>."+ "\n")
+ # out.write("\t" +"</span>"+ "\n")
+ if 'title' in dictio:
+ out.write("\t" + "<span property=\"schema:name\"> "+dictio['title']+ ".</span>"+ "\n")
+ elif 'booktitle' in dictio:
+ out.write("\t" + "<span property=\"schema:name\"> "+dictio['booktitle']+ ".</span>"+ "\n")
+ else:
+ print(f"No title or booktitle found for entry {x}")
+ problemlist.append(f"Check for missing title or booktitle at entry {x}")
+
+ out.write("\t" +"<i property=\"schema:publisher\" typeof=\"schema:Organization\"> "+ dictio['publisher'] +"</i>"+ "\n")
year = dictio['year']
- out.write("\t" +" (<time property=\"schema:datePublished\" datatype=\"xsd:gYear\" dateTime=\"" + year + "\">"+year+"</time>)."+ "\n")
+ out.write("\t" + " (<time property=\"schema:datePublished\" datatype=\"xsd:gYear\" dateTime=\"" + year + "\">"+year+"</time>)."+ "\n")
out.write("</li>" + "\n"+ "\n")
-main()
\ No newline at end of file
+main()
+
diff --git a/code/output.txt b/code/output.txt
index e8c7c81aa25e43ec947afbe60af3e7fd799c5ba5..37753205d60bdb16e4becdfdba272d5205da4d9b 100644
--- a/code/output.txt
+++ b/code/output.txt
@@ -1,13 +1,392 @@
{/*<!-- Citation num 1--> */}
<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
<span property="schema:author" typeof="schema:Person">
- <span property="schema:Name"> Fischhoff, B.</span>
- </span>
- <span property="schema:name"> The sciences of science communication. </span>
- <i property="schema:publisher" typeof="schema:Organization"> Proceedings of the National Academy of Sciences</i>
- <b property="issueNumber" typeof="PublicationIssue"> 110</b>,
- <span property="schema:pageBegin"> 14033</span>-<span property="schema:pageEnd">14039</span>
- (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2013">2013</time>).
- <a className="doi" href="https://doi.org/10.1073/pnas.1213273110"> doi: 10.1073/pnas.1213273110</a>
+ <span property="schema:Name"> Cloarec-Ung, F.</span>
+ <span property="schema:Name"> Beaulieu, J.</span>
+ <span property="schema:Name"> Suthananthan, A.</span>
+ <span property="schema:Name"> Lehnertz, B.</span>
+ <span property="schema:Name"> Sauvageau, G.</span>
+ <span property="schema:Name"> Sheppard, H. M.</span>
+ <span property="schema:Name"> Knapp, D. J. H. F.</span>
+ </span>
+ <span property="schema:name">
+Near-perfect precise on-target editing of human hematopoietic stem and
+progenitor cells
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> eLife</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 12</b>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2024">2024</time>).
+ <a className="doi" href="https://doi.org/10.7554/eLife.91288"> doi: 10.7554/eLife.91288</a>
+</li>
+
+{/*<!-- Citation num 2--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-2">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Nelson, J. W.</span>
+ <span property="schema:Name"> Randolph, P. B.</span>
+ <span property="schema:Name"> Shen, S. P.</span>
+ <span property="schema:Name"> Everette, K. A.</span>
+ <span property="schema:Name"> Chen, P. J.</span>
+ <span property="schema:Name"> Anzalone, A. V.</span>
+ <span property="schema:Name"> An, M.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name"> Engineered pegRNAs improve prime editing efficiency</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Nature Biotechnology</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 40</b>
+ , <span property="schema:pageBegin"> 402</span>-<span property="schema:pageEnd">410</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2022">2022</time>).
+ <a className="doi" href="https://doi.org/10.1038/s41587-021-01039-7"> doi: 10.1038/s41587-021-01039-7</a>
+</li>
+
+{/*<!-- Citation num 3--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-3">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Doench, J. G.</span>
+ <span property="schema:Name"> Fusi, N.</span>
+ <span property="schema:Name"> Sullender, M.</span>
+ <span property="schema:Name"> Hegde, M.</span>
+ <span property="schema:Name"> Vaimberg, E. W.</span>
+ <span property="schema:Name"> Donovan, K. F.</span>
+ <span property="schema:Name"> Smith, I.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name">
+Optimized sgRNA design to maximize activity and minimize off-target effects
+of CRISPR-Cas9
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Nature Biotechnology</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 34</b>
+ , <span property="schema:pageBegin"> 184</span>-<span property="schema:pageEnd">191</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2016">2016</time>).
+ <a className="doi" href="https://doi.org/10.1038/nbt.3437"> doi: 10.1038/nbt.3437</a>
+</li>
+
+{/*<!-- Citation num 4--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-4">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> White, N.</span>
+ <span property="schema:Name"> Sadeeshkumar, H.</span>
+ <span property="schema:Name"> Sun, A.</span>
+ <span property="schema:Name"> Sudarsan, N.</span>
+ <span property="schema:Name"> Breaker, R. R.</span>
+ </span>
+ <span property="schema:name">
+Na+ riboswitches regulate genes for diverse physiological processes in
+bacteria
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Nature Chemical Biology</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 18</b>
+ , <span property="schema:pageBegin"> 878</span>-<span property="schema:pageEnd">885</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2022">2022</time>).
+ <a className="doi" href="https://doi.org/10.1038/s41589-022-01086-4"> doi: 10.1038/s41589-022-01086-4</a>
+</li>
+
+{/*<!-- Citation num 5--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-5">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Iwawaki, T.</span>
+ <span property="schema:Name"> Akai, R.</span>
+ </span>
+ <span property="schema:name">
+Analysis of the XBP1 splicing mechanism using endoplasmic reticulum
+stress-indicators
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Biochemical and Biophysical Research Communications</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 350</b>
+ , <span property="schema:pageBegin"> 709</span>-<span property="schema:pageEnd">715</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2006">2006</time>).
+ <a className="doi" href="https://doi.org/10.1016/j.bbrc.2006.09.100"> doi: 10.1016/j.bbrc.2006.09.100</a>
+</li>
+
+{/*<!-- Citation num 6--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-6">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Zhang, Y.</span>
+ <span property="schema:Name"> Lin, S.</span>
+ <span property="schema:Name"> Yao, J.</span>
+ <span property="schema:Name"> Cai, W.</span>
+ <span property="schema:Name"> Chen, H.</span>
+ <span property="schema:Name"> Aierken, A.</span>
+ <span property="schema:Name"> Wang, Z.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name">
+XBP1 splicing contributes to endoplasmic reticulum stress-induced human islet
+amyloid polypeptide up-regulation
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Genes & Diseases</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 11</b>
+ <span property="schema:pageBegin">101148</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2023">2023</time>).
+ <a className="doi" href="https://doi.org/10.1016/j.gendis.2023.101148"> doi: 10.1016/j.gendis.2023.101148</a>
+</li>
+
+{/*<!-- Citation num 7--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-7">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Wei, T.</span>
+ <span property="schema:Name"> Sun, Y.</span>
+ <span property="schema:Name"> Cheng, Q.</span>
+ <span property="schema:Name"> Chatterjee, S.</span>
+ <span property="schema:Name"> Traylor, Z.</span>
+ <span property="schema:Name"> Johnson, L. T.</span>
+ <span property="schema:Name"> Coquelin, M. L.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name">
+Lung SORT LNPs enable precise homology-directed repair mediated
+CRISPR/Cas genome correction in cystic fibrosis models
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Nature Communications</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 14</b>
+ <span property="schema:pageBegin">7322</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2023">2023</time>).
+ <a className="doi" href="https://doi.org/10.1038/s41467-023-42948-2"> doi: 10.1038/s41467-023-42948-2</a>
+</li>
+
+{/*<!-- Citation num 8--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-8">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Ibrahim, M.</span>
+ <span property="schema:Name"> Ramadan, E.</span>
+ <span property="schema:Name"> Elsadek, N. E.</span>
+ <span property="schema:Name"> Emam, S. E.</span>
+ <span property="schema:Name"> Shimizu, T.</span>
+ <span property="schema:Name"> Ando, H.</span>
+ <span property="schema:Name"> Ishima, Y.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name">
+Polyethylene glycol (PEG): The nature, immunogenicity, and role in the
+hypersensitivity of PEGylated products
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Journal of Controlled Release</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 351</b>
+ , <span property="schema:pageBegin"> 215</span>-<span property="schema:pageEnd">230</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2022">2022</time>).
+ <a className="doi" href="https://doi.org/https://doi.org/10.1016/j.jconrel.2022.09.031"> doi: https://doi.org/10.1016/j.jconrel.2022.09.031</a>
+</li>
+
+{/*<!-- Citation num 9--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-9">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Jiang, A. Y.</span>
+ <span property="schema:Name"> Witten, J.</span>
+ <span property="schema:Name"> Raji, I. O.</span>
+ <span property="schema:Name"> Eweje, F.</span>
+ <span property="schema:Name"> MacIsaac, C.</span>
+ <span property="schema:Name"> Meng, S.</span>
+ <span property="schema:Name"> Oladimeji, F. A.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name">
+Combinatorial development of nebulized mRNA delivery formulations for the
+lungs
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Nature Nanotechnology</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 19</b>
+ , <span property="schema:pageBegin"> 364</span>-<span property="schema:pageEnd">375</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2024">2024</time>).
+ <a className="doi" href="https://doi.org/10.1038/s41565-023-01548-3"> doi: 10.1038/s41565-023-01548-3</a>
+</li>
+
+{/*<!-- Citation num 10--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-10">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Vilà -González, M.</span>
+ <span property="schema:Name"> Pinte, L.</span>
+ <span property="schema:Name"> Fradique, R.</span>
+ <span property="schema:Name"> Causa, E.</span>
+ <span property="schema:Name"> Kool, H.</span>
+ <span property="schema:Name"> Rodrat, M.</span>
+ <span property="schema:Name"> Morell, C. M.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name">
+In vitro platform to model the function of ionocytes in the human airway
+epithelium
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Respiratory Research</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 25</b>
+ <span property="schema:pageBegin">180</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2024">2024</time>).
+ <a className="doi" href="https://doi.org/10.1186/s12931-024-02800-7"> doi: 10.1186/s12931-024-02800-7</a>
+</li>
+
+{/*<!-- Citation num 11--> */}
+<li typeof="schema:Book" role="doc-biblioentry" property="schema:citation" id="desc-11">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Paris, K.</span>
+ </span>
+ <span property="schema:name"> Genome Editing and Biological Weapons: Assessing the Risk of Misuse.</span>
+ <i property="schema:publisher" typeof="schema:Organization"> Springer Nature Switzerland AG</i>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2023">2023</time>).
+</li>
+
+{/*<!-- Citation num 12--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-12">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Wickiser, J. K.</span>
+ </span>
+ <span property="schema:name">
+The democratization of biology: how CRISPR and synthetic biology usher in new
+biosecurity threats
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Defense Horizons</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 85</b>
+ , <span property="schema:pageBegin"> 1</span>-<span property="schema:pageEnd">16</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2020">2020</time>).
+</li>
+
+{/*<!-- Citation num 13--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-13">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Cohen, J.</span>
+ <span property="schema:Name"> Desai, T.</span>
+ </span>
+ <span property="schema:name">
+Security implications of CRISPR-enabled genome editing: New weapons of mass
+disruption?
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Journal of Bioethical Inquiry</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 16</b>
+ , <span property="schema:pageBegin"> 219</span>-<span property="schema:pageEnd">228</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2019">2019</time>).
+ <a className="doi" href="https://doi.org/10.1007/s11673-019-09914-5"> doi: 10.1007/s11673-019-09914-5</a>
+</li>
+
+{/*<!-- Citation num 14--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-14">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Doudna, J. A.</span>
+ <span property="schema:Name"> Charpentier, E.</span>
+ </span>
+ <span property="schema:name">
+The rise of synthetic biology: New biosecurity risks and regulatory
+challenges
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Nature Reviews Genetics</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 21</b>
+ , <span property="schema:pageBegin"> 144</span>-<span property="schema:pageEnd">156</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2020">2020</time>).
+ <a className="doi" href="https://doi.org/10.1038/s41576-019-0182-7"> doi: 10.1038/s41576-019-0182-7</a>
+</li>
+
+{/*<!-- Citation num 15--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-15">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Shwartz, M.</span>
+ <span property="schema:Name"> Conklin, B.</span>
+ </span>
+ <span property="schema:name">
+Public perception of CRISPR and genome editing: Misconceptions and media
+portrayal
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Journal of Science Communication</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 18</b>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2019">2019</time>).
+ <a className="doi" href="https://doi.org/10.22323/2.18040202"> doi: 10.22323/2.18040202</a>
+</li>
+
+{/*<!-- Citation num 16--> */}
+<li typeof="schema:Book" role="doc-biblioentry" property="schema:citation" id="desc-16">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Chadwick, R. F.</span>
+ </span>
+ <span property="schema:name"> Encyclopedia of applied ethics.</span>
+ <i property="schema:publisher" typeof="schema:Organization"> Academic Press</i>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2012">2012</time>).
+</li>
+
+{/*<!-- Citation num 17--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-17">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Rubeis, G.</span>
+ <span property="schema:Name"> Steger, F.</span>
+ </span>
+ <span property="schema:name"> Risks and benefits of human germline genome editing: An ethical analysis</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Asian Bioethics Review</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 10</b>
+ , <span property="schema:pageBegin"> 133</span>-<span property="schema:pageEnd">141</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2018">2018</time>).
+ <a className="doi" href="https://doi.org/10.1007/s41649-018-0056-x"> doi: 10.1007/s41649-018-0056-x</a>
+</li>
+
+{/*<!-- Citation num 18--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-18">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Ansah, E. O.</span>
+ </span>
+ <span property="schema:name">
+Ethical Challenges and Controversies in the Practice and Advancement of Gene
+Therapy
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Advances in Cell and Gene Therapy</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 2022</b>
+ , <span property="schema:pageBegin"> 1</span>-<span property="schema:pageEnd">5</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2022">2022</time>).
+ <a className="doi" href="https://doi.org/10.1155/2022/1015996"> doi: 10.1155/2022/1015996</a>
+</li>
+
+{/*<!-- Citation num 19--> */}
+<li typeof="schema:Book" role="doc-biblioentry" property="schema:citation" id="desc-19">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Pugh, J.</span>
+ </span>
+ <span property="schema:name"> Autonomy, Rationality, and Contemporary Bioethics.</span>
+ <i property="schema:publisher" typeof="schema:Organization"> Oxford University PressOxford</i>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
+</li>
+
+{/*<!-- Citation num 20--> */}
+<li typeof="schema:Book" role="doc-biblioentry" property="schema:citation" id="desc-20">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Gstraunthaler, G.</span>
+ <span property="schema:Name"> Lindl, T.</span>
+ </span>
+ <span property="schema:name"> Allgemeine Aspekte der Primärkultur.</span>
+ <i property="schema:publisher" typeof="schema:Organization"> Springer</i>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2013">2013</time>).
+</li>
+
+{/*<!-- Citation num 21--> */}
+<li typeof="schema:Book" role="doc-biblioentry" property="schema:citation" id="desc-21">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Thiele, F.</span>
+ </span>
+ <span property="schema:name"> International Encyclopedia of the Social & Behavioral Sciences.</span>
+ <i property="schema:publisher" typeof="schema:Organization"> Elsevier</i>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2001">2001</time>).
+</li>
+
+{/*<!-- Citation num 22--> */}
+<li typeof="schema:Book" role="doc-biblioentry" property="schema:citation" id="desc-22">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Gethmann, C.</span>
+ </span>
+ <span property="schema:name"> Research: Ethical Aspects of Long-term Responsibilities.</span>
+ <i property="schema:publisher" typeof="schema:Organization"> Elsevier</i>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2001">2001</time>).
+</li>
+
+{/*<!-- Citation num 23--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-23">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Kiani, A. K.</span>
+ <span property="schema:Name"> Pheby, D.</span>
+ <span property="schema:Name"> Henehan, G.</span>
+ <span property="schema:Name"> Brown, R.</span>
+ <span property="schema:Name"> Sieving, P.</span>
+ <span property="schema:Name"> Sykora, P.</span>
+ <span property="schema:Name"> Marks, R.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name"> Ethical considerations regarding animal experimentation</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Journal of Preventive Medicine and Hygiene</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 63</b>
+ , <span property="schema:pageBegin"> E255</span>-<span property="schema:pageEnd">E266</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2022">2022</time>).
+ <a className="doi" href="https://doi.org/10.15167/2421-4248/jpmh2022.63.2S3.2768"> doi: 10.15167/2421-4248/jpmh2022.63.2S3.2768</a>
</li>
diff --git a/code/safety-bibtex.bib b/code/safety-bibtex.bib
new file mode 100644
index 0000000000000000000000000000000000000000..b5a4e9c5d4f8e43068d91c4d39be65b118c02223
--- /dev/null
+++ b/code/safety-bibtex.bib
@@ -0,0 +1,645 @@
+@article{Cloarec-Ung_Beaulieu_Suthananthan_Lehnertz_Sauvageau_Sheppard_Knapp_2024,
+ title = {
+ Near-perfect precise on-target editing of human hematopoietic stem and
+ progenitor cells
+ },
+ author = {
+ Cloarec-Ung, Fanny-Mei and Beaulieu, Jamie and Suthananthan, Arunan and
+ Lehnertz, Bernhard and Sauvageau, Guy and Sheppard, Hilary M. and Knapp,
+ David J. H. F.
+ },
+ year = 2024,
+ month = jun,
+ journal = {eLife},
+ volume = 12,
+ pages = {RP91288},
+ doi = {10.7554/eLife.91288},
+ issn = {2050-084X},
+ abstractnote = {
+ Precision gene editing in primary hematopoietic stem and progenitor cells
+ (HSPCs) would facilitate both curative treatments for monogenic disorders as
+ well as disease modelling. Precise efficiencies even with the CRISPR/Cas
+ system, however, remain limited. Through an optimization of guide RNA
+ delivery, donor design, and additives, we have now obtained mean precise
+ editing efficiencies >90% on primary cord blood HSCPs with minimal toxicity
+ and without observed off-target editing. The main protocol modifications
+ needed to achieve such high efficiencies were the addition of the DNA-PK
+ inhibitor AZD7648, and the inclusion of spacer-breaking silent mutations in
+ the donor in addition to mutations disrupting the PAM sequence. Critically,
+ editing was even across the progenitor hierarchy, did not substantially
+ distort the hierarchy or affect lineage outputs in colony-forming cell assays
+ or the frequency of high self-renewal potential long-term culture initiating
+ cells. As modelling of many diseases requires heterozygosity, we also
+ demonstrated that the overall editing and zygosity can be tuned by adding in
+ defined mixtures of mutant and wild-type donors. With these optimizations,
+ editing at near-perfect efficiency can now be accomplished directly in human
+ HSPCs. This will open new avenues in both therapeutic strategies and disease
+ modelling.
+ },
+ language = {eng}
+}
+@article{Nelson_Randolph_Shen_Everette_Chen_Anzalone_An_Newby_Chen_Hsu_et,
+ title = {Engineered pegRNAs improve prime editing efficiency},
+ author = {
+ Nelson, James W. and Randolph, Peyton B. and Shen, Simon P. and Everette,
+ Kelcee A. and Chen, Peter J. and Anzalone, Andrew V. and An, Meirui and
+ Newby, Gregory A. and Chen, Jonathan C. and Hsu, Alvin and Liu, David R.
+ },
+ year = 2022,
+ month = mar,
+ journal = {Nature Biotechnology},
+ publisher = {Nature Publishing Group},
+ volume = 40,
+ number = 3,
+ pages = {402–410},
+ doi = {10.1038/s41587-021-01039-7},
+ issn = {1546-1696},
+ rights = {
+ 2021 The Author(s), under exclusive licence to Springer Nature America, Inc.
+ },
+ abstractnote = {
+ Prime editing enables the installation of virtually any combination of point
+ mutations, small insertions or small deletions in the DNA of living cells. A
+ prime editing guide RNA (pegRNA) directs the prime editor protein to the
+ targeted locus and also encodes the desired edit. Here we show that
+ degradation of the 3′ region of the pegRNA that contains the reverse
+ transcriptase template and the primer binding site can poison the activity of
+ prime editing systems, impeding editing efficiency. We incorporated
+ structured RNA motifs to the 3′ terminus of pegRNAs that enhance their
+ stability and prevent degradation of the 3′ extension. The resulting
+ engineered pegRNAs (epegRNAs) improve prime editing efficiency 3–4-fold in
+ HeLa, U2OS and K562 cells and in primary human fibroblasts without increasing
+ off-target editing activity. We optimized the choice of 3′ structural motif
+ and developed pegLIT, a computational tool to identify non-interfering
+ nucleotide linkers between pegRNAs and 3′ motifs. Finally, we showed that
+ epegRNAs enhance the efficiency of the installation or correction of
+ disease-relevant mutations.
+ },
+ language = {en}
+}
+@article{Doench_Fusi_Sullender_Hegde_Vaimberg_Donovan_Smith_Tothova_Wilen_Orchard_et,
+ title = {
+ Optimized sgRNA design to maximize activity and minimize off-target effects
+ of CRISPR-Cas9
+ },
+ author = {
+ Doench, John G. and Fusi, Nicolo and Sullender, Meagan and Hegde, Mudra and
+ Vaimberg, Emma W. and Donovan, Katherine F. and Smith, Ian and Tothova,
+ Zuzana and Wilen, Craig and Orchard, Robert and Virgin, Herbert W. and
+ Listgarten, Jennifer and Root, David E.
+ },
+ year = 2016,
+ month = feb,
+ journal = {Nature Biotechnology},
+ publisher = {Nature Publishing Group},
+ volume = 34,
+ number = 2,
+ pages = {184–191},
+ doi = {10.1038/nbt.3437},
+ issn = {1546-1696},
+ rights = {2015 Springer Nature America, Inc.},
+ abstractnote = {
+ Genome-wide sgRNA libraries based on rules for on-target activity improve
+ results of Cas9-based screens and facilitate a further refinement of on- and
+ off-target prediction algorithms.
+ },
+ language = {en}
+}
+@article{White_Sadeeshkumar_Sun_Sudarsan_Breaker_2022,
+ title = {
+ Na+ riboswitches regulate genes for diverse physiological processes in
+ bacteria
+ },
+ author = {
+ White, Neil and Sadeeshkumar, Harini and Sun, Anna and Sudarsan, Narasimhan
+ and Breaker, Ronald R.
+ },
+ year = 2022,
+ month = aug,
+ journal = {Nature Chemical Biology},
+ publisher = {Nature Publishing Group},
+ volume = 18,
+ number = 88,
+ pages = {878–885},
+ doi = {10.1038/s41589-022-01086-4},
+ issn = {1552-4469},
+ rights = {2022 The Author(s)},
+ abstractnote = {
+ Only one protein factor is known that senses Na+ and controls gene
+ expression. The Breaker Laboratory describes a bacterial riboswitch class
+ selective for Na+ that regulates genes important for Na+ homeostasis, pH
+ maintenance, osmotic stress response and ATP synthesis.
+ },
+ language = {en}
+}
+@article{Iwawaki_Akai_2006,
+ title = {
+ Analysis of the XBP1 splicing mechanism using endoplasmic reticulum
+ stress-indicators
+ },
+ author = {Iwawaki, Takao and Akai, Ryoko},
+ year = 2006,
+ month = nov,
+ journal = {Biochemical and Biophysical Research Communications},
+ volume = 350,
+ number = 3,
+ pages = {709–715},
+ doi = {10.1016/j.bbrc.2006.09.100},
+ issn = {0006-291X},
+ abstractnote = {
+ Under endoplasmic reticulum (ER) stress conditions, XBP1 mRNA is processed by
+ unconventional splicing and translated into a functional transcription
+ factor. ER stress-specific XBP1 splicing is also known to be activated by
+ IRE1. However, many aspects of the molecular mechanism of XBP1 splicing
+ remain to be elucidated. We previously developed an indicator system that
+ enabled detection of XBP1 splicing using fluorescent proteins as the reporter
+ signals. Here, we use a modification of this method that employs modified ER
+ stress-indicators and mutant IRE1 in vivo and in vitro to analyze XBP1
+ splicing mechanisms. Our analyses suggest that the 506–579nt region of the
+ XBP1 mRNA is necessary and sufficient for XBP1 splicing, that XBP1 splicing
+ can occur in the cytoplasm, and that cleavage and ligation of XBP1 mRNA
+ during splicing may occur as a coupled reaction.
+ }
+}
+@article{Zhang_Lin_Yao_Cai_Chen_Aierken_Wang_Song_2023,
+ title = {
+ XBP1 splicing contributes to endoplasmic reticulum stress-induced human islet
+ amyloid polypeptide up-regulation
+ },
+ author = {
+ Zhang, Yun and Lin, Susan and Yao, Jing and Cai, Wantong and Chen, Huaqiu and
+ Aierken, Ailikemu and Wang, Zhe and Song, Weihong
+ },
+ year = 2023,
+ month = oct,
+ journal = {Genes & Diseases},
+ volume = 11,
+ number = 5,
+ pages = 101148,
+ doi = {10.1016/j.gendis.2023.101148},
+ issn = {2352-4820},
+ abstractnote = {
+ As a pathological hallmark of type 2 diabetes mellitus (T2DM), islet amyloid
+ is formed by the aggregation of islet amyloid polypeptide (IAPP). Endoplasmic
+ reticulum (ER) stress interacts with IAPP aggregates and has been implicated
+ in the pathogenesis of T2DM. To examine the role of ER stress in T2DM, we
+ cloned the hIAPP promoter and analyzed its promoter activity in human
+ β-cells. We found that ER stress significantly enhanced hIAPP promoter
+ activity and expression in human β-cells via triggering X-box binding protein
+ 1 (XBP1) splicing. We identified a binding site of XBP1 in the hIAPP
+ promoter. Disruption of this binding site by substitution or deletion
+ mutagenesis significantly diminished the effects of ER stress on hIAPP
+ promoter activity. Blockade of XBP splicing by MKC3946 treatment inhibited ER
+ stress-induced hIAPP up-regulation and improved human β-cell survival and
+ function. Our study uncovers a link between ER stress and IAPP at the
+ transcriptional level and may provide novel insights into the role of ER
+ stress in IAPP cytotoxicity and the pathogenesis of T2DM.
+ }
+}
+@article{wei_lung_2023,
+ title = {
+ Lung {SORT} {LNPs} enable precise homology-directed repair mediated
+ {CRISPR}/{Cas} genome correction in cystic fibrosis models
+ },
+ author = {
+ Wei, Tuo and Sun, Yehui and Cheng, Qiang and Chatterjee, Sumanta and Traylor,
+ Zachary and Johnson, Lindsay T. and Coquelin, Melissa L. and Wang, Jialu and
+ Torres, Michael J. and Lian, Xizhen and Wang, Xu and Xiao, Yufen and Hodges,
+ Craig A. and Siegwart, Daniel J.
+ },
+ year = 2023,
+ month = nov,
+ journal = {Nature Communications},
+ volume = 14,
+ number = 1,
+ pages = 7322,
+ doi = {10.1038/s41467-023-42948-2},
+ issn = {2041-1723},
+ url = {https://www.nature.com/articles/s41467-023-42948-2},
+ urldate = {2024-04-16},
+ copyright = {2023 The Author(s)},
+ note = {Publisher: Nature Publishing Group},
+ abstract = {
+ Approximately 10\% of Cystic Fibrosis (CF) patients, particularly those with
+ CF transmembrane conductance regulator (CFTR) gene nonsense mutations, lack
+ effective treatments. The potential of gene correction therapy through
+ delivery of the CRISPR/Cas system to CF-relevant organs/cells is hindered by
+ the lack of efficient genome editor delivery carriers. Herein, we report
+ improved Lung Selective Organ Targeting Lipid Nanoparticles (SORT LNPs) for
+ efficient delivery of Cas9 mRNA, sgRNA, and donor ssDNA templates, enabling
+ precise homology-directed repair-mediated gene correction in CF models.
+ Optimized Lung SORT LNPs deliver mRNA to lung basal cells in Ai9 reporter
+ mice. SORT LNP treatment successfully corrected the CFTR mutations in
+ homozygous G542X mice and in patient-derived human bronchial epithelial cells
+ with homozygous F508del mutations, leading to the restoration of CFTR protein
+ expression and chloride transport function. This proof-of-concept study will
+ contribute to accelerating the clinical development of mRNA LNPs for CF
+ treatment through CRISPR/Cas gene correction.
+ },
+ language = {en},
+ keywords = {Biomedical engineering, CRISPR-Cas9 genome editing, Gene delivery}
+}
+8:
+@article{IBRAHIM2022215,
+ title = {
+ Polyethylene glycol (PEG): The nature, immunogenicity, and role in the
+ hypersensitivity of PEGylated products
+ },
+ author = {
+ Mohamed Ibrahim and Eslam Ramadan and Nehal E. Elsadek and Sherif E. Emam and
+ Taro Shimizu and Hidenori Ando and Yu Ishima and Omar Helmy Elgarhy and Hatem
+ A. Sarhan and Amal K. Hussein and Tatsuhiro Ishida
+ },
+ year = 2022,
+ journal = {Journal of Controlled Release},
+ volume = 351,
+ pages = {215--230},
+ doi = {https://doi.org/10.1016/j.jconrel.2022.09.031},
+ issn = {0168-3659},
+ url = {https://www.sciencedirect.com/science/article/pii/S0168365922006265},
+ keywords = {
+ Polyethylene glycol (PEG), anti-PEG antibodies, Hypersensitivity, COVID-19
+ mRNA vaccines, complement activation-related pseudoallergy (CARPA)
+ },
+ abstract = {
+ Polyethylene glycol (PEG) is a versatile polymer that is widely used as an
+ additive in foods and cosmetics, and as a carrier in PEGylated therapeutics.
+ Even though PEG is thought to be less immunogenic, or perhaps even
+ non-immunogenic, with a variety of physicochemical properties, there is
+ mounting evidence that PEG causes immunogenic responses when conjugated with
+ other materials such as proteins and nanocarriers. Under these conditions,
+ PEG with other materials can result in the production of anti-PEG antibodies
+ after administration. The antibodies that are induced seem to have a
+ deleterious impact on the therapeutic efficacy of subsequently administered
+ PEGylated formulations. In addition, hypersensitivity to PEGylated
+ formulations could be a significant barrier to the utility of PEGylated
+ products. Several reports have linked the presence of anti-PEG antibodies to
+ incidences of complement activation-related pseudoallergy (CARPA) following
+ the administration of PEGylated formulations. The use of COVID-19 mRNA
+ vaccines, which are composed mainly of PEGylated lipid nanoparticles (LNPs),
+ has recently gained wide acceptance, although many cases of post-vaccination
+ hypersensitivity have been documented. Therefore, our review focuses not only
+ on the importance of PEGs and its great role in improving the therapeutic
+ efficacy of various medications, but also on the hypersensitivity reactions
+ attributed to the use of PEGylated products that include PEG-based mRNA
+ COVID-19 vaccines.
+ }
+}
+9:
+@article{jiang_combinatorial_2024,
+ title = {
+ Combinatorial development of nebulized {mRNA} delivery formulations for the
+ lungs
+ },
+ author = {
+ Jiang, Allen Y. and Witten, Jacob and Raji, Idris O. and Eweje, Feyisayo and
+ MacIsaac, Corina and Meng, Sabrina and Oladimeji, Favour A. and Hu, Yizong
+ and Manan, Rajith S. and Langer, Robert and Anderson, Daniel G.
+ },
+ year = 2024,
+ month = mar,
+ journal = {Nature Nanotechnology},
+ volume = 19,
+ number = 3,
+ pages = {364--375},
+ doi = {10.1038/s41565-023-01548-3},
+ issn = {1748-3387, 1748-3395},
+ url = {https://www.nature.com/articles/s41565-023-01548-3},
+ urldate = {2024-09-10},
+ language = {en}
+}
+10:
+@article{vila-gonzalez_vitro_2024,
+ title = {
+ In vitro platform to model the function of ionocytes in the human airway
+ epithelium
+ },
+ author = {
+ Vilà -González, Marta and Pinte, Laetitia and Fradique, Ricardo and Causa,
+ Erika and Kool, Heleen and Rodrat, Mayuree and Morell, Carola Maria and
+ Al-Thani, Maha and Porter, Linsey and Guo, Wenrui and Maeshima, Ruhina and
+ Hart, Stephen L. and McCaughan, Frank and Granata, Alessandra and Sheppard,
+ David N. and Floto, R. Andres and Rawlins, Emma L. and Cicuta, Pietro and
+ Vallier, Ludovic
+ },
+ year = 2024,
+ month = apr,
+ journal = {Respiratory Research},
+ volume = 25,
+ number = 1,
+ pages = 180,
+ doi = {10.1186/s12931-024-02800-7},
+ issn = {1465-993X},
+ url = {
+ https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-024-02800-7
+ },
+ urldate = {2024-09-10},
+ abstract = {
+ Background  Pulmonary ionocytes have been identified in the airway epithelium
+ as a small population of ion transporting cells expressing high levels of
+ CFTR (cystic fibrosis transmembrane conductance regulator), the gene mutated
+ in cystic fibrosis. By providing an infinite source of airway epithelial
+ cells (AECs), the use of human induced pluripotent stem cells (hiPSCs) could
+ overcome some challenges of studying ionocytes. However, the production of
+ AEC epithelia containing ionocytes from hiPSCs has proven difficult. Here, we
+ present a platform to produce hiPSCderived AECs (hiPSC-AECs) including
+ ionocytes and investigate their role in the airway epithelium.
+
+ Methods  hiPSCs were differentiated into lung progenitors, which were
+ expanded as 3D organoids and matured by air-liquid interface culture as
+ polarised hiPSC-AEC epithelia. Using CRISPR/Cas9 technology, we generated a
+ hiPSCs knockout (KO) for FOXI1, a transcription factor that is essential for
+ ionocyte specification. Differences between FOXI1 KO hiPSC-AECs and their
+ wild-type (WT) isogenic controls were investigated by assessing gene and
+ protein expression, epithelial composition, cilia coverage and motility, pH
+ and transepithelial barrier properties.
+
+ Results  Mature hiPSC-AEC epithelia contained basal cells, secretory cells,
+ ciliated cells with motile cilia, pulmonary neuroendocrine cells (PNECs) and
+ ionocytes. There was no difference between FOXI1 WT and KO hiPSCs in terms of
+ their capacity to differentiate into airway progenitors. However, FOXI1 KO
+ led to mature hiPSC-AEC epithelia without ionocytes with reduced capacity to
+ produce ciliated cells.
+
+ Conclusion  Our results suggest that ionocytes could have role beyond
+ transepithelial ion transport by regulating epithelial properties and
+ homeostasis in the airway epithelium.
+ },
+ language = {en}
+}
+11:
+
+@book{book,
+ title = {Genome Editing and Biological Weapons: Assessing the Risk of Misuse},
+ author = {Paris, Katherine},
+ year = 2023,
+ month = {01},
+ publisher = {Springer Nature Switzerland AG},
+ pages = {},
+ doi = {10.1007/978-3-031-21820-0},
+ isbn = {978-3-031-21819-4}
+}
+12:
+@article{wickiser2020biosecurity,
+ title = {
+ The democratization of biology: how CRISPR and synthetic biology usher in new
+ biosecurity threats
+ },
+ author = {Wickiser, Jason K., et al.},
+ year = 2020,
+ journal = {Defense Horizons},
+ volume = 85,
+ pages = {1--16},
+ url = {
+ https://ndupress.ndu.edu/Media/News/News-Article-View/Article/2386026/democratization-of-biology-crispr-synthetic-biology-new-biosecurity-threats/
+ }
+}
+13:
+@article{cohen2019security,
+ title = {
+ Security implications of CRISPR-enabled genome editing: New weapons of mass
+ disruption?
+ },
+ author = {Cohen, Jon and Desai, Tej},
+ year = 2019,
+ journal = {Journal of Bioethical Inquiry},
+ publisher = {Springer},
+ volume = 16,
+ number = 2,
+ pages = {219--228},
+ doi = {10.1007/s11673-019-09914-5},
+ url = {https://doi.org/10.1007/s11673-019-09914-5}
+}
+14:
+@article{doudna2020synthetic,
+ title = {
+ The rise of synthetic biology: New biosecurity risks and regulatory
+ challenges
+ },
+ author = {Doudna, Jennifer A. and Charpentier, Emmanuelle},
+ year = 2020,
+ journal = {Nature Reviews Genetics},
+ publisher = {Nature},
+ volume = 21,
+ number = 3,
+ pages = {144--156},
+ doi = {10.1038/s41576-019-0182-7},
+ url = {https://www.nature.com/articles/s41576-019-0182-7}
+}
+15:
+@article{shwartz2019public,
+ title = {
+ Public perception of CRISPR and genome editing: Misconceptions and media
+ portrayal
+ },
+ author = {Shwartz, Mark and Conklin, Brian},
+ year = 2019,
+ journal = {Journal of Science Communication},
+ volume = 18,
+ number = 4,
+ pages = {A02},
+ doi = {10.22323/2.18040202},
+ url = {https://jcom.sissa.it/archive/18/04/JCOM_1804_2019_A02}
+}
+16:
+@book{Chadwick_2012,
+ title = {Encyclopedia of applied ethics},
+ author = {Chadwick, Ruth F.},
+ year = 2012,
+ publisher = {Academic Press},
+ address = {London},
+ isbn = {978-0-12-373932-2},
+ edition = {2nd ed},
+ language = {eng}
+}
+17:
+@article{Rubeis_Steger_2018,
+ title = {Risks and benefits of human germline genome editing: An ethical analysis},
+ author = {Rubeis, Giovanni and Steger, Florian},
+ year = 2018,
+ month = jul,
+ journal = {Asian Bioethics Review},
+ volume = 10,
+ number = 2,
+ pages = {133–141},
+ doi = {10.1007/s41649-018-0056-x},
+ issn = {1793-8759, 1793-9453},
+ language = {en}
+}
+18:
+@article{Ansah_2022,
+ title = {
+ Ethical Challenges and Controversies in the Practice and Advancement of Gene
+ Therapy
+ },
+ author = {Ansah, Emmanuel Owusu},
+ year = 2022,
+ month = aug,
+ journal = {Advances in Cell and Gene Therapy},
+ volume = 2022,
+ pages = {1–5},
+ doi = {10.1155/2022/1015996},
+ issn = {2573-8461},
+ rights = {https://creativecommons.org/licenses/by/4.0/},
+ abstractnote = {
+ One of the most important technologies in modern medicine is gene therapy,
+ which allows therapeutic genes to be introduced into cells of the body. The
+ approach involves genetics and recombinant DNA techniques that allow
+ manipulating vectors for delivery of exogenous material to target cells. The
+ efficacy and safety of the delivery system are a key step towards the success
+ of gene therapy. Somatic cell gene therapy is the easiest in terms of
+ technology and the least problematic in terms of ethics. Although genetic
+ manipulation of germline cells at the gene level has the potential to
+ permanently eradicate certain hereditary disorders, major ethical issues such
+ as eugenics, enhancement, mosaicism, and the transmission of undesirable
+ traits or side effects to patients’ descendants currently stymie its
+ development, leaving only somatic gene therapy in the works. However, moral,
+ social, and ethical arguments do not imply that germline gene therapy should
+ be banned forever. This review discusses in detail the current challenges
+ surrounding the practice of gene therapy, focusing on the moral arguments and
+ scientific claims that affect the advancement of the technology. The review
+ also suggests precautionary principles as a means to navigate ethical
+ uncertainties.
+ },
+ editor = {Miao, Carol H.},
+ language = {en}
+}
+19:
+@book{Pugh_2020,
+ title = {Autonomy, Rationality, and Contemporary Bioethics},
+ author = {Pugh, Jonathan},
+ year = 2020,
+ month = apr,
+ publisher = {Oxford University PressOxford},
+ doi = {10.1093/oso/9780198858584.001.0001},
+ isbn = {978-0-19-885858-4},
+ url = {https://academic.oup.com/book/33778},
+ edition = 1,
+ rights = {https://creativecommons.org/licenses/by-nc-nd/4.0/},
+ abstractnote = {
+ Abstract Personal autonomy is often lauded as a key value in
+ contemporary Western bioethics, and the claim that there is an important
+ relationship between autonomy and rationality is often treated as an
+ uncontroversial claim in this sphere. Yet, there is also considerable
+ disagreement about how we should cash out the relationship between
+ rationality and autonomy. In particular, it is unclear whether a rationalist
+ view of autonomy can be compatible with legal judgments that enshrine a
+ patient’s right to refuse medical treatment, regardless of whether ‘… the
+ reasons for making the choice are rational, irrational, unknown or even
+ non-existent’. This book brings recent philosophical work on the nature of
+ rationality to bear on the question of how we should understand autonomy in
+ contemporary bioethics. In doing so, the author develops a new framework for
+ thinking about the concept, one that is grounded in an understanding of the
+ different roles that rational beliefs and rational desires have to play in
+ personal autonomy. Furthermore, the account outlined here allows for a deeper
+ understanding of different forms of controlling influence, and the
+ relationship between our freedom to act, and our capacity to decide
+ autonomously. The author contrasts his rationalist account with other
+ prominent accounts of autonomy in bioethics, and outlines the revisionary
+ implications it has for various practical questions in bioethics in which
+ autonomy is a salient concern, including questions about the nature of
+ informed consent and decision-making capacity.
+ },
+ language = {en}
+}
+20:
+@inbook{Gstraunthaler_Lindl_2013,
+ title = {Allgemeine Aspekte der Primärkultur},
+ author = {Gstraunthaler, Gerhard and Lindl, Toni},
+ year = 2013,
+ booktitle = {Zell- und Gewebekultur: Allgemeine Grundlagen und spezielle Anwendungen},
+ publisher = {Springer},
+ address = {Berlin, Heidelberg},
+ pages = {151–162},
+ doi = {10.1007/978-3-642-35997-2_16},
+ isbn = {978-3-642-35997-2},
+ url = {https://doi.org/10.1007/978-3-642-35997-2_16},
+ abstractnote = {
+ Definitionsgemäß versteht man unter Primärkultur alle In-vitro-Züchtungen von
+ Zellen, Geweben und Organen, die direkt aus dem Organismus entnommen wurden.
+ Wird diese Erstkultur weiter subkultiviert, spricht man von einer
+ Sekundärkultur und in weiterer Folge bereits von einer Zelllinie (Schaeffer,
+ 1990) (Abb. 16-1). In den meisten Fällen kann eine Primärkultur nicht mehr
+ weitergezüchtet werden (Abschn. 16.2). Während eine Organkultur nicht in
+ ihrer Struktur- und Organisationseinheit zerstört werden soll (Kap. 23), ist
+ die Gewebekultur von einer mehr oder minder starken Desintegration aus einem
+ Organismus abhängig. Für die Gewinnung einer Zellkultur ist eine vollständige
+ Dissoziation des Gewebes bzw. des Organs in Einzelzellen notwendig.
+ },
+ editor = {Gstraunthaler, Gerhard and Lindl, Toni},
+ language = {de}
+}
+21:
+@book{book1,
+ author = {Thiele, F.},
+ year = 2001,
+ booktitle = {International Encyclopedia of the Social & Behavioral Sciences},
+ publisher = {Elsevier},
+ pages = {13224–13227},
+ doi = {10.1016/B0-08-043076-7/00191-1},
+ isbn = {978-0-08-043076-8},
+ url = {https://linkinghub.elsevier.com/retrieve/pii/B0080430767001911},
+ rights = {https://www.elsevier.com/tdm/userlicense/1.0/},
+ language = {en}
+}
+22:
+@inbook{Gethmann_2001,
+ title = {Research: Ethical Aspects of Long-term Responsibilities},
+ author = {Gethmann, C.F.},
+ year = 2001,
+ booktitle = {International Encyclopedia of the Social & Behavioral Sciences},
+ publisher = {Elsevier},
+ pages = {13227–13231},
+ doi = {10.1016/B0-08-043076-7/00159-5},
+ isbn = {978-0-08-043076-8},
+ url = {https://linkinghub.elsevier.com/retrieve/pii/B0080430767001595},
+ rights = {https://www.elsevier.com/tdm/userlicense/1.0/},
+ language = {en}
+}
+23:
+@article{Kiani_Pheby_Henehan_Brown_Sieving_Sykora_Marks_Falsini_Capodicasa_Miertus_et,
+ title = {Ethical considerations regarding animal experimentation},
+ author = {
+ Kiani, Aysha Karim and Pheby, Derek and Henehan, Gary and Brown, Richard and
+ Sieving, Paul and Sykora, Peter and Marks, Robert and Falsini, Benedetto and
+ Capodicasa, Natale and Miertus, Stanislav and Lorusso, Lorenzo and
+ Dondossola, Daniele and Tartaglia, Gianluca Martino and Ergoren, Mahmut
+ Cerkez and Dundar, Munis and Michelini, Sandro and Malacarne, Daniele and
+ Bonetti, Gabriele and Dautaj, Astrit and Donato, Kevin and Medori, Maria
+ Chiara and Beccari, Tommaso and Samaja, Michele and Connelly, Stephen
+ Thaddeus and Martin, Donald and Morresi, Assunta and Bacu, Ariola and Herbst,
+ Karen L. and Kapustin, Mykhaylo and Stuppia, Liborio and Lumer, Ludovica and
+ Farronato, Giampietro and Bertelli, Matteo and INTERNATIONAL BIOETHICS STUDY
+ GROUP
+ },
+ year = 2022,
+ month = jun,
+ journal = {Journal of Preventive Medicine and Hygiene},
+ volume = 63,
+ number = {2 Suppl 3},
+ pages = {E255–E266},
+ doi = {10.15167/2421-4248/jpmh2022.63.2S3.2768},
+ issn = {2421-4248},
+ abstractnote = {
+ Animal experimentation is widely used around the world for the identification
+ of the root causes of various diseases in humans and animals and for
+ exploring treatment options. Among the several animal species, rats, mice and
+ purpose-bred birds comprise almost 90% of the animals that are used for
+ research purpose. However, growing awareness of the sentience of animals and
+ their experience of pain and suffering has led to strong opposition to animal
+ research among many scientists and the general public. In addition, the
+ usefulness of extrapolating animal data to humans has been questioned. This
+ has led to Ethical Committees’ adoption of the “four Rs†principles
+ (Reduction, Refinement, Replacement and Responsibility) as a guide when
+ making decisions regarding animal experimentation. Some of the essential
+ considerations for humane animal experimentation are presented in this review
+ along with the requirement for investigator training. Due to the ethical
+ issues surrounding the use of animals in experimentation, their use is
+ declining in those research areas where alternative in vitro or in silico
+ methods are available. However, so far it has not been possible to dispense
+ with experimental animals completely and further research is needed to
+ provide a road map to robust alternatives before their use can be fully
+ discontinued.
+ },
+ language = {eng}
+}
diff --git a/src/App/App.css b/src/App/App.css
index 4f65c5a6f3d7a86a67ea5167d7d75ffe19fa5ce3..3ed4099b92ef823144ee0bfd2f45e79b6fe16c43 100644
--- a/src/App/App.css
+++ b/src/App/App.css
@@ -74,8 +74,8 @@ html{
display: none;
}
-.scrolllink span{
- color: var(--background) !important;
+nav .scrolllink span{
+ color: white!important;
}
.small-row{
@@ -336,15 +336,35 @@ td, th {
padding: 8px;
}
-tr:nth-child(even) {
+.min-w-full{
+ min-width: 100% !important;
+}
+
+.parttable thead tr td:nth-child(4){ /* length */
+ max-width: 40px !important;
+}
+.parttable thead tr td:nth-child(5){ /* type */
+ max-width: 40px !important;
+}
+.parttable thead tr td:nth-child(2){ /* code */
+ max-width: 60px !important;
+}
+.parttable thead tr td:nth-child(1){ /* name */
+ max-width: 60px !important;
+}
+
+thead tr {
+ background-color: var(--text-primary) !important;
+ color: var(--background);
+}
+
+tbody tr:nth-child(even) {
background-color: #ededed;
}
-tr:nth-child(odd) {
+tbody tr:nth-child(odd) {
background-color: #f3f3f3;
}
-tr:nth-child(1) {
- background-color: var(--accent-gradient-one-of-three) !important;
-}
+
/* * * * * * * */
@@ -376,6 +396,7 @@ margin-bottom: 10vw !important;
}
.bg-d{
background-color: var(--text-primary) !important;
+ color: white;
}
.bg-l{
background-color: var(--text-primary) !important;
@@ -3849,4 +3870,26 @@ height: min-content !important;
letter-spacing: 1px;
text-transform: uppercase;
align-self: center;
+}
+
+.gif{
+ align-self: center;
+ display: inline;
+}
+
+.gif-wrapper{
+ display: flex;
+ align-items: center;
+ justify-content: center;
+}
+
+.eng-box{
+ border-radius: 3px;
+ border-style: solid;
+ border-color: var(--text-primary);
+ border-radius: 10px;
+}
+
+.eng-box p {
+ padding: 30px;
}
\ No newline at end of file
diff --git a/src/App/HP.css b/src/App/HP.css
index b82ee94d1ad96a753b4a8ac44bfa4cab9b9e65c7..5aca53d1ea7ef1e282ac2d699a5f32cf93b5ed00 100644
--- a/src/App/HP.css
+++ b/src/App/HP.css
@@ -23,4 +23,19 @@
padding: 30px 20px;
border-radius: 20px;
margin-left: 60px;
+ }
+
+ .act-version, .reflect-version, .engage-version /*, .anticipate-version */{
+ display: none !important;
+ }
+
+ #g744{
+ display: block !important;
+ }
+
+ #hp3-wrapper{
+ display: inline-flex;
+ justify-content: center;
+ max-width: 70%;
+ max-height: 60%;
}
\ No newline at end of file
diff --git a/src/components/BFH-Timeline.tsx b/src/components/BFH-Timeline.tsx
index 766ec0a76d5a05b78d7644272704f86fea2ef8d6..c422283cedfe10de81ec8dfea8d055135883cefb 100644
--- a/src/components/BFH-Timeline.tsx
+++ b/src/components/BFH-Timeline.tsx
@@ -1,6 +1,6 @@
import { NoButtTimelineItem, PanelTimelineItem, TimelineItemPic, TimelineItemTwoPic } from "./VerticalTimeline";
import SimpleSlider from "./Slider";
-import { SupScrollLink } from "./ScrollLink";
+import { ScrollLink, SupScrollLink } from "./ScrollLink";
export function BFHTimeline () {
return(
@@ -57,7 +57,7 @@ export function BFHTimeline () {
csstag="wikiworkshop"
vorname="Christian"
nachname="Kolland"
- heading="placeholder"
+ heading="Building Professional Websites: A Workshop on HTML and CSS Essentials"
text="Learning the basics of Wiki coding and design. In this workshop, the participants geined expertise to elevate their teams wiki."
>
<div id="wikiworkshop" style={{display: "none"}}>
@@ -196,10 +196,7 @@ export function BFHTimeline () {
</div>
<span>
- </span>
- <div id="teampres" style={{display: "none"}}>
- So much more
- </div>
+ </span>
</NoButtTimelineItem>
<NoButtTimelineItem
url="https://static.igem.wiki/teams/5247/placeholders/placehilderperson.jpeg"
@@ -208,8 +205,8 @@ export function BFHTimeline () {
color='var(--accent-primary)'
>
- <h5>Poster Exhibition Booth </h5>
- [Link virtual exhibition]
+ <h5>Poster Exhibition Booth</h5>
+ <p> Visit the <ScrollLink label="Virtual Poster Exhibition" targetId="BFH European MeetUp4H" />!</p>
<div className="col bfh-slider">
<SimpleSlider>
<img className="" src="https://static.igem.wiki/teams/5247/photos/meetup/exhibition/posterexhibition-plasmid-factory.webp"/>
@@ -284,6 +281,7 @@ export function BFHTimeline () {
nachname2="Malmendier"
color='var(--text-primary)'
csstag="commworkshop"
+ heading="Effective Science Communication: Strategies for Success"
text="Experience how science communication could be. Learn creative and funny ways to communicate difficult topics. Think outside the box and train your skills. "
>
<br></br>
@@ -354,8 +352,24 @@ export function BFHTimeline () {
"
>
<div id="pitch" style={{display: "none"}}>
- So much more
- </div>
+ <p>The "Perfect Project Pitch" workshop was part of the second phase of workshops during the inaugural BFH meet-up, hosted at Bielefeld University. It was led by Madeleine Mussgnug, a startup consultant at the Goethe University's entrepreneurship center in Frankfurt, Germany. Madeleine studied International Management and Tourism and has extensive experience, including several years at the scale-up company Limehome. Currently, she also works as a freelance consultant specializing in online marketing, social media, and supporting individuals in becoming self-employed. </p>
+ <p>The workshop focused on the essential skills and strategies for delivering an effective project pitch, covering the following key areas: </p>
+ <ol>
+ <li> Crafting compelling narratives to present complex ideas clearly and engagingly, ensuring they remain memorable for the audience. </li>
+ <li> Structuring and organizing pitches to highlight critical elements such as innovation, market potential, and team strengths, thus communicating your message effectively. </li>
+ <li> Tailoring pitches to resonate with different target audiences, including investors and collaborators, making them adaptable and impactful. </li>
+ <li> Building confidence and mastering persuasive techniques to convincingly communicate the value of your project. </li>
+ <li> Utilizing creative and visually appealing pitch materials, with a focus on integrating visuals and data effectively to enhance the presentation. </li>
+ </ol>
+ <p>Madeleine Mussgnug delivered these insights through a balanced mix of presentation and interactive discussions. She provided real-world examples and engaged the audience by prompting them to reflect on specific techniques, images, and stylistic choices. For instance, she demonstrated the strategic use of numbers and icons on slides, discussing how their size and placement can influence the viewer’s perception. By showing different slide constellations, she encouraged the audience to discuss their visual impact. The workshop concluded with a focus on the importance of networking. According to Mussgnug, knowing whom to approach and how to engage with them is key—this, she emphasized, is the essence of successful pitching. </p>
+ <p>We immediately put what we learned into practice in various areas, such as: </p>
+ <ul>
+ <li><b>Meet-up Münster Presentation:</b> We adopted a fresh, innovative approach when preparing for the Münster meet-up, integrating many of the techniques from the workshop. </li>
+ <li><b>Correspondence with Potential Partners and Sponsors: </b> Our communication became more targeted and effective, allowing us to build stronger connections with potential partners and sponsors. </li>
+ <li><b>Improved Steering Committee Communication:</b> We also saw a noticeable improvement in our interactions with the steering committee, using clearer and more persuasive messaging. </li>
+ </ul>
+ <p>In essence, the workshop not only enhanced our pitching skills but also significantly improved our overall communication strategies, enabling us to present our ideas with greater confidence and impact. </p>
+ </div>
</TimelineItemPic>
<TimelineItemPic
url="https://static.igem.wiki/teams/5247/photos/meetup/speakers/michael.jpg"
@@ -365,22 +379,24 @@ export function BFHTimeline () {
csstag="multimedia"
vorname="Michael"
nachname="Gröning"
- heading="placeholder"
+ heading="Mastering Filmmaking: From Basics to iGEM Video Production"
text="Learn the basics of filmmaking and video production.
Look behind the scenes and get in touch with professionals.
Train your skills to direct iGEM-related videos and movies."
>
<div id="multimedia" style={{display: "none"}}>
- So much more
- </div>
+ <p>Michael Gröning, who has many years of experience in a range of multimedia disciplines, including 3D animation, video and cinematography, film and audio production, post-production, voiceover and media design, held the practical workshop on multimedia. Firstly, the significance of the Promotion Video was elucidated, and the paramount importance of the general external representation was clarified. Questions and tricks provided the participants a basis for finding ideas for their videos, which were combined with story and mood boards and the reasonable use of AI.</p>
+ <p>A wide-ranging overview of various camera shots, lighting techniques and transitions was presented to the participants, equipping them with a useful toolkit for the production of cinematographic videos. Illustrative graphics, such as the Exposure Triangle, helped them to experiment with professional camera settings on their mobile phones. Through the implementation of voice warm-up exercises, the workshop participants were able to gain insights into the preparation of voice-overs. An introduction to various microphones and audio editing software enabled them to learn how voice recording is converted to studio quality.</p>
+ <p>The participants were able to gain valuable practical insights into the world of multimedia and thus prepare themselves to produce breathtaking videos. </p>
+ </div>
</TimelineItemPic>
<PanelTimelineItem></PanelTimelineItem>
<TimelineItemPic
url="https://static.igem.wiki/teams/5247/photos/meetup/speakers/middendorf.jpeg"
date='iGEMer Ted Talks'
- tag= 'Talks'
+ tag= 'Talks'
color='var(--lightblue)'
heading="Secrets to award-winning bioinformatics tools"
text="Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et"
diff --git a/src/components/Link.tsx b/src/components/Link.tsx
new file mode 100644
index 0000000000000000000000000000000000000000..a45c8e4897219e6bd137d0e30877c72918bdca25
--- /dev/null
+++ b/src/components/Link.tsx
@@ -0,0 +1,8 @@
+import { useNavigation } from "../utils"
+
+export function TabScrollLink({tab, scrollId, num}:{tab: string, scrollId: string, num: string}){
+ const {goToPageWithTabAndScroll} = useNavigation();
+ return(
+ <sup><a onClick={() => goToPageWithTabAndScroll({path: "", tabId: tab, scrollToId: scrollId})}>{num}</a></sup>
+ )
+}
\ No newline at end of file
diff --git a/src/components/Table.tsx b/src/components/Table.tsx
new file mode 100644
index 0000000000000000000000000000000000000000..ee88868bdba213cb83db7e9bc515339268c4ab23
--- /dev/null
+++ b/src/components/Table.tsx
@@ -0,0 +1,40 @@
+import { Part } from "../data/parts";
+
+export function PartTable({data, cols}: {data: Array<Part>, cols: Array<string>}){
+ let list = [];
+ for (let index = 0; index < data.length; index++) {
+ list.push(
+ <tr>
+ <td>{data[index].partname}</td>
+ <td><a href={data[index].url}>{data[index].registrycode}</a></td>
+ <td>{data[index].description}</td>
+ <td>{data[index].length}</td>
+ <td>{data[index].type}</td>
+ </tr>
+ )
+ }
+ let heads = [];
+ for (let index = 0; index < cols.length; index++) {
+ heads.push(<td><b>{cols[index]}</b></td>)
+ }
+ return(
+ <div className="flex flex-col">
+ <div className="min-w-full overflow-x-auto">
+ <div className="inline-block min-w-full py-4">
+ <div className="overflow-hidden p-2">
+ <table className="text-center parttable">
+ <thead className="bg-d">
+ <tr>
+ {heads}
+ </tr>
+ </thead>
+ <tbody>
+ {list}
+ </tbody>
+ </table>
+ </div>
+ </div>
+ </div>
+ </div>
+ )
+}
\ No newline at end of file
diff --git a/src/components/Tabs.tsx b/src/components/Tabs.tsx
index 42396a732bd8e1a77224d3e94e521cb40e193b4e..4c52c8d176090f9397d5aacb06bd620167140399 100644
--- a/src/components/Tabs.tsx
+++ b/src/components/Tabs.tsx
@@ -19,6 +19,7 @@ export function ButtonRowTabs({data, cla}: {data: Array<TabDatensatz>, cla: stri
import React from "react";
import { BlockQuoteB } from "./Quotes";
import { TimelineDatenpunkt } from "../data/hptimelinedata";
+import Collapsible from "./Collapsible";
/* import { stringToSlug } from "../utils"; */
@@ -136,7 +137,13 @@ import { TimelineDatenpunkt } from "../data/hptimelinedata";
<img src={data[i].pictureurl_aim} className="hp-timeline-img hti-left"/>
</div></>
}
-
+ let int = <></>;
+ if (data[i].interview) {
+ int = <Collapsible title="Interview" id="joshuainv">
+ {data[i].interview}
+ </Collapsible>
+ }
+
let node = <>
<br/>
@@ -182,6 +189,7 @@ import { TimelineDatenpunkt } from "../data/hptimelinedata";
{imp_img}
</div>
+ {int}
{refs}
</>
if(problem){
@@ -214,6 +222,8 @@ import { TimelineDatenpunkt } from "../data/hptimelinedata";
return rows;
}
+ /* Interview */
+
export function OLDBFHStyleTabs({data, cla}: {data: Array<NodeDatensatz>, cla: string}) {
let rows = []
for ( let i = 0; i < data.length; i++ ){
diff --git a/src/contents/Contribution/BFH/bfh-about.tsx b/src/contents/Contribution/BFH/bfh-about.tsx
index 43763dba0665c018c04cea7ef14644c058fb1528..a4b80e53097bf16983c5c284963af8a86489130a 100644
--- a/src/contents/Contribution/BFH/bfh-about.tsx
+++ b/src/contents/Contribution/BFH/bfh-about.tsx
@@ -11,7 +11,7 @@ export function About(){
<BlockQuoteB text="This was the best meet up ever in the history of iGEM. Thank you so much!" cite="Nemanja Stijepovic"></BlockQuoteB>
<H4 id="" text="Introduction"/>
- <p>This year, we hosted the first BFH European Meet-Up ever. Over the course of three full days, we embarked on a journey where minds met, and ideas ignited. Our mission: </p>
+ <p>This year, we hosted the first BFH European Meet-Up ever. Over the course of three full days, we embarked on a journey where minds met and ideas ignited. Our mission: </p>
<p className="bfh-motto"><b>Ignite. Innovate. Inspire.</b></p>
<p>This event was designed to unite the brightest minds from across Europe and beyond, providing a platform for sharing groundbreaking ideas and fostering international connections during the early stages of the iGEM competition. </p>
<H4 text="About Our Cooperation"/>
diff --git a/src/contents/Contribution/Wiki/Filterables.tsx b/src/contents/Contribution/Wiki/Filterables.tsx
new file mode 100644
index 0000000000000000000000000000000000000000..8b0d913e72bd280b6847a9cfef77a5dfa8182f03
--- /dev/null
+++ b/src/contents/Contribution/Wiki/Filterables.tsx
@@ -0,0 +1,29 @@
+import Collapsible from "../../../components/Collapsible";
+import { H5 } from "../../../components/Headings";
+import { Troubleshoot } from "./trouble-data";
+
+
+export function Filterables(data: Array<Troubleshoot>){
+ let count = 2;
+ let results = [];
+ for (let index = 0; index < data.length; index++) {
+ let tags = ""
+ for (let i = 0; i < data[index].tags.length; i++) {
+ tags += data[index].tags[i] + " ";
+ }
+ results.push(
+ <div className={`filterable all ${tags}`} id={`wiki-trouble-${count}`}>
+ <Collapsible title={data[index].title} id={`wiki-trouble-${count}-collapsible`}>
+ {data[index].text}
+ <H5 text="Example"/>
+ {data[index].examplechildren}
+ <H5 text="Solution"/>
+ {data[index].solutionchildren}
+ </Collapsible>
+ </div>
+ )
+ count ++;
+ }
+ return results;
+}
+
diff --git a/src/contents/Contribution/Wiki/trouble-data.tsx b/src/contents/Contribution/Wiki/trouble-data.tsx
new file mode 100644
index 0000000000000000000000000000000000000000..d2288f80320e016d4f1a36774afc3d8cc67531b1
--- /dev/null
+++ b/src/contents/Contribution/Wiki/trouble-data.tsx
@@ -0,0 +1,233 @@
+import { Code } from "../../../components/Code";
+
+export interface Troubleshoot{
+ tags: Array<Searchcriteria>;
+ title: string;
+ examplechildren: React.ReactNode;
+ solutionchildren: React.ReactNode;
+ text?: React.ReactNode;
+}
+
+type Searchcriteria = "html" | "script" | "css" | "react" | "type" | "properties" | "pipeline" | "module" | "browser" | "console" |"overload" ;
+
+export const troubledata: Array<Troubleshoot> = [
+ {
+ tags: ["react", "type"],
+ title: "Type X is not assignable to type Y.",
+ examplechildren: <></>,
+ solutionchildren: <></>
+ },
+ {
+ tags: ["pipeline"],
+ title: "The pipeline passed but the Wiki is not visible under the url",
+ text: <><p>This error could be a result of a wrong base url in the vite.config.js file.</p>
+ <p>E.g. if you switched from plain HTML to the react framework. </p></>,
+ examplechildren: <><Code>
+ <p>return defineConfig({</p>
+ <p>base: `/`,</p>
+ <p>...</p>
+ </Code></>,
+ solutionchildren: <><p>Change the base url to reflect the correct team url.</p>
+ <Code>
+ <p>return defineConfig({</p>
+ <p>base: `/${stringToSlug(env.VITE_TEAM_NAME)}/`,</p>
+ <p>...</p>
+ </Code></>
+ },
+ {
+ tags: ["console"],
+ title: "NS_ERROR_CORRUPTED_CONTENT error in console",
+ text: <><p> → See also "The pipeline passed but the Wiki is not visible under the url" as these errors can be connected.</p>
+ <p> This error for css and js files can be the result of wrong <b>rollupOptions</b> in for the build, to be specific wrong <b>output</b> and <b>assetFileNames</b> options and possibly wrong/empty <b>css</b> options in your vite.config.js. </p>
+ </>,
+ examplechildren: <><p>In our case, we had the following code on our vite.config.js</p>
+ <Code>
+ <p>build: { </p>
+ <p>outDir: "dist",</p>
+ <p>rollupOptions: {</p>
+ <p>output: {</p>
+ <p> assetFileNames: `assets/[ext]/[name]-[hash].[ext]`</p>
+ <p>} } } , </p>
+ </Code>
+ <p> Our <b>css</b> options were empty, which could also have played a factor for the css files.</p>
+ <Code>
+ <p>css: {</p>
+ <p>preprocessorOptions: {</p>
+ <p>css: {</p>
+ <p> //javascriptEnabled: true, // Enable JavaScript in CSS (useful for certain CSS preprocessor plugins)</p>
+ <p> } } },</p>
+ </Code></>,
+ solutionchildren: <></>
+ },
+ {
+ tags: ["browser", "console"],
+ title: "Blocked due to MIME type (“text/htmlâ€) mismatch (X-Content-Type-Options: nosniff) (Firefox)",
+ examplechildren: <><p> → See also "Refused to apply style from <<css file>> because its MIME type ('text/html') is not a supported stylesheet MIME type, strict MIME checking is enabled (Edge)"</p>
+ </>,
+ solutionchildren: <></>
+ },
+ {
+ tags: ["console", "browser"],
+ title: "Refused to apply style from <<css file>> because its MIME type ('text/html') is not a supported stylesheet MIME type, strict MIME checking is enabled (Edge)",
+ examplechildren: <><p> → See also "Blocked due to MIME type (“text/htmlâ€) mismatch (X-Content-Type-Options: nosniff) (Firefox)"</p> </>,
+ solutionchildren: <><p>This error could </p></>
+ },
+ {
+ tags: ["react", "type"],
+ title: "Type 'undefined' cannot be used as an index type",
+ examplechildren: <></>,
+ solutionchildren: <></>
+ },
+ {
+ tags: ["react", "overload"],
+ title: "No overload matches this call.",
+ examplechildren: <></>,
+ solutionchildren: <></>
+ },
+ {
+ tags: ["react", "module"],
+ title: "Module Z has already exported a member named A. Consider explicitly re-exporting to resolve the ambiguity.",
+ examplechildren: <>index.tsx:
+ <p className="problem-error"> Module "./Bfh.tsx" has already exported a member named 'LabTabs'. Consider explicitly re-exporting to resolve the ambiguity.</p>
+ </>,
+ solutionchildren: <><p>Simply rename the function in one of the modules or consider making it a component if you plan on using it frequently.
+ </p></>
+ },
+ {
+ tags: ["pipeline"],
+ title: "error TS6133: 'event' is declared but its value is never read.",
+ examplechildren: <>HorizontalTimeline.tsx:
+ <div className="terminal-box">
+ $ yarn build
+ <p>yarn run v1.22.19</p>
+ <p>$ tsc && vite build</p>
+ <p className="terminal-error">src/components/HorizontalTimeline.tsx(67,23): error TS6133: 'event' is declared but its value is never read.
+ error Command failed with exit code 2.</p>
+ <p>info Visit https://yarnpkg.com/en/docs/cli/run for documentation about this command.</p>
+ </div>
+ <p>in</p>
+ <Code>
+ const openPop = (event : React.MouseEvent<HTMLButtonElement, MouseEvent>) => {}
+ </Code></>,
+ solutionchildren: <><p>Change to: </p>
+ <Code>
+ const openPop = (_event : React.MouseEvent<HTMLButtonElement, MouseEvent>) => {}
+ </Code></>
+ },
+ {
+ tags: ["html"],
+ title: "Unexpected token. Did you mean `{'>'}` or `>`?\" id=\"wiki-trouble-16",
+ examplechildren: <></>,
+ solutionchildren: <></>
+ },
+ {
+ tags: ["react", "type"],
+ title: "Type 'x | undefined' is not assignable to type 'x'",
+ examplechildren: <></>,
+ solutionchildren: <></>
+ },
+ {
+ tags: ["react", "type", "properties"],
+ title: "Type X is missing the following properties from type Y: a, b, c",
+ examplechildren: <><p className="problem-error">
+ Type '{ date: string; text: string; }' is missing the following properties from type 'TextEventProps': marker, card
+ </p>
+ <p>In reference of the interface TextEventProps:</p>
+ <Code>
+ <p>interface TextEventProps { </p>
+ <p>date: string; </p>
+ <p>text: string; </p>
+ <p>marker: React.ReactNode; </p>
+ <p>id: string; </p>
+ <p>card: Function; </p>
+ }
+ </Code>
+ <p>For the code:</p>
+ <Code>
+ <p> <TextEvent </p>
+ <p> id="05"</p>
+ <p> date="14-06-2024"</p>
+ <p> text="Test test"</p>
+ <p> /></p>
+ </Code></>,
+ solutionchildren: <>
+ <h6>Solutions</h6>
+ <p>One solution could be getting rid of the properties you do not need everywhere and create new property interfaces for all cases.</p>
+ <p>If you want to stick to more general Interfaces, you can make properties optional:</p>
+ <Code>
+ <p>interface TextEventProps { </p>
+ <p>date: string; </p>
+ <p>text: string; </p>
+ <p>marker?: React.ReactNode; </p>
+ <p>id: string; </p>
+ <p>card?: Function; </p>
+ }
+ </Code>
+ <p>Remember that this can lead to different return cases for your functions.</p></>
+ },
+ {
+ tags: ["react", "type", "properties"],
+ title: "Property x does not exist on type Y.",
+ examplechildren: <></>,
+ solutionchildren: <></>
+ },
+ {
+ tags: ["react", "type", "properties"],
+ title: "Property x is missing in type y but required in type z.",
+ examplechildren: <><p className="problem-error"> Argument of type '{ [x: string]: any; }' is not assignable to parameter of type '{ classNames: string[]; }'.
+ Property 'classNames' is missing in type '{ [x: string]: any; }' but required in type '{ classNames: string[]; }'.</p>
+ <p> for </p>
+ <Code>className={joinClassNames({['text-event', className]})} </Code>
+ </>,
+ solutionchildren: <><p>In this example, the problem was that the property "classNames" was not explicitly named.</p>
+ <p>Changing it to </p>
+ <Code>className={joinClassNames({<b>classNames:</b>['text-event ', className]})}</Code>
+ </>
+ },
+ {
+ tags: ["css"],
+ title: "I added css styles but they do not show",
+ examplechildren: <><p>The color is not showing on hover.</p>
+ <Code>.nav-link:hover {
+ color: var(--darkpurple);
+ background-color: var(--yellow) !important;
+ border-radius: 3px;
+ }</Code></>,
+ solutionchildren: <><p>Styles not showing is often a case of a different style overriding your style. Some styles are pre defined by bootstrap or other packages you may use. </p>
+ <p> If an external package is overriding your style, you need to add the <b>!important</b> tag to your style. </p>
+ <p> If one of your own styles is overriding the new style, you can change your old style or define a new, more specific style case. E.g. by using a more specific css path. But you may still need to add the <b>!important</b> tag. </p>
+ <Code> .nav-link:hover {
+ color: var(--darkpurple) <b>!important</b>;
+ background-color: var(--yellow) !important;
+ border-radius: 3px;
+ }
+ </Code></>
+ },
+ {
+ tags: ["css", "script"],
+ title: "(subtabs[i] as HTMLElement).style.display = \"x\"; is not working.",
+ examplechildren: <></>,
+ solutionchildren: <></>
+ },
+ {
+ tags: ["react", "script"],
+ title: "Property 'style' does not exist on type 'Element'.",
+ examplechildren: <>
+ <p className="problem-error">
+ Property 'style' does not exist on type 'Element'.
+ </p>
+ <p>for the Code: </p>
+ <Code>
+ const subtabs = document.getElementsByClassName("sidesubtab");
+
+ for (let i = 0; i < subtabs.length; i++) {
+ (subtabs[i]).style.display = "none";
+ console.log(\`Hiding subtab: ${subtabs[i].id}\`);
+ }
+ </Code>
+ </>,
+ solutionchildren: <></>
+ },
+
+
+ ]
\ No newline at end of file
diff --git a/src/contents/Contribution/Wiki/troubleshooting.tsx b/src/contents/Contribution/Wiki/troubleshooting.tsx
index 0f0e23972728f8f15b95bad81301854f01591779..27512116f44bb91228565ff8d8b9595dc36e943f 100644
--- a/src/contents/Contribution/Wiki/troubleshooting.tsx
+++ b/src/contents/Contribution/Wiki/troubleshooting.tsx
@@ -1,9 +1,9 @@
-import { Code } from "../../../components/Code";
-import Collapsible from "../../../components/Collapsible";
import { WikiSelector } from "../../../components/Filter";
+import { Filterables } from "./Filterables";
+import { troubledata } from "./trouble-data";
export function Troubleshooting(){
-
+ let items = Filterables(troubledata)
return(
<div>
Please select what you want to troubleshoot for.
@@ -11,203 +11,16 @@ export function Troubleshooting(){
<div id="nono" className="noshow">
This combination returns no instances.
</div>
- <div className="filterable all react type property">
- <Collapsible id="wiki-trouble-1" title="Argument of type X is not assignable to parameter of type Y. ">
- <h6>Example</h6>
- <h6>Solutions</h6>
-
- </Collapsible>
- </div>
- <div className="filterable all react type">
- <Collapsible id="wiki-trouble-2" title="Type X is not assignable to type Y.">
- <h6>Example</h6>
- <h6>Solutions</h6>
- </Collapsible>
- </div>
- <div className="filterable all css">
- <Collapsible id="wiki-trouble-3" title="I added css styles but they do not show">
- <h6>Example</h6>
- <p>The color is not showing on hover.</p>
- <Code>.nav-link:hover {
- color: var(--darkpurple);
- background-color: var(--yellow) !important;
- border-radius: 3px;
- }</Code>
- <h6>Solution</h6>
- <p>Styles not showing is often a case of a different style overriding your style. Some styles are pre defined by bootstrap or other packages you may use. </p>
- <p> If an external package is overriding your style, you need to add the <b>!important</b> tag to your style. </p>
- <p> If one of your own styles is overriding the new style, you can change your old style or define a new, more specific style case. E.g. by using a more specific css path. But you may still need to add the <b>!important</b> tag. </p>
- <Code> .nav-link:hover {
- color: var(--darkpurple) <b>!important</b>;
- background-color: var(--yellow) !important;
- border-radius: 3px;
- }
- </Code>
- </Collapsible>
- </div>
- <div className="filterable all react type property">
- <Collapsible id="wiki-trouble-4" title="Property x is missing in type y but required in type z.">
- <h6>Example</h6>
- <p className="problem-error"> Argument of type '{ [x: string]: any; }' is not assignable to parameter of type '{ classNames: string[]; }'.
- Property 'classNames' is missing in type '{ [x: string]: any; }' but required in type '{ classNames: string[]; }'.</p>
- <p> for </p>
- <Code>className={joinClassNames({['text-event', className]})} </Code>
- <h6>Solutions</h6>
- <p>In this example, the problem was that the property "classNames" was not explicitly named.</p>
- <p>Changing it to </p>
- <Code>className={joinClassNames({<b>classNames:</b>['text-event ', className]})}</Code>
- </Collapsible>
- </div>
- <div className="filterable all react type property">
- <Collapsible id="wiki-trouble-5" title="Property x does not exist on type Y.">
- <h6>Example</h6>
- <h6>Solutions</h6>
- </Collapsible>
- </div>
- <div className="filterable all react type property">
- <Collapsible id="wiki-trouble-6" title="Type X is missing the following properties from type Y: a, b, c">
- <h6>Example</h6>
- <p className="problem-error">
- Type '{ date: string; text: string; }' is missing the following properties from type 'TextEventProps': marker, card
- </p>
- <p>In reference of the interface TextEventProps:</p>
- <Code>
- <p>interface TextEventProps { </p>
- <p>date: string; </p>
- <p>text: string; </p>
- <p>marker: React.ReactNode; </p>
- <p>id: string; </p>
- <p>card: Function; </p>
- }
- </Code>
- <p>For the code:</p>
- <Code>
- <p> <TextEvent </p>
- <p> id="05"</p>
- <p> date="14-06-2024"</p>
- <p> text="Test test"</p>
- <p> /></p>
- </Code>
- <h6>Solutions</h6>
- <p>One solution could be getting rid of the properties you do not need everywhere and create new property interfaces for all cases.</p>
- <p>If you want to stick to more general Interfaces, you can make properties optional:</p>
- <Code>
- <p>interface TextEventProps { </p>
- <p>date: string; </p>
- <p>text: string; </p>
- <p>marker?: React.ReactNode; </p>
- <p>id: string; </p>
- <p>card?: Function; </p>
- }
- </Code>
- <p>Remember that this can lead to different return cases for your functions.</p>
- </Collapsible>
- </div>
- <div className="filterable all react type">
- <Collapsible id="wiki-trouble-7" title="Type 'x | undefined' is not assignable to type 'x'.">
- <h6>Example</h6>
- <h6>Solutions</h6>
- </Collapsible>
- </div>
- <div className="filterable all pipeline">
- <Collapsible id="wiki-trouble-8" title="The pipeline passed but the Wiki is not visible under the url">
- <p>This error could be a result of a wrong base url in the vite.config.js file.</p>
- <p>E.g. if you switched from plain HTML to the react framework. </p>
- <h6>Example</h6>
- <Code>
- <p>return defineConfig({</p>
- <p>base: `/`,</p>
- <p>...</p>
- </Code>
- <h6>Solution</h6>
- <p>Change the base url to reflect the correct team url.</p>
- <Code>
- <p>return defineConfig({</p>
- <p>base: `/${stringToSlug(env.VITE_TEAM_NAME)}/`,</p>
- <p>...</p>
- </Code>
- </Collapsible>
- </div>
- <div className="filterable all console">
- <Collapsible id="wiki-trouble-9" title="NS_ERROR_CORRUPTED_CONTENT error in console">
- <p> → See also "The pipeline passed but the Wiki is not visible under the url" as these errors can be connected.</p>
- <p> This error for css and js files can be the result of wrong <b>rollupOptions</b> in for the build, to be specific wrong <b>output</b> and <b>assetFileNames</b> options and possibly wrong/empty <b>css</b> options in your vite.config.js. </p>
- <h6>Example</h6>
- <p>In our case, we had the following code on our vite.config.js</p>
- <Code>
- <p>build: { </p>
- <p>outDir: "dist",</p>
- <p>rollupOptions: {</p>
- <p>output: {</p>
- <p> assetFileNames: `assets/[ext]/[name]-[hash].[ext]`</p>
- <p>} } } , </p>
- </Code>
- <p> Our <b>css</b> options were empty, which could also have played a factor for the css files.</p>
- <Code>
- <p>css: {</p>
- <p>preprocessorOptions: {</p>
- <p>css: {</p>
- <p> //javascriptEnabled: true, // Enable JavaScript in CSS (useful for certain CSS preprocessor plugins)</p>
- <p> } } },</p>
- </Code>
- </Collapsible>
- </div>
- <div className="filterable all console">
- <Collapsible id="wiki-trouble-10" title="Blocked due to MIME type (“text/htmlâ€) mismatch (X-Content-Type-Options: nosniff) (Firefox)">
- <p> → See also "Refused to apply style from <<css file>> because its MIME type ('text/html') is not a supported stylesheet MIME type, strict MIME checking is enabled (Edge)"</p>
- <p>This error could </p>
- </Collapsible>
- </div>
- <div className="filterable all console">
- <Collapsible id="wiki-trouble-11" title="Refused to apply style from <<css file>> because its MIME type ('text/html') is not a supported stylesheet MIME type, strict MIME checking is enabled (Edge)">
- <p> → See also "Blocked due to MIME type (“text/htmlâ€) mismatch (X-Content-Type-Options: nosniff) (Firefox)"</p>
- <p>This error could </p>
- </Collapsible>
- </div>
- <div className="filterable all react type">
- <Collapsible id="wiki-trouble-12" title="Type 'undefined' cannot be used as an index type">
- <h6>Example</h6>
- <h6>Solutions</h6>
- </Collapsible>
- </div>
- <div className="filterable all react overload">
- <Collapsible id="wiki-trouble-13" title="No overload matches this call.">
- <h6>Example</h6>
- <h6>Solutions</h6>
- </Collapsible>
- </div>
- <div className="filterable all react module">
- <Collapsible id="wiki-trouble-14" title="Module Z has already exported a member named A. Consider explicitly re-exporting to resolve the ambiguity.">
- <h6>Example</h6>
- index.tsx:
- <p className="problem-error"> Module "./Bfh.tsx" has already exported a member named 'LabTabs'. Consider explicitly re-exporting to resolve the ambiguity.</p>
- <h6>Solutions</h6>
- Simply rename the function in one of the modules or consider making it a component if you plan on using it frequently.
- </Collapsible>
- </div>
- <div className="filterable all pipeline">
- <Collapsible id="wiki-trouble-15" title="error TS6133: 'event' is declared but its value is never read.">
- <h6>Example</h6>
- HorizontalTimeline.tsx:
- <div className="terminal-box">
- $ yarn build
- <p>yarn run v1.22.19</p>
- <p>$ tsc && vite build</p>
- <p className="terminal-error">src/components/HorizontalTimeline.tsx(67,23): error TS6133: 'event' is declared but its value is never read.
- error Command failed with exit code 2.</p>
- <p>info Visit https://yarnpkg.com/en/docs/cli/run for documentation about this command.</p>
- </div>
- <p>in</p>
- <Code>
- const openPop = (event : React.MouseEvent<HTMLButtonElement, MouseEvent>) => {}
- </Code>
- <h6>Solutions</h6>
- <p>Change to: </p>
- <Code>
- const openPop = (_event : React.MouseEvent<HTMLButtonElement, MouseEvent>) => {}
- </Code>
- </Collapsible>
- </div>
+ {items}
+
+
+
+
+
+
+
+
+
</div>
)
}
diff --git a/src/contents/Contribution/Wiki/wiki-overview.tsx b/src/contents/Contribution/Wiki/wiki-overview.tsx
new file mode 100644
index 0000000000000000000000000000000000000000..89f284c4d00edac269fb8d3ae350a93e33308370
--- /dev/null
+++ b/src/contents/Contribution/Wiki/wiki-overview.tsx
@@ -0,0 +1,14 @@
+
+export function WikiOverview(){
+
+ return(
+ <div>
+ <p>To help teams get started, we wrote down what we wished we would have easily found while building our wiki with React.</p>
+ <p><b>Getting startet</b> explains some basics that are important to know. This especially concerns the differences between using plain HTML and React, but the structure of the wiki, too. </p>
+ <p><b>Troubleshooting</b> is an iteractive search for problems that may arise and how we solved them. </p>
+ <p><b>Components</b> contains some components we used that we found very helpful. Many packages that offer components such as timelines were not exactly what we were looking for or did not work with our packages. The solution was to create our own components. </p>
+ <p><b>Downloads</b> contains svgs we created - not all of them we were able to use. </p>
+ <p><b>Resources</b> contains links zu helpful external. </p>
+ </div>
+ )
+}
\ No newline at end of file
diff --git a/src/contents/Contribution/Wiki/wiki-start.tsx b/src/contents/Contribution/Wiki/wiki-start.tsx
index 669aab33a5d4e4017d6f275fd211222840c31104..9f2a15727801af13b8b3cc6cac1f003a56089b75 100644
--- a/src/contents/Contribution/Wiki/wiki-start.tsx
+++ b/src/contents/Contribution/Wiki/wiki-start.tsx
@@ -3,18 +3,21 @@ export function Started(){
return(
<>
<h3>Differences between React and plain HTML</h3>
- <p>There are some differences in the syntax that can lead to errors.</p>
+ <p>These can lead to confusing errors if you are used to HTML.</p>
<table>
- <tr>
- <th></th>
- <th>Plain HTML</th>
- <th>Using React</th>
- </tr>
+ <thead>
+ <tr>
+ <th></th>
+ <th>Plain HTML</th>
+ <th>Using React</th>
+ </tr>
+ </thead>
+ <tbody>
<tr>
<th> <code><tags> </code> </th>
<th>
<p> Most tags have to be opened and closed, but some can be only opened. </p>
- <p> e.g. img, br, ... <code> <img src:"somesource" alt="alt"> </code> </p>
+ <p> e.g. img, br, ... <code> <img src:"somesource" alt="alt"> </code> </p>
</th>
<th>
<p> Every tag has to be closed. </p>
@@ -48,7 +51,9 @@ export function Started(){
<p> style={{<var>attribute</var>: "<var>value</var>", <var>attribute</var>: "<var>value</var>" }}</p>
</th>
</tr>
+ </tbody>
</table>
+ <h3>Good to knows</h3>
</>
)
}
diff --git a/src/contents/Contribution/Wiki/wiki-tabs.tsx b/src/contents/Contribution/Wiki/wiki-tabs.tsx
index 71d63da43c1ad6bb846e4cb56dcb75f29ca9d880..c95bff1142dfe8f0fa99b48de53c73d09c68bccc 100644
--- a/src/contents/Contribution/Wiki/wiki-tabs.tsx
+++ b/src/contents/Contribution/Wiki/wiki-tabs.tsx
@@ -4,6 +4,7 @@ import React from "react";
import { Started } from "./wiki-start";
import { Sources } from "./wiki-sources";
import { Troubleshooting } from "./troubleshooting";
+import { WikiOverview } from "./wiki-overview";
export function WikiTabs() {
const [value, setValue] = React.useState('1');
@@ -17,7 +18,7 @@ export function WikiTabs() {
<TabContext value={value}>
<Box sx={{ borderBottom: 1, borderColor: 'divider' }}>
<TabList onChange={handleChange} aria-label="lab API tabs example">
- <Tab label="About" value="1" />
+ <Tab label="Overview" value="1" />
<Tab label="Getting started" value="6" />
<Tab label="Troubleshooting" value="2" />
<Tab label="Components" value="3" />
@@ -26,7 +27,7 @@ export function WikiTabs() {
</TabList>
</Box>
- <TabPanel value="1"> </TabPanel>
+ <TabPanel value="1"> <WikiOverview/> </TabPanel>
<TabPanel value="6"> <Started/> </TabPanel>
<TabPanel value="2"> <Troubleshooting/> </TabPanel>
<TabPanel value="3"> </TabPanel>
diff --git a/src/contents/Human Practices/Further Engagement/Education.tsx b/src/contents/Human Practices/Further Engagement/Education.tsx
index 361f6cd7b840c8eb1e2f856127da3e9d27cae0dc..1dbd250a1f6832cd0a9219f0389cbfbfaafd6605 100644
--- a/src/contents/Human Practices/Further Engagement/Education.tsx
+++ b/src/contents/Human Practices/Further Engagement/Education.tsx
@@ -1,7 +1,6 @@
import { ButtonOne } from "../../../components/Buttons";
import { H4 } from "../../../components/Headings";
-import { H5 } from "../../../components/Headings";
-import { LoremMedium } from "../../../components/Loremipsum";
+import { H5 } from "../../../components/Headings"
export function HPEducation(){
@@ -17,34 +16,49 @@ export function HPEducation(){
<div className="col">
<ButtonOne openclass="edu-cycletab" text="Schüler*innen Akademie" open="akademie"></ButtonOne>
</div>
-
<div id="edu-overview" className="edu-cycletab" style={{display: "block"}}>
<H4 id="edu-heading" text="Our education and outreach"/>
- <LoremMedium/>
+ <p>Education and outreach remain vital, even without being a special prize focus. They help us share knowledge, inspire people, and create lasting impact. By making information accessible, we empower the public to make informed decisions and engage in meaningful discussions.</p>
+ <p></p>
<H4 id="edu-why-heading" text="If not as a special prize - then why?"/>
- <LoremMedium/>
+ <p>Human-centered design is essential for our Integrated Human Practices, ensuring that our project is aligned with the real needs and concerns of the people it aims to serve. Outreach and education are key components of this approach, as they allow us to communicate our goals and inform the public about both our project and the critical issue of cystic fibrosis (CF). By engaging with diverse audiences—patients, families, schools, and the wider community—we raise awareness about CF, while fostering a deeper understanding of the challenges involved. This feedback-driven interaction not only builds trust but also helps us refine our work to have a meaningful impact on those affected by CF. Through educational programs, workshops, and outreach initiatives, we aim to bridge the gap between scientific research and the public, ensuring that our project is both accessible and impactful.</p>
+ <p></p>
</div>
+
<div id="akademie" className="edu-cycletab" style={{display: "none"}}>
<H4 id="student-academy-heading" text="Student academy on the topic of synthetic biology"/>
- <H5 id="Scüler*innen Akademie" text="Teaching the Next Generation of SynBio Pioneers The Center for Biotechnology (CeBiTec) at Bielefeld University organizes the annual CeBiTec Student Academy for “Biotechnology and Biomedicine.†Supported by the Osthushenrich Foundation and the Detmold district government, the academy offers students a unique opportunity to deepen their understanding of biology, genetics, and molecular biology through hands-on experiments and expert lectures. Key topics include nanopore sequencing, tumor diagnostics, and the evolution of SARS-CoV-2. The program is especially valuable for students transitioning from school to potential studies in the natural sciences."/>
- <p>
-Due to our collaboration with the Student Academy, we conducted the nanopore sequencing experiment and served as teachers, assisting in experiment preparation, execution, offering guidance, and answering questions. This role allowed us to teach the students about laboratory work, the critical aspects of conducting experiments, and essential safety considerations. The experiment involved isolating bacterial DNA, preparing samples for sequencing, and performing both sequencing and data analysis.
-Since we presented our iGEM project PreCyse to them as well, the students were introduced to study-related projects like iGEM. They learned about the daily tasks, challenges, and responsibilities involved in iGEM through project discussions. Many students were captivated by the iGEM concept and expressed interest in participating during their future studies. They were particularly fascinated by the opportunity to develop real research projects, work independently in the lab, learn extensively about synthetic biology, and implement creative ideas while collaborating with an international team.</p>
+ <H5 id="Schüler*innen Akademie" text="Teaching the Next Generation of SynBio Pioneers "/>
+ <p> The Center for Biotechnology (CeBiTec) at Bielefeld University organizes the annual. <a href="https://www.cebitec.uni-bielefeld.de/events/futher-events/648-11-schuelerakademie" title="CeBiTec Student Academy for “Biotechnology and Biomedicine" > CeBiTec Student Academy for “Biotechnology and Biomedicine </a> Supported by <a href="https://www.osthushenrich-stiftung.de" title="Osthushenrich Foundation" > Osthushenrich Foundation </a> and the <a href="https://www.bezreg-detmold.nrw.de/" title="Detmold district government" > Detmold district government </a>, the academy offers students a unique opportunity to deepen their understanding of biology, genetics, and molecular biology through hands-on experiments and expert lectures. Key topics include nanopore sequencing, tumor diagnostics, and the evolution of SARS-CoV-2. The program is especially valuable for students transitioning from school to potential studies in the natural sciences.
+Due to our collaboration with the Student Academy, we conducted the nanopore sequencing experiment and served as teachers, assisting in experiment preparation, execution, offering guidance, and answering questions. This role allowed us to teach the students about laboratory work, the critical aspects of conducting experiments, and essential safety considerations. The experiment involved isolating bacterial DNA, preparing samples for sequencing, and performing both sequencing and data analysis.</p>
+<div className="row align-items-center">
+ <div className="col">
+ <img src="https://static.igem.wiki/teams/5247/photos/edcation-and-outreach/schielerakademie-vortrag-joern.jpg"></img>
+ </div>
+ <div className="col">
+ <img src="https://static.igem.wiki/teams/5247/photos/edcation-and-outreach/schielerakademie-lisa-gruppe2.jpg"></img>
+ </div>
+ </div>
+
+<p></p>
+<p></p>
+ <p>Since we presented our iGEM project PreCyse to them as well, the students were introduced to study-related projects like iGEM. They learned about the daily tasks, challenges, and responsibilities involved in iGEM through project discussions. Many students were captivated by the iGEM concept and expressed interest in participating during their future studies. They were particularly fascinated by the opportunity to develop real research projects, work independently in the lab, learn extensively about synthetic biology, and implement creative ideas while collaborating with an international team.</p>
</div>
+
<div id="teutoruft" className="edu-cycletab" style={{display: "none"}}>
<H4 id="teuroruft-heading" text="Educational city tour for young and old"/>
- <H5 id="Der Teuto ruft!" text="“Der Teuto ruft!†and why we participate"/>
- <p> </p>
- </div>
-
-"Der Teuto ruft!" is an outreach event located all over the city of Bielefeld where various local companies and institutions engage with the public to inform them about their work. Since we wanted to raise awareness for cystic fibrosis and present our approach to developing an optimized gene therapy to combat this disease, our participation in the "Der Teuto ruft!" event in Bielefeld was the perfect opportunity to do so.
+ <H5 id="Der Teuto ruft!" text=" What is “Der Teuto ruft!†and why we participate"/>
+<p>"Der Teuto ruft!" is an outreach event located all over the city of Bielefeld where various local companies and institutions engage with the public to inform them about their work. Since we wanted to raise awareness for cystic fibrosis and present our approach to developing an optimized gene therapy to combat this disease, our participation in the "Der Teuto ruft!" event in Bielefeld was the perfect opportunity to do so.</p>
<H5 id="What was our strategy?" text="What is our strategy?"/>
<p>Our goal was to educate children about the challenges faced by CF patients, especially the ones with lung problems. The knowledge which we gained at the Science Communication Workshop as part of the BFH Meetup was the optimal basis to plan our outreach to the public. We engaged the children with activities like coloring lung images and conducting experiments to experience and understand lung related symptoms.
One such experiment involved creating a lung model from balloons and straws, demonstrating the difficulty patients have in breathing by having the children blow into the straws. Additionally, we set up a tank with a mixture of starch and water to simulate mucus and placed a ball on top. The children tried to blow the ball across the surface, illustrating how hard it is for air to move through mucus compared to water, where the ball moved much more easily.
The very little ones could paint coloring pages which we designed and printed for them. For the adults, we provided information about our project and discussed the implications and potential of gene therapy for cystic fibrosis. These conversations made it abundantly clear that degrees of knowledge on this topic widely vary throughout the public and we were happy to fill in the existing gaps in people's knowledge and exchange points of view on gene therapy.
-Moreover, we connected with other institutions and participants at the event. We shared our booth at Bielefeld’s “Skulpturenpark†on the outside with btS, the life science student initiative from Bielefeld University [LINK], with whose members we had stimulating discussions as well. We were more than delighted when the city of Bielefeld featured us on their Instagram, highlighting our presence during "Der Teuto ruft!". This collaboration helped us reach a wider audience and raise awareness about our research efforts.</p>
+Moreover, we connected with other institutions and participants at the event. We shared our booth at Bielefeld’s “Skulpturenpark†on the outside with <a href="https://bts-ev.de/bielefeld/" title="btS" > btS </a>, the life science student initiative from Bielefeld University, with whose members we had stimulating discussions as well. We were more than delighted when the city of Bielefeld featured us on their Instagram, highlighting our presence during "Der Teuto ruft!". This collaboration helped us reach a wider audience and raise awareness about our research efforts.</p>
+<p></p>
+<a href="https://unibielefeldde.sharepoint.com/sites/iGEM2024teams/_layouts/15/stream.aspx?id=%2Fsites%2FiGEM2024teams%2FFreigegebene%20Dokumente%2FGeneral%2FFotos%2C%20Videos%20und%20Co%2FTeuto%20ruft%2FVideo%20Insta%20Teuto%20Ruft%2Emov&ga=1&referrer=StreamWebApp%2EWeb&referrerScenario=AddressBarCopied%2Eview%2Ee4a43a55%2Dfff3%2D4b44%2Db081%2Dad26306f93e0" title="video Teuto ruft" > watch me</a>
+<p></p>
<H5 id="conclusion? " text="What is our conclusion"/>
<p>Despite the changeable weather, we could educate many people of Bielefeld's community about cystic fibrosis, our therapeutic approach and gene therapy in general and had the opportunity to improve our science communication for the future as well so it was a successful event! </p>
+
<div className="row align-items-center">
<div className="col">
<img src="https://static.igem.wiki/teams/5247/photos/edcation-and-outreach/teutoruft-experminet.jpeg"></img>
@@ -55,5 +69,6 @@ Moreover, we connected with other institutions and participants at the event. We
</div>
</div>
</div>
+ </div>
);
}
\ No newline at end of file
diff --git a/src/contents/Human Practices/Further Engagement/Entrepreneurship.tsx b/src/contents/Human Practices/Further Engagement/Entrepreneurship.tsx
index 0076342f486512c4bb9e5a75b4dbe379cc9f50be..5e30c2e06f8e57e44123152354d3b9353390162d 100644
--- a/src/contents/Human Practices/Further Engagement/Entrepreneurship.tsx
+++ b/src/contents/Human Practices/Further Engagement/Entrepreneurship.tsx
@@ -1,6 +1,6 @@
import { ButtonOne } from "../../../components/Buttons";
import { H4 } from "../../../components/Headings";
-import { LoremMedium } from "../../../components/Loremipsum";
+
export function HPEntrepreneur(){
@@ -11,18 +11,24 @@ export function HPEntrepreneur(){
<ButtonOne openclass="ent-cycletab" text="Overview" open="ent-overview"></ButtonOne>
</div>
<div className="col">
- <ButtonOne openclass="ent-interview" text="ent-interview" open="ent-interview"></ButtonOne>
+ <ButtonOne openclass="ent-interview" text="GxP" open="ent-interview"></ButtonOne>
</div>
</div>
+
<div id="ent-overview" className="ent-interview" style={{display: "block"}}>
- <H4 id="ent-heading" text="Our education and outreach"/>
- <LoremMedium/>
+ <H4 id="ent-heading" text="Entrepreneurship"/>
+ <p> It helps us transform innovative ideas into real-world solutions, drive change, and create long-lasting impact. By building sustainable business models and engaging with stakeholders, we empower communities to benefit from our work and enable broader adoption of our solutions.</p>
+ <p></p>
<H4 id="ent-why-heading" text="If not as a special prize - then why?"/>
- <LoremMedium/>
+ <p>Human-centered design is also at the heart of our entrepreneurial efforts, ensuring that our innovations directly address the real needs of the people we aim to serve. Entrepreneurship is a key component of this process, as it allows us to not only develop effective solutions but also bring them to market in a meaningful way. By interacting with patients, families, healthcare professionals, and the broader community, we refine our product based on their input and the specific challenges they face, such as those associated with cystic fibrosis (CF). This approach builds trust, fosters collaboration, and ensures that our solutions can reach those who need them most. Through entrepreneurial initiatives, business strategies, and partnerships, we aim to create sustainable and scalable impact, bridging the gap between scientific innovation and everyday life.</p>
+ <p></p>
</div>
<div id="ent-interview" className="ent-interview" style={{display: "none"}}>
- <H4 id="ent-interview-heading" text="Heading"/>
+ <H4 id="ent-course-heading" text="GxP course"/>
+
+ <H4 id="ent-expert-heading" text="GxP Expert"/>
+
</div>
</div>
diff --git a/src/contents/Human Practices/Further Engagement/Outreach.tsx b/src/contents/Human Practices/Further Engagement/Outreach.tsx
index 1c9cb23e9f50de9772e7ff53261308a1f083e0e7..9a16f2d2786daec1a82c451e19996b28c6822a39 100644
--- a/src/contents/Human Practices/Further Engagement/Outreach.tsx
+++ b/src/contents/Human Practices/Further Engagement/Outreach.tsx
@@ -15,7 +15,7 @@ export function HPOutreach(){
<ButtonOne openclass="out-cycletab" text="MUKOmove" open="mukomove"></ButtonOne>
</div>
<div className="col">
- <ButtonOne openclass="out-cycletab" text="waffel sale" open="waffel sale"></ButtonOne>
+ <ButtonOne openclass="out-cycletab" text="Waffle Sale" open="Waffle sale"></ButtonOne>
</div>
</div>
@@ -27,8 +27,8 @@ export function HPOutreach(){
<LoremMedium/>
</div>
- <div id="waffle sale" className="out-cycletab" style={{display: "none"}}>
- <H4 id="waffle sale" text="Waffle sale"/>
+ <div id="Waffle sale" className="out-cycletab" style={{display: "none"}}>
+ <H4 id="Waffle sale" text="Waffle sale"/>
<div className="row">
<div className="full-small col3">
</div>
@@ -38,6 +38,11 @@ export function HPOutreach(){
<p>To support our research project and raise funds for our iGEM team at Bielefeld University, we decided to organize a waffle sale in the main hall of the university. This initiative was aimed at raising awareness about our project and collecting funds for our research into cystic fibrosis. </p>
<p>The sale took place in cystic fibrosis awareness month May in the Great Hall of our University. As people passed by, we engaged them by introducing our research group and explaining our project’s objectives. We shared information about cystic fibrosis and why we are raising money. Our goal was to not only just to sell waffles, but also to educate the university community about our research and its’ potential impact. The response has been overwhelmingly positive. Many were genuinely interested in our work and asked for more details about our research and the goals of our project. This enthusiasm strengthened our commitment to the project and highlighted the importance of community involvement in scientific research. </p>
<p>The waffle sale was a great success, both in terms of raising funds and increasing awareness about our work within the university. It was a collaborative effort that brought our team closer together and demonstrated the power of community support in advancing scientific research. </p>
+ <div className="col">
+ <img src="https://static.igem.wiki/teams/5247/photos/edcation-and-outreach/screenshot-2024-09-25-202008.png" style={{width:"60%", height:"70%"}}/>
+ </div>
+ </div>
+
</div>
<div id="mukomove" className="out-cycletab" style={{display: "none"}}>
<H4 id="cf-month" text="Cystic fibrosis awareness month"/>
@@ -90,6 +95,5 @@ export function HPOutreach(){
<p>The MUKOmove was therefore a complete success, and we take pride in having contributed to the goal while raising more awareness for cystic fibrosis in our region and Germany as a whole.</p>
</div>
</div>
- </div>
);
}
\ No newline at end of file
diff --git a/src/contents/Human Practices/HP svgs/hp3.tsx b/src/contents/Human Practices/HP svgs/hp3.tsx
index ea2c09c7954262468fd191b19debc1afcf0ab626..5f6dff36399db319453d1c2e389daaef80c44aba 100644
--- a/src/contents/Human Practices/HP svgs/hp3.tsx
+++ b/src/contents/Human Practices/HP svgs/hp3.tsx
@@ -1,10 +1,10 @@
+import { openClasses } from "../../../utils/openClass";
export const HP3new = () => (
<svg
viewBox="0 0 1255.0403 780"
- height={780}
width={1255.0403}
xmlSpace="preserve"
id="svg2"
@@ -1185,6 +1185,7 @@ export const HP3new = () => (
/>
<g
id="anticipate-bg"
+ className="hp3 anticipate-version"
style={{
display: "inline",
}}
@@ -1204,6 +1205,7 @@ export const HP3new = () => (
</g>
<g
id="act-bg"
+ className="hp3 act-version"
transform="translate(2.6205244,1.2265449)"
style={{
display: "inline",
@@ -1232,7 +1234,8 @@ export const HP3new = () => (
</g>
</g>
<g
- id="engange-bg"
+ id="engage-bg"
+ className="hp3 engage-version"
transform="translate(3.7202792,0.94249264)"
style={{
display: "inline",
@@ -1262,6 +1265,7 @@ export const HP3new = () => (
</g>
<g
id="reflect-bg"
+ className="hp3 reflect-version"
transform="translate(-0.02575515,3.2368515)"
style={{
display: "inline",
@@ -1327,13 +1331,14 @@ export const HP3new = () => (
/>
<g
id="anticipate"
+ className="hp3 anticipate-version"
style={{
display: "inline",
}}
- >
+ > <a onClick={openClasses({className: "hp3 anticipate-version", classtoHide: "hp3"})}>
<path
- id="path54"
+ id="anticipate-anticipate"
style={{
fill: "#b85bd1",
fillOpacity: 1,
@@ -1341,9 +1346,10 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 894.5,890.03 -6.48,-51.8 -49.57,-6.19 c 31.63,-32.57 51.12,-77.01 51.12,-126.01 0,-40.17 -13.1,-77.27 -35.24,-107.28 l 6.5,-52.11 50.2,-6.28 c 36.97,45.11 59.17,102.8 59.17,165.67 0,71.76 -28.91,136.76 -75.7,184 z"
- />
+ /> </a>
+ <a onClick={openClasses({className: "hp3 act-version", classtoHide: "hp3"})}>
<path
- id="path56"
+ id="anticipate-act"
style={{
fill: "#850e78",
fillOpacity: 1,
@@ -1352,8 +1358,10 @@ export const HP3new = () => (
}}
d="m 708.7,967.43 c -71.73,0 -136.71,-28.9 -183.94,-75.69 l 51.78,-6.48 6.19,-49.58 c 32.57,31.64 77,51.13 125.97,51.13 40.16,0 77.25,-13.1 107.25,-35.25 l 52.1,6.51 6.27,50.21 c -45.09,36.96 -102.76,59.15 -165.62,59.15 z"
/>
+ </a>
+ <a onClick={openClasses({className: "hp3 engage-version", classtoHide: "hp3"})}>
<path
- id="path58"
+ id="anticipate-engage"
style={{
fill: "#ce9fc9",
fillOpacity: 1,
@@ -1361,9 +1369,10 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 506.41,871.67 c -36.97,-45.1 -59.16,-102.79 -59.16,-165.66 0,-71.76 28.9,-136.76 75.7,-184 l 6.46,51.79 49.59,6.2 c -31.64,32.57 -51.13,77.01 -51.13,126.01 0,40.16 13.1,77.26 35.25,107.28 l -6.51,52.11 z"
- />
+ /> </a>
+ <a onClick={openClasses({className: "hp3 reflect-version", classtoHide: "hp3"})}>
<path
- id="path60"
+ id="anticipate-reflect"
style={{
fill: "#a0a7f3",
fillOpacity: 1,
@@ -1371,7 +1380,7 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 834.68,576.23 c -32.57,-31.63 -77.01,-51.12 -126.01,-51.12 -40.16,0 -77.26,13.1 -107.27,35.24 l -52.12,-6.5 -6.27,-50.2 c 45.1,-36.98 102.78,-59.17 165.66,-59.17 71.76,0 136.75,28.91 184.01,75.7 l -51.81,6.48 z"
- />
+ /> </a>
<path
id="path62"
style={{
@@ -1746,7 +1755,7 @@ export const HP3new = () => (
}}
d="m 579.06,708.6 c 0,67.3 58.08,121.86 129.72,121.86 71.64,0 129.72,-54.56 129.72,-121.86 0,-67.3 -58.08,-121.86 -129.72,-121.86 -71.64,0 -129.72,54.56 -129.72,121.86 z"
/>
- <g id="g744">
+ {/* <g id="g744">
<g clipPath="url(#clipPath750)" id="g746">
<g transform="matrix(248.64,0,0,214.56,592.56,608.04)" id="g752">
<image
@@ -1760,7 +1769,7 @@ export const HP3new = () => (
/>
</g>
</g>
- </g>
+ </g> */}
<g
id="g5"
style={{
@@ -1779,7 +1788,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -1812,7 +1821,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -1845,7 +1854,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -1911,7 +1920,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -1944,7 +1953,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -1977,7 +1986,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2010,7 +2019,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2043,7 +2052,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2076,7 +2085,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2101,14 +2110,16 @@ export const HP3new = () => (
</g>
<g
id="engage"
+ className="hp3 engage-version"
style={{
display: "inline",
}}
transform="rotate(-179.05687,708.83946,705.80079)"
>
+ <a onClick={openClasses({className: "hp3 anticipate-version", classtoHide: "hp3"})}>
<path
- id="path54-8"
+ id="engage-anticipate"
style={{
fill: "#b85bd1",
fillOpacity: 1,
@@ -2116,9 +2127,10 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 894.5,890.03 -6.48,-51.8 -49.57,-6.19 c 31.63,-32.57 51.12,-77.01 51.12,-126.01 0,-40.17 -13.1,-77.27 -35.24,-107.28 l 6.5,-52.11 50.2,-6.28 c 36.97,45.11 59.17,102.8 59.17,165.67 0,71.76 -28.91,136.76 -75.7,184 z"
- />
+ /></a>
+ <a onClick={openClasses({className: "hp3 act-version", classtoHide: "hp3"})}>
<path
- id="path56-1"
+ id="anticipate-act"
style={{
fill: "#850e78",
fillOpacity: 1,
@@ -2126,9 +2138,10 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 708.7,967.43 c -71.73,0 -136.71,-28.9 -183.94,-75.69 l 51.78,-6.48 6.19,-49.58 c 32.57,31.64 77,51.13 125.97,51.13 40.16,0 77.25,-13.1 107.25,-35.25 l 52.1,6.51 6.27,50.21 c -45.09,36.96 -102.76,59.15 -165.62,59.15 z"
- />
+ /> </a>
+ <a onClick={openClasses({className: "hp3 engage-version", classtoHide: "hp3"})}>
<path
- id="path58-0"
+ id="anticipate-engage"
style={{
fill: "#ce9fc9",
fillOpacity: 1,
@@ -2136,7 +2149,8 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 506.41,871.67 c -36.97,-45.1 -59.16,-102.79 -59.16,-165.66 0,-71.76 28.9,-136.76 75.7,-184 l 6.46,51.79 49.59,6.2 c -31.64,32.57 -51.13,77.01 -51.13,126.01 0,40.16 13.1,77.26 35.25,107.28 l -6.51,52.11 z"
- />
+ /> </a>
+ <a onClick={openClasses({className: "hp3 reflect-version", classtoHide: "hp3"})}>
<path
id="path60-3"
style={{
@@ -2146,7 +2160,7 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 834.68,576.23 c -32.57,-31.63 -77.01,-51.12 -126.01,-51.12 -40.16,0 -77.26,13.1 -107.27,35.24 l -52.12,-6.5 -6.27,-50.2 c 45.1,-36.98 102.78,-59.17 165.66,-59.17 71.76,0 136.75,28.91 184.01,75.7 l -51.81,6.48 z"
- />
+ /> </a>
<path
id="path64-44"
style={{
@@ -2400,6 +2414,21 @@ export const HP3new = () => (
d="m 916.06,598.88 -6.53,-13.33 -3.04,1.49 4.75,9.7 -3.98,1.95 -4.42,-9.03 -3.03,1.49 4.42,9.02 -4.9,2.4 -4.91,-10.05 -3.03,1.49 6.69,13.67 z"
/>
</g>
+ {/* <g id="g744-0" transform="rotate(180)" >
+ <g clipPath="url(#clipPath750)" id="g746">
+ <g transform="matrix(248.64,0,0,214.56,592.56,608.04)" id="g752">
+ <image
+ id="image758"
+ mask="url(#mask754)"
+ xlinkHref="data:image/png;base64,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"
+ transform="matrix(1,0,0,-1,0,1)"
+ preserveAspectRatio="none"
+ height={1}
+ width={1}
+ />
+ </g>
+ </g>
+ </g> */}
</g>
<path
id="path354-2"
@@ -2499,7 +2528,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2513,9 +2542,9 @@ export const HP3new = () => (
<tspan
id="tspan628"
y={0}
- x="0 11.14224 16.55304 21.001921 32.144161 42.204239 46.653118 57.795361 68.937599 80.079842 85.530724 95.55072 106.69296 113.36628 117.81516 128.9574 134.52852 144.44832 150.01944 161.16168 166.65263 172.0434 183.18564 187.63452 193.20564 198.67656 209.8188 216.5322 227.67444 238.81668 244.3878"
+ x="0"
>
- {"o include variety of different "}
+ {"to include variety of different "}
</tspan>
</text>
</g>
@@ -2533,7 +2562,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2567,7 +2596,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2601,7 +2630,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2635,7 +2664,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2669,7 +2698,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2703,7 +2732,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2733,7 +2762,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2767,7 +2796,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2801,7 +2830,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -2826,13 +2855,15 @@ export const HP3new = () => (
</g>
<g
id="reflect"
+ className="hp3 reflect-version"
style={{
display: "inline",
}}
transform="rotate(89.858097,707.83655,706.96323)"
>
+ <a onClick={openClasses({className: "hp3 anticipate-version", classtoHide: "hp3"})}>
<path
- id="path54-8-4"
+ id="reflect-anticipate"
style={{
fill: "#b85bd1",
fillOpacity: 1,
@@ -2840,9 +2871,10 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 894.5,890.03 -6.48,-51.8 -49.57,-6.19 c 31.63,-32.57 51.12,-77.01 51.12,-126.01 0,-40.17 -13.1,-77.27 -35.24,-107.28 l 6.5,-52.11 50.2,-6.28 c 36.97,45.11 59.17,102.8 59.17,165.67 0,71.76 -28.91,136.76 -75.7,184 z"
- />
+ /> </a>
+ <a onClick={openClasses({className: "hp3 act-version", classtoHide: "hp3"})}>
<path
- id="path56-1-0"
+ id="reflect-act"
style={{
fill: "#850e78",
fillOpacity: 1,
@@ -2850,9 +2882,10 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 708.7,967.43 c -71.73,0 -136.71,-28.9 -183.94,-75.69 l 51.78,-6.48 6.19,-49.58 c 32.57,31.64 77,51.13 125.97,51.13 40.16,0 77.25,-13.1 107.25,-35.25 l 52.1,6.51 6.27,50.21 c -45.09,36.96 -102.76,59.15 -165.62,59.15 z"
- />
+ /> </a>
+ <a onClick={openClasses({className: "hp3 engage-version", classtoHide: "hp3"})}>
<path
- id="path58-0-3"
+ id="reflect-engage"
style={{
fill: "#ce9fc9",
fillOpacity: 1,
@@ -2860,9 +2893,10 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 506.41,871.67 c -36.97,-45.1 -59.16,-102.79 -59.16,-165.66 0,-71.76 28.9,-136.76 75.7,-184 l 6.46,51.79 49.59,6.2 c -31.64,32.57 -51.13,77.01 -51.13,126.01 0,40.16 13.1,77.26 35.25,107.28 l -6.51,52.11 z"
- />
+ /> </a>
+ <a onClick={openClasses({className: "hp3 reflect-version", classtoHide: "hp3"})}>
<path
- id="path60-3-9"
+ id="reflect-reflect"
style={{
fill: "#a0a7f3",
fillOpacity: 1,
@@ -2870,7 +2904,7 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 834.68,576.23 c -32.57,-31.63 -77.01,-51.12 -126.01,-51.12 -40.16,0 -77.26,13.1 -107.27,35.24 l -52.12,-6.5 -6.27,-50.2 c 45.1,-36.98 102.78,-59.17 165.66,-59.17 71.76,0 136.75,28.91 184.01,75.7 l -51.81,6.48 z"
- />
+ /></a>
<path
id="path64-44-1"
style={{
@@ -3223,7 +3257,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -3257,7 +3291,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -3291,7 +3325,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -3325,7 +3359,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -3355,7 +3389,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -3423,7 +3457,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -3457,7 +3491,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -3491,7 +3525,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -3525,7 +3559,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -3553,40 +3587,21 @@ export const HP3new = () => (
display: "inline",
}}
>
- <g clipPath="url(#clipPath614)" id="g610">
- <text
- id="text618"
- style={{
- fontVariant: "normal",
- fontWeight: "normal",
- fontSize: "20.04px",
- fontFamily: "ArialMT",
-
-
- fill: "#000000",
- fillOpacity: 1,
- fillRule: "nonzero",
- stroke: "none",
- }}
- transform="matrix(1,0,0,-1,102.96,811.54)"
- >
- <tspan id="tspan616" y={0} x={0}>
- {"t"}
- </tspan>
- </text>
- </g>
+
</g>
</g>
</g>
<g
id="act"
+ className="hp3 act-version"
transform="rotate(-89.578632,709.26907,706.40575)"
style={{
display: "inline",
}}
- >
+ > <a onClick={openClasses({className: "hp3 anticipate-version", classtoHide: "hp3"})}>
<path
- id="path54-1"
+ id="act-anticipate"
+
style={{
fill: "#b85bd1",
fillOpacity: 1,
@@ -3594,9 +3609,11 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 894.5,890.03 -6.48,-51.8 -49.57,-6.19 c 31.63,-32.57 51.12,-77.01 51.12,-126.01 0,-40.17 -13.1,-77.27 -35.24,-107.28 l 6.5,-52.11 50.2,-6.28 c 36.97,45.11 59.17,102.8 59.17,165.67 0,71.76 -28.91,136.76 -75.7,184 z"
- />
+ /></a>
+ <a onClick={openClasses({className: "hp3 act-version", classtoHide: "hp3"})}>
<path
- id="path56-9"
+ id="act-act"
+
style={{
fill: "#850e78",
fillOpacity: 1,
@@ -3604,9 +3621,11 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 708.7,967.43 c -71.73,0 -136.71,-28.9 -183.94,-75.69 l 51.78,-6.48 6.19,-49.58 c 32.57,31.64 77,51.13 125.97,51.13 40.16,0 77.25,-13.1 107.25,-35.25 l 52.1,6.51 6.27,50.21 c -45.09,36.96 -102.76,59.15 -165.62,59.15 z"
- />
+ /> </a>
+ <a onClick={openClasses({className: "hp3 engage-version", classtoHide: "hp3"})}>
<path
- id="path58-4"
+ id="act-engage"
+
style={{
fill: "#ce9fc9",
fillOpacity: 1,
@@ -3614,9 +3633,11 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 506.41,871.67 c -36.97,-45.1 -59.16,-102.79 -59.16,-165.66 0,-71.76 28.9,-136.76 75.7,-184 l 6.46,51.79 49.59,6.2 c -31.64,32.57 -51.13,77.01 -51.13,126.01 0,40.16 13.1,77.26 35.25,107.28 l -6.51,52.11 z"
- />
+ /> </a>
+ <a onClick={openClasses({className: "hp3 reflect-version", classtoHide: "hp3"})}>
<path
- id="path60-7"
+ id="act-reflect"
+
style={{
fill: "#a0a7f3",
fillOpacity: 1,
@@ -3624,9 +3645,10 @@ export const HP3new = () => (
stroke: "none",
}}
d="m 834.68,576.23 c -32.57,-31.63 -77.01,-51.12 -126.01,-51.12 -40.16,0 -77.26,13.1 -107.27,35.24 l -52.12,-6.5 -6.27,-50.2 c 45.1,-36.98 102.78,-59.17 165.66,-59.17 71.76,0 136.75,28.91 184.01,75.7 l -51.81,6.48 z"
- />
+ /> </a>
<path
id="path62-8"
+
style={{
fill: "#FFF6F2",
fillOpacity: 1,
@@ -3637,6 +3659,7 @@ export const HP3new = () => (
/>
<path
id="path64-4"
+
style={{
fill: "#000000",
fillOpacity: 1,
@@ -3647,6 +3670,7 @@ export const HP3new = () => (
/>
<path
id="path66-5"
+
style={{
fill: "#000000",
fillOpacity: 1,
@@ -3657,6 +3681,7 @@ export const HP3new = () => (
/>
<path
id="path68-0"
+
style={{
fill: "#000000",
fillOpacity: 1,
@@ -3668,6 +3693,7 @@ export const HP3new = () => (
<g id="g70-3">
<g clipPath="url(#clipPath76-3)" id="g72-6">
<path
+
id="path78-1"
style={{
fill: "#000000",
@@ -3682,6 +3708,7 @@ export const HP3new = () => (
<g id="g80-0">
<g clipPath="url(#clipPath86-7)" id="g82-6">
<path
+
id="path88-3"
style={{
fill: "#000000",
@@ -3696,6 +3723,7 @@ export const HP3new = () => (
<g id="g90-2">
<g clipPath="url(#clipPath96-3)" id="g92-0">
<path
+
id="path98-6"
style={{
fill: "#000000",
@@ -3711,6 +3739,7 @@ export const HP3new = () => (
<g clipPath="url(#clipPath106-6)" id="g102-5">
<path
id="path108-5"
+
style={{
fill: "#000000",
fillOpacity: 1,
@@ -3725,6 +3754,7 @@ export const HP3new = () => (
<g clipPath="url(#clipPath116-9)" id="g112-7">
<path
id="path118-6"
+
style={{
fill: "#000000",
fillOpacity: 1,
@@ -3739,6 +3769,7 @@ export const HP3new = () => (
<g clipPath="url(#clipPath126-2)" id="g122-6">
<path
id="path128-9"
+
style={{
fill: "#000000",
fillOpacity: 1,
@@ -3753,6 +3784,7 @@ export const HP3new = () => (
<g clipPath="url(#clipPath136-0)" id="g132-7">
<path
id="path138-4"
+
style={{
fill: "#000000",
fillOpacity: 1,
@@ -3767,6 +3799,7 @@ export const HP3new = () => (
<g clipPath="url(#clipPath146-3)" id="g142-2">
<path
id="path148-5"
+
style={{
fill: "#000000",
fillOpacity: 1,
@@ -3781,6 +3814,7 @@ export const HP3new = () => (
<g clipPath="url(#clipPath156-0)" id="g152-7">
<path
id="path158-4"
+
style={{
fill: "#000000",
fillOpacity: 1,
@@ -3975,6 +4009,7 @@ export const HP3new = () => (
/>
<g
id="act-text"
+ className="hp3 act-version"
style={{
display: "inline",
}}
@@ -3987,7 +4022,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -4015,7 +4050,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -4043,7 +4078,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -4071,7 +4106,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -4099,7 +4134,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -4127,7 +4162,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -4155,7 +4190,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -4183,7 +4218,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
@@ -4211,7 +4246,7 @@ export const HP3new = () => (
style={{
fontVariant: "normal",
fontWeight: "normal",
- fontSize: "20.04px",
+ fontSize: "20px",
fontFamily: "ArialMT",
diff --git a/src/contents/Human Practices/HP svgs/hp4.tsx b/src/contents/Human Practices/HP svgs/hp4.tsx
index 124cc3bd8a103085ae0a2aaa0d0f686c5b7a7ebe..1d238bc856e68f40e9a6a7543cdf9656d7e00b9e 100644
--- a/src/contents/Human Practices/HP svgs/hp4.tsx
+++ b/src/contents/Human Practices/HP svgs/hp4.tsx
@@ -1,3 +1,4 @@
+/* <a onClick={openElement({elementToOpen: "under-responsibility", classToHide: "understandingtab"})}> */
const HP4 = () => (
<svg
diff --git a/src/contents/Human Practices/IHP.tsx b/src/contents/Human Practices/IHP.tsx
index 97f69898c690a0f9c0b8bb0e98dc856ffecdfb7f..b52c4325db0251fefb74bfd03f7f7ed30ed51aed 100644
--- a/src/contents/Human Practices/IHP.tsx
+++ b/src/contents/Human Practices/IHP.tsx
@@ -3,7 +3,6 @@ import { HPTimeline } from "../../components/HP-timeline";
import { LoremMedium, LoremShort } from "../../components/Loremipsum";
import { Section, Subesction } from "../../components/sections";
import { HP3new } from "./HP svgs/hp3";
-import HP4 from "./HP svgs/hp4";
import { HPUnderstanding } from "./HP svgs/understanding";
export function HPIntegrated(){
@@ -55,7 +54,7 @@ export function HPIntegrated(){
</div>
</div>
<div className="col framecycletab" id="mendelow" style={{display: "none"}}>
- <HP3new/>
+
</div>
<div className="col framecycletab" id="swot" style={{display: "none"}}>
@@ -99,7 +98,13 @@ export function HPIntegrated(){
<div className="col framecycletab" id="thirdparty" style={{display: "none"}}>
none
</div>
- <div className="col framecycletab" id="feedcycle" style={{display: "none"}}><HP4/> </div>
+ <div className="col framecycletab" id="feedcycle" style={{display: "none"}}>
+ <div id="hp3-wrapper">
+ <div className="col">
+ <HP3new/>
+ </div>
+ </div>
+ </div>
<div className="col framecycletab" id="refcycle" style={{display: "none"}}>refcycle </div>
</Subesction>
<Subesction title="Timeline" id="Integrated Human Practices2">
diff --git a/src/contents/description.tsx b/src/contents/description.tsx
index a1c88c47dde56b13ff0bf4cd744ac75aba34b6b0..71f65bb142f07756a9c82c2d3676711962cb7b4c 100644
--- a/src/contents/description.tsx
+++ b/src/contents/description.tsx
@@ -11,7 +11,6 @@ import PieChart from "../components/Graph";
import PreCyse from "../components/precyse";
import { Section, Subesction } from "../components/sections";
-import { stringToSlug } from "../utils";
import { symptomdata, SymptomDatensatz } from "../data/symptom-data";
import { drugdata, DrugDatensatz } from "../data/drug-data";
import { useTabNavigation } from "../utils/TabNavigation";
@@ -25,6 +24,17 @@ export function Description() {
<Section title="Abstract" id="Abstract">
<p id="obenindescription" >We are proud to introduce our next-generation prime editing technology <PreCyse/> . We aim to develop an innovative gene therapy against cystic fibrosis, tackling the most common mutation ΔF508 of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. We optimize lipid nanoparticles (LNPs) for the efficient and cell-specific delivery of our therapeutic mRNA. Current treatment strategies are limited in terms of speed, precision and effectiveness, often failing to achieve long-lasting improvements. In addition, high costs and limited accessibility of pharmaceuticals contribute to adverse prognosis of many patients. We want to develop a monthly applied which represents a cure that is more advanced and user-friendly compared to other medications due to its longer lasting time, lowering the frequency of use. </p>
</Section>
+ <Section title="Our Motivation" id="Our Motivation">
+ <p>We chose to focus on CF and specifically the ΔF508 mutation due to its prevalence and the severe impact it has on patients' lives. Additionally, our team includes members who have close friends affected by this condition, giving us a personal connection and a strong motivation to find a solution. By targeting the ΔF508 mutation, we aim to develop a therapy that could potentially, not only benefit many CF patients and make a significant improvement in their lives, but also can serve as a template, which research groups can use to target other genetic diseases. </p>
+ <div className="row align-items-center">
+ <div className="col" >
+ </div>
+ <div className="col" >
+ <img className="img" src="https://static.igem.wiki/teams/5247/placeholders/placehilderperson.jpeg"/>
+ </div>
+ </div>
+ <p>Max</p>
+ </Section>
<Section title="Cystic Fibrosis" id="Cystic Fibrosis">
<Subesction title="Overview" id="Cystic Fibrosis1">
<div className="row align-items-center">
@@ -32,6 +42,13 @@ export function Description() {
<p data-aos="zoom-y-out" >Cystic fibrosis (CF) is the most common life-limiting genetic disorder in the Caucasian population. In Europe, CF affecting about 1 in 3,000 newborns
<SupScrollLink label="1"/>.</p>
<p> It is caused by mutations in the CFTR gene, which controls ions and water movement in cells. This leads to thick mucus, clogging airways, and frequent infections. The defective CFTR protein impacts the respiratory and digestive systems, causing chronic lung infections, breathing difficulties, and malnutrition. CF's severity varies, but it reduces life quality and expectancy. There are over 1,700 CFTR mutations; the ΔF508 mutation is most common, present in 70% of cases. It prevents proper protein folding, affecting its function. </p>
+ <Collapsible id="fanzorcas-collapsible" title="Cas vs. Fanzor">
+ <p>The mutations can be divided into six classes [9]:</p>
+ <p>Class I mutations prevent the synthesis of CFTR proteins altogether, meaning no channels are produced.</p>
+ <p>Class II mutations, which include the common F508del mutation (responsible for about 85% of cases [10]), disrupt the maturation process of the protein. As a result, the defective channels are quickly degraded by the cell.</p>
+ <p>Class III mutations, known as “gating†mutations, reduce the likelihood that the CFTR channel will open correctly, impairing its function.</p>
+ <p>Class IV, V, and VI mutations are rare. These mutations result in the production of unstable or inefficient CFTR proteins, which do not function adequately and are produced in insufficient numbers.</p>
+ </Collapsible>
<p><LoremMedium/></p>
</div>
<div className="row-if-small col-2 ">
@@ -63,7 +80,9 @@ export function Description() {
</div>
<div className="col">
<p>Text about CFTR <LoremMedium/></p>
- <img src="https://static.igem.wiki/teams/5247/fanzor/cftr.gif"></img>
+ <div className="col gif-wrapper">
+ <img className="fanzor gif" src="https://static.igem.wiki/teams/5247/fanzor/cftr-wt.gif"></img>
+ </div>
</div>
</div>
</Subesction>
@@ -77,8 +96,7 @@ export function Description() {
<p>It is a deletion of the three nucleotides "CTT" at position 508, which removes the phenylalanine residue
without causing a frameshift. This deletion leads to defects in the kinetic and thermodynamic folding
of the NBD1 domain <SupScrollLink label="16"/>. However, this not only leads to misfolding of CFTR but also to defects in
- trafficking and premature degradation, resulting in reduced surface expression of CFTR <SupScrollLink label="17"/>. </p>
-
+ trafficking and premature degradation, resulting in reduced surface expression of CFTR <SupScrollLink label="17"/>. </p>
<div className="row">
<div className="col">
<img src="https://static.igem.wiki/teams/5247/charts-maps/cfper10-000.png"/>
@@ -91,7 +109,7 @@ export function Description() {
</Subesction>
<Subesction title="Symptoms" id="Cystic Fibrosis4">
- <p>Text about symptoms</p>
+ <p>Since the CFTR gene is expressed in nearly all tissues of the human body, cystic fibrosis affects as a metabolic disease a wide range of vital organs.</p>
<Collapsible id="symptoms-collapsible" title="How the symptoms affect different parts of the body" >
<TabButtonRow data={symptombuttonrowdata} opentype="meditabs" closing=""/>
<ButtonRowTabs data={symptombuttonrowdata} cla="meditabs"/>
@@ -110,27 +128,18 @@ export function Description() {
</div>
</Subesction>
<Subesction title="Treatment" id="Cystic Fibrosis6">
- <img src="https://static.igem.wiki/teams/5247/placeholders/placehilderperson.jpeg"/>
+ <p>Cystic fibrosis therapy means inevitably a complex and customized treatment plan for each patient. It consists of a range of components. These include medication such as CFTR modulators and antibiotics as well as inhalation therapy and mucolytics, physiotherapy, nutritional therapy and sports therapy. It is therefore essential that CF patients receive treatment at a specialist centre [1].</p>
<Collapsible id="drugs-collapsible" title="Different types of drugs" >
<TabButtonRow data={medibuttonrowdata} opentype="symptabs" closing=""/>
<ButtonRowTabs data={medibuttonrowdata} cla="symptabs"/>
</Collapsible>
- <p>Why we still need other options</p>
+ <H2 text="CF treatment with gene therapy"></H2>
+ <p>While mentioned medications have improved the quality of life for numerous CF patients, they only manage symptoms rather than cure the disease. Moreover, most of them are expensive and not world-wide accessible. Our research is focused on the development of a gene therapy that targets the underlying cause of CF by correcting the defective CFTR gene. <PreCyse/> aims to halt disease progression and reduce the treatment burden for patients.</p>
<img src="https://static.igem.wiki/teams/5247/charts-maps/cfper10-000.png"/>
</Subesction>
</Section>
- <Section title="Our Motivation" id="Our Motivation">
- <p>We chose to focus on CF and specifically the ΔF508 mutation due to its prevalence and the severe impact it has on patients' lives. Additionally, our team includes members who have close friends affected by this condition, giving us a personal connection and a strong motivation to find a solution. By targeting the ΔF508 mutation, we aim to develop a therapy that could potentially, not only benefit many CF patients and make a significant improvement in their lives, but also can serve as a template, which research groups can use to target other genetic diseases. </p>
- <div className="row align-items-center">
- <div className="col" >
- </div>
- <div className="col" >
- <img className="img" src="https://static.igem.wiki/teams/5247/placeholders/placehilderperson.jpeg"/>
- </div>
- </div>
- <p>Max</p>
- </Section>
<Section title="Approach" id="Approach">
+ <Subesction title="Mechanism" id="Approach1">
<p>To correct the mutation, we are utilizing Prime Editing technologies. Prime Editing is a genome editing technique that allows precise DNA modifications without causing double-strand breaks<SupScrollLink label="2"/>. Structurally, the Prime Editing complex consists of a Cas9 endonuclease fused to a reverse transcriptase (RT) and guided by a pegRNA, which directs the complex to the target site in the genome. </p>
<InfoBox title="Prime Editing" id="prime-editing">
<details>
@@ -150,22 +159,25 @@ export function Description() {
<Collapsible id="fanzorcas-collapsible" title="Cas vs. Fanzor"> child </Collapsible>
<p>The pegRNA is optimized via an extension by a stem loop, which stabilizes the RNA by protecting it from RNases and serves as a binding site for the MCP, which also supports the secondary RNA structure.
This represents a major biosafety feature in that the complex is switched off after successful DNA editing and the subsequent increased influx of chloride ions into the cell. The pegRNA is combined with an optimized sgRNA resulting in higher on-target effect. Overall, its optimization leads to a longer shelf life and an increase in the biosafety of the complex. </p>
- </Section>
- <Section title="Delivery" id="Delivery">
+
+ </Subesction>
+ <Subesction title="Delivery" id="Approach2">
<img className="img-left img-half spin" src="https://static.igem.wiki/teams/5247/scientific-figures/lnp.png" height={"200vw"}/>
- <div>
- <p>We chose LNPs as the delivery system of our Next-Generation Prime Editing Technology. Because of their large capacity and less immunogenic side effects compared to other delivery systems like Adeno-associated Viruses (AVV)<SupScrollLink label="6"/>. Our aim is to optimize the LNP formulation to improve delivery to lung tissue via inhalation. Because of our collaborations, we are able to test and optimize different delivery systems to improve our organ specific therapeutic approach. Therefore, our LNP design focusses on stability and targeting. Stability is achieved by a polyethylene glycol (PEG) coating that protects the LNPs from degradation by the immune system<SupScrollLink label="7"/>. Moreover, we use capsaicin in combination with chitosan to improve the uptake of our construct through their mucus-adhesive properties<SupScrollLink label="8"/>. </p>
- </div>
- <div className="row align-items-center">
- <div className="col">
- Lagertemperatur der Parts <LoremShort/>
+ <div>
+ <p>We chose LNPs as the delivery system of our Next-Generation Prime Editing Technology. Because of their large capacity and less immunogenic side effects compared to other delivery systems like Adeno-associated Viruses (AVV)<SupScrollLink label="6"/>. Our aim is to optimize the LNP formulation to improve delivery to lung tissue via inhalation. Because of our collaborations, we are able to test and optimize different delivery systems to improve our organ specific therapeutic approach. Therefore, our LNP design focusses on stability and targeting. Stability is achieved by a polyethylene glycol (PEG) coating that protects the LNPs from degradation by the immune system<SupScrollLink label="7"/>. Moreover, we use capsaicin in combination with chitosan to improve the uptake of our construct through their mucus-adhesive properties<SupScrollLink label="8"/>. </p>
</div>
- <div className="col">
- Trocknung <LoremShort/>
- </div>
- </div>
- <br/>
- <p>We are furthermore optimising the LNPs for pulmonary therapy and investigating delivery by nebulisation as a non-invasive method compared to systemic approaches to make the therapy more convenient for patients. For specific targeting, we are focussing on marker proteins of basal cells and ionocytes that produce particularly high levels of CFTR protein and which we want to target with appropriate antibodies<SupScrollLink label="9"/>. Our workflow includes testing our next generation Prime Editing Technology delivered by our optimized LNPs in cell culture lines but also in primary nasal epithelial cells of CF patients to evaluate our optimizations and further improvements in vitro. We can also provide the outlook on the adaptation of the delivery system enabling systemic applications as well. </p>
+ <div className="row align-items-center">
+ <div className="col">
+ Lagertemperatur der Parts <LoremShort/>
+ </div>
+ <div className="col">
+ Trocknung <LoremShort/>
+ </div>
+ </div>
+ <br/>
+ <p>We are furthermore optimising the LNPs for pulmonary therapy and investigating delivery by nebulisation as a non-invasive method compared to systemic approaches to make the therapy more convenient for patients. For specific targeting, we are focussing on marker proteins of basal cells and ionocytes that produce particularly high levels of CFTR protein and which we want to target with appropriate antibodies<SupScrollLink label="9"/>. Our workflow includes testing our next generation Prime Editing Technology delivered by our optimized LNPs in cell culture lines but also in primary nasal epithelial cells of CF patients to evaluate our optimizations and further improvements in vitro. We can also provide the outlook on the adaptation of the delivery system enabling systemic applications as well. </p>
+
+ </Subesction>
</Section>
<Section title="Our Vision" id="Our Vision">
<p>We are envisioning a potential integration into a broader therapeutic framework involving customized gene editing tools for various genetic disorders, that present similar problems/difficulties to the F508del mutation, as well as other genetic diseases of different causes. This could include collaborations with pharmaceutical companies to develop new treatment modalities for genetic diseases beyond cystic fibrosis, utilizing advanced delivery systems and personalized medicine approaches. </p>
@@ -476,20 +488,25 @@ export function Description() {
let medibuttonrowdata =[
{
node: createDrugSteckbrief(drugdata[0]),
- buttonname: "About",
+ buttonname: "Modulators",
cssname: "Med-First",
main: true
},
{
node: createDrugSteckbrief(drugdata[1]),
- buttonname: "Modulators",
- cssname: "modulators"
+ buttonname: "Mucolytics",
+ cssname: "Mucolytics"
},
{
node: createDrugSteckbrief(drugdata[2]),
- buttonname: "Inhalations",
- cssname: "inhalations"
+ buttonname: "Antibiotics",
+ cssname: "Antibiotics"
+ },
+ {
+ node: createDrugSteckbrief(drugdata[3]),
+ buttonname: "Enzymes",
+ cssname: "Enzymes"
},
]
@@ -498,25 +515,51 @@ export function Description() {
let symptombuttonrowdata = [
{
node: createSymptomSteckbrief(symptomdata[0]),
- buttonname: "About",
+ buttonname: "Pancreas",
cssname: "Symp-First",
main: true
},
{
node: createSymptomSteckbrief(symptomdata[1]),
+ buttonname: "Intestines",
+ cssname: "intestines"
+ },
+ {
+ node: createSymptomSteckbrief(symptomdata[2]),
+ buttonname: "Liver",
+ cssname: "liver"
+ },
+ {
+ node: createSymptomSteckbrief(symptomdata[3]),
+ buttonname: "Sexual glands",
+ cssname: "Sexual glands"
+ },
+ {
+ node: createSymptomSteckbrief(symptomdata[4]),
buttonname: "Lungs",
cssname: "lungs"
},
{
- node: createSymptomSteckbrief(symptomdata[2]),
- buttonname: "Pancreas",
- cssname: "pancreas"
+ node: createSymptomSteckbrief(symptomdata[5]),
+ buttonname: "Skeletal System",
+ cssname: "Skeletal System"
},
{
- node: <H4 id="mental-btn" text="Mental Health"/>,
- buttonname: "Mental Health",
- cssname: "mental"
+ node: createSymptomSteckbrief(symptomdata[6]),
+ buttonname: "Skin",
+ cssname: "skin"
},
+ {
+ node: createSymptomSteckbrief(symptomdata[7]),
+ buttonname: "Nasal mucosa",
+ cssname: "Nasal mucosa"
+ },
+ {
+ node: createSymptomSteckbrief(symptomdata[8]),
+ buttonname: "Brain",
+ cssname: "brain"
+ },
+
]
@@ -524,23 +567,15 @@ let symptombuttonrowdata = [
function createSymptomSteckbrief(data: SymptomDatensatz){
let examplelist = [];
- for (let index = 0; index < data.subsections.length; index++) {
- let absaetze = []
- for (let i = 0; i < data.subsections[index].text.length; i++) {
- absaetze.push(
- <p>{data.subsections[index].text[i]}</p>
+ for (let index = 0; index < data.introduction.length; index++) {
+ examplelist.push(
+ <li>{data.introduction[index]}</li>
)
- }
- examplelist.push(
- <div className="drug">
- <H4 text={data.subsections[index].title}/>
- <p>{data.subsections[index].text}</p>
- </div>
- )
+
}
return(
<div>
- <H4 id={`${data.name}-btn`} text={stringToSlug(data.name)}/>
+ <H4 id={`${data.name}-btn`} text={data.name}/>
<div className="row">
<div className="col-2">
<div className="symptom-img-wrapper">
@@ -548,14 +583,11 @@ function createSymptomSteckbrief(data: SymptomDatensatz){
</div>
</div>
<div className="col">
- {data.introduction}
+ <ul>{examplelist}</ul>
</div>
</div>
- <div className="col">
- {examplelist}
- </div>
</div>
)
}
@@ -567,21 +599,21 @@ function createDrugSteckbrief(data: DrugDatensatz){
let absaetze = []
for (let i = 0; i < data.examples[index].text.length; i++) {
absaetze.push(
- <p>{data.examples[index].text[i]}</p>
+ <li>{data.examples[index].text[i]}</li>
)
}
examplelist.push(
<div className="drug">
<H4 text={data.examples[index].title}/>
- <p>{data.examples[index].text}</p>
+ <ul>{absaetze}</ul>
</div>
)
}
return(
<div>
- <H4 id={`${data.name}-btn`} text={stringToSlug(data.name)}/>
+ <H4 id={`${data.name}-btn`} text={data.name}/>
<div className="row">
<div className="col-2">
<div className="symptom-img-wrapper">
diff --git a/src/contents/engineering.tsx b/src/contents/engineering.tsx
index 2fd73c3f2ff7a00a5ac7d7751445da4748380442..dc13142a8d3c97d6a27277d1a15aaf3c607fa3ec 100644
--- a/src/contents/engineering.tsx
+++ b/src/contents/engineering.tsx
@@ -17,7 +17,7 @@ export function Engineering() {
<br/> <br/> <br/>
<div id="tab-our-cycle" className="enginneeringtab" style={{display: "block"}}>
<section > <br id="obenengineering"/>
- <div className="bg-lb box" >
+ <div className="eng-box box" >
<H3 text="Our cycle" id="ourcycle"></H3>
<p>Hallo Prime Editing diesdas</p>
</div>
@@ -36,7 +36,7 @@ export function Engineering() {
<div id="tab-proof-of-concept" className="enginneeringtab" style={{display: "none"}}>
<section >
- <div className="bg-lb box" >
+ <div className="eng-box box" >
<H3 id="Proof of Concept" text="Proof of Concept"></H3>
<p>To test prime editors, a reliable model system is required. HEK293 cells are a human derived cell line and widely used in a variety of fields in biology[1]. Apart from easy handling and comparatively easy transfection, they have, as we found out in our exchange with Mattijs Bulcaen, one advantage over other models: They are naturally impaired in DNA repair mechanisms and therefore easier to edit. To properly compare editing efficiencies, a high transfection efficiency is of utmost importance. This engineering cycle focuses on our work in simulating prime editing using the PEAR reporter system[2] and optimizing transfection protocols.</p>
</div>
@@ -109,7 +109,7 @@ export function Engineering() {
<div className="enginneeringtab" id="tab-pe-systems" style={{display: "none"}}>
<section id="PE Systems sec" >
- <div className="bg-lb box" >
+ <div className="eng-box box" >
<H3 id="PE Systems" text="PE Systems"></H3>
<p><LoremShort></LoremShort></p>
</div>
@@ -165,7 +165,7 @@ export function Engineering() {
</div>
<div className="enginneeringtab" id="tab-nikase" style={{display: "none"}}>
<section id="Nikase sec" >
- <div className="bg-lb box" >
+ <div className="eng-box box" >
<H3 id="Nikase" text="Nikase"></H3>
<p><LoremShort></LoremShort></p>
<img src="https://static.igem.wiki/teams/5247/fanzor/movie4-ezgif-com-video-to-gif-converter.gif"></img>
@@ -232,7 +232,7 @@ export function Engineering() {
</div>
<div className="enginneeringtab" id="tab-pegrna" style={{display: "none"}}>
<section id="pegRNA sec" >
- <div className="bg-lb box" >
+ <div className="eng-box box" >
<H3 id="pegRNA" text="pegRNA"></H3>
<p><LoremShort></LoremShort></p>
</div>
@@ -297,7 +297,7 @@ export function Engineering() {
</div>
<div className="enginneeringtab" id="tab-delivery" style={{display: "none"}}>
<section id="Delivery sec" >
- <div className="bg-lb box" >
+ <div className="eng-box box" >
<H3 id="Delivery" text="Delivery"></H3>
<p><LoremShort></LoremShort></p>
</div>
@@ -339,7 +339,7 @@ export function Engineering() {
<div className="enginneeringtab" id="tab-references" style={{display: "none"}}>
<section id="References sec" >
- <div className="bg-lb box" >
+ <div className="eng-box box" >
<H3 id="References" text="References"></H3>
<p><LoremShort></LoremShort></p>
</div>
diff --git a/src/contents/igem-bielefeld.tsx b/src/contents/igem-bielefeld.tsx
index dff96585ae3cc85753eb6650c702b230d807b6af..27868d2e511c409ee2f51b5165c76f0ec1e8c882 100644
--- a/src/contents/igem-bielefeld.tsx
+++ b/src/contents/igem-bielefeld.tsx
@@ -9,20 +9,22 @@ export function igemBielefeld() {
return (
<>
<Section title="History" id="History">
+ <div className="row">
+ <div className="col">
+ <img src="https://static.igem.wiki/teams/5247/sponsors/uni-bielefeld-dunkel.png" style={{width:"50%", height:"50%"}}/>
+ </div>
+ <div className="col">
+ <img src="https://static.igem.wiki/teams/5247/sponsors/cebitec-logo-hinterlegt.png" style={{width:"50%", height:"50%"}}/>
+ </div>
+ </div>
+ <br/>
<p>The glorious history of the iGEM team Bielefeld began in 2010 and marked its debut on the global stage
- of synthetic biology. Since then, the teams were composed of over 160 enthusiastic students from various disciplines, including biology, chemistry, and engineering. Their initial project focused on the development of a biosensor for the measurement of spiciness in food, which resulted in the team being awarded a gold medal at the competition. Following this successful debut, the teams continued to evolve, both in size and expertise.
-
-Over more than ten years, the iGEM Team Bielefeld-CeBiTec engaged in a multitude of projects, each pushing the boundaries of synthetic biology. The teams earned 13 gold medals and have achieved a ranking within the top 16 teams twice (2011, 2012). One of the most notable achievements was reached in 2013, when the iGEM Team Bielefeld won the European Jamboree, were the First Runner Up at the Giant Jamboree and secured several Track and Special Prizes. Their project “Ecolectricity†focused on creating a microbial fuel cell, by transforming E. coli into an electro-active bacterium and incorporating it into a fuel cell that provides an environmentally friendly alternative for generating electricity. Their innovative approach and careful execution impressed the jury and solidified the Bielefeld team's reputation in the iGEM community. In acknowledgment of the pivotal role played by the Center for Biotechnology (CeBiTec) in the team’s success since the beginning, the name of the team was officially changed to Bielefeld-CeBiTec in 2014. This change highlighted the close collaboration between the team and the research center, thereby underscoring the importance of institutional support in advancing scientific research and education related to the iGEM competition.
-
-In recent years, the teams continued to pursue innovative avenues of enquiry. Their projects ranged from developing biological systems for medical applications to creating sustainable solutions for industrial and environmental challenges. For instance, in 2018, the project "nanoFactory" aimed to scavenge heavy metal ions using optimized E. coli cells to accumulate heavy metal ions inside the cytoplasm addressing the issue of increasing scarcity of metal resources due to global consumption of electronics.
-
-In the previous year, the iGEM team Bielefeld-CeBiTec developed a platform for diagnosis and therapy of brain tumors called "ASTERISK". The team focusing on a modular genetic system to target gliomas by designing mRNA molecules that, upon detection of a tumor-specific mutation or amplification, lead to the translation of a toxic protein that selectively kills cancer cells without harming healthy cells. This innovative approach is a perfect example of how synthetic biology can be used to improve the specificity and efficacy of medical treatments, providing valuable tools to the iGEM community.
-
-A significant aspect of iGEM Bielefeld-CeBiTec’s success has been their emphasis on collaboration and community engagement. The team regularly collaborates with other iGEM teams, institutions, companies, and scientists sharing knowledge and resources. They also engage with the local community through outreach programs and workshops.
-
-
-
-The history of iGEM Bielefeld is a story of motivation, dedication, and scientific curiosity. From their early beginnings to their current endeavors, the team has consistently demonstrated the power of synthetic biology to tackle complex global challenges. As they continue to participate in the iGEM competition, they remain to demonstrate innovation and collaboration within the scientific community. </p>
+ of synthetic biology. Since then, the teams were composed of over 160 enthusiastic students from various disciplines, including biology, chemistry, and engineering.</p>
+ <p>Their initial project focused on the development of a biosensor for the measurement of spiciness in food, which resulted in the team being awarded a gold medal at the competition. Following this successful debut, the teams continued to evolve, both in size and expertise.
+ Over more than ten years, the iGEM Team Bielefeld-CeBiTec engaged in a multitude of projects, each pushing the boundaries of synthetic biology. The teams earned 13 gold medals and have achieved a ranking within the top 16 teams twice (2011, 2012). One of the most notable achievements was reached in 2013, when the iGEM Team Bielefeld won the European Jamboree, were the First Runner Up at the Giant Jamboree and secured several Track and Special Prizes. Their project “Ecolectricity†focused on creating a microbial fuel cell, by transforming E. coli into an electro-active bacterium and incorporating it into a fuel cell that provides an environmentally friendly alternative for generating electricity. Their innovative approach and careful execution impressed the jury and solidified the Bielefeld team's reputation in the iGEM community. In acknowledgment of the pivotal role played by the Center for Biotechnology (CeBiTec) in the team’s success since the beginning, the name of the team was officially changed to Bielefeld-CeBiTec in 2014. This change highlighted the close collaboration between the team and the research center, thereby underscoring the importance of institutional support in advancing scientific research and education related to the iGEM competition.</p>
+ <p>In recent years, the teams continued to pursue innovative avenues of enquiry. Their projects ranged from developing biological systems for medical applications to creating sustainable solutions for industrial and environmental challenges. For instance, in 2018, the project "nanoFactory" aimed to scavenge heavy metal ions using optimized E. coli cells to accumulate heavy metal ions inside the cytoplasm addressing the issue of increasing scarcity of metal resources due to global consumption of electronics.
+ In the previous year, the iGEM team Bielefeld-CeBiTec developed a platform for diagnosis and therapy of brain tumors called "ASTERISK". The team focusing on a modular genetic system to target gliomas by designing mRNA molecules that, upon detection of a tumor-specific mutation or amplification, lead to the translation of a toxic protein that selectively kills cancer cells without harming healthy cells. This innovative approach is a perfect example of how synthetic biology can be used to improve the specificity and efficacy of medical treatments, providing valuable tools to the iGEM community.</p>
+ <p>A significant aspect of iGEM Bielefeld-CeBiTec’s success has been their emphasis on collaboration and community engagement. The team regularly collaborates with other iGEM teams, institutions, companies, and scientists sharing knowledge and resources. They also engage with the local community through outreach programs and workshops. he history of iGEM Bielefeld is a story of motivation, dedication, and scientific curiosity. From their early beginnings to their current endeavors, the team has consistently demonstrated the power of synthetic biology to tackle complex global challenges. As they continue to participate in the iGEM competition, they remain to demonstrate innovation and collaboration within the scientific community.</p>
</Section>
diff --git a/src/contents/parts.tsx b/src/contents/parts.tsx
index 8707ab369a0d1c21fbc34ac2056c8894df8de0c6..02ae30de9bc49ac8372b33aab6d860ce32cbc887 100644
--- a/src/contents/parts.tsx
+++ b/src/contents/parts.tsx
@@ -1,9 +1,12 @@
import { LoremMedium } from "../components/Loremipsum";
import { Section, Subesction } from "../components/sections";
+import { PartTable } from "../components/Table";
import { useTabNavigation } from "../utils/TabNavigation";
+import { BasicParts, CompositeParts } from "../data/parts";
export function Parts() {
useTabNavigation();
+ let headcols = ["Part Name", "Registry Code", "Part Description", "length [bp]", "type"]
return (
<div className="col">
<Section title="Introduction" id="Introduction">
@@ -38,10 +41,10 @@ export function Parts() {
<LoremMedium/>
</Subesction>
<Subesction title="Basic Parts" id="Parts Collection2">
- <LoremMedium/>
+ <PartTable cols={headcols} data={BasicParts}/>
</Subesction>
<Subesction title="Composite Parts" id="Parts Collection3">
- <LoremMedium/>
+ <PartTable cols={headcols} data={CompositeParts}/>
</Subesction>
</Section>
</div>
diff --git a/src/contents/safety.tsx b/src/contents/safety.tsx
index b3685caaadaea00bea07346901bb0d4b96d7a04d..6391ef14df1220c3c194d2a6a966f8261f29aa8b 100644
--- a/src/contents/safety.tsx
+++ b/src/contents/safety.tsx
@@ -1,10 +1,11 @@
-import { H4 } from "../components/Headings";
+import { H4, H5 } from "../components/Headings";
import { LoremMedium } from "../components/Loremipsum";
import { SupScrollLink } from "../components/ScrollLink";
import { Section, Subesction } from "../components/sections";
import { useTabNavigation } from "../utils/TabNavigation";
+// message for test commit.
export const Safety: React.FC = () =>{
@@ -13,7 +14,32 @@ export const Safety: React.FC = () =>{
return (
<>
<Section title="Role in iGEM" id="Role">
- <LoremMedium/>
+ <p>
+ As part of our project to develop a prime-editing complex to correct the F508del mutation in cystic fibrosis, we place great emphasis on safety at all stages of research. Our final construct will be tested in primary cultures of epithelial cells obtained from nasal swabs, isolated from both patients and healthy individuals. from nasal swabs [link primär Kulturen]. To guarantee safety and ensure the highest level of precision and reliability of our results, we have introduced a series of carefully planned checkpoints during the experiments. These milestones allow for continuous monitoring, timely adjustments and validation at each critical stage. This ensures that potential issues are identified and addressed immediately, minimizing risk and improving the overall quality of the experimental results. [link zu den Experimenten]
+ </p>
+ </Section>
+ <Section title="Check-Ins" id="Check-Ins">
+ <div>
+ <p>
+ iGEM places great emphasis on biosafety, ensuring that all projects adhere to strict safety standards. One of these measures is the iGEM White List, which includes organisms and parts that are pre-approved for use based on their safety profile. Any components or organisms not covered by this White List must be submitted as 'Check-ins' to the iGEM Safety Committee for approval. Check-ins are formal safety evaluations that allow the committee to assess the potential risks and ensure proper containment and handling procedures are in place. Although we used some parts and organisms that were not included on the White List, these were assessed as critical for our project and submitted as Check-ins to the iGEM Safety Committee. Furthermore, we were in active exchange with the committee throughout the process. The Check-ins provide a clear picture of the biosafety aspects of our project, reflecting our commitment to safety and compliance with iGEM standards.
+ </p>
+ <p>
+ We adhere to good laboratory practices by ensuring proper handling of materials, effective emergency procedures, and correct waste disposal methods. This commitment guarantees a safe and compliant research environment. Our project, which involved a wide range of techniques was conducted in strict compliance with safety regulations. All experiments were carried out in Prof. Dr. Kristian Müller’s laboratory at Bielefeld University, following BSL-1 standard operating procedures. Properly equipped facilities are crucial to prevent contamination, exposure, or accidental release of modified organisms, ensuring the highest level of safety in our laboratories.
+ Before commencing laboratory work, all participants were required to attend a mandatory safety briefing. In compliance with German regulations, each team member's participation had to be confirmed with a personal signature. The briefing, conducted by Prof. Dr. Kristian Müller must be renewed annually in accordance with §12 ArbSchG. It covered the following areas:
+ </p>
+ <p>
+ General laboratory safety
+ </p>
+ <p>
+ Regulations regarding hazardous and toxic substances
+ </p>
+ <p>
+ Regulations concerning biological materials
+ </p>
+ <p>
+ Regulations on genetic engineering. In addition to the general safety briefing, specific instructions for the safe operation of each device were provided. The Safety and Security Officer within the laboratory highlighted the potential hazards and necessary precautionary measures. We have focused on planning our laboratory activities to minimize risk for safer practices. This ensures not only the safe and proper use of equipment but also the generation of reliable data. To meet all safety requirements, additional safety protocols have been put in place for all targeted areas of the laboratory equipment.
+ </p>
+ </div>
</Section>
<Section title="Check-Ins" id="Check-Ins">
<div>
@@ -36,7 +62,7 @@ export const Safety: React.FC = () =>{
<p>
<strong>Safe handling of cell lines:</strong> The cell lines used for experiments were handled in accordance with the applicable safety regulations. This included regular checks for contamination and the safe storage and disposal of cell cultures.
</p>
- <H4 text="Checkin for the Prime-Editing Komplex "></H4>
+ <H4 text="Check-in for the Prime-Editing Komplex "></H4>
<p>
<strong>Reverse transcriptase:</strong> Reverse transcriptase plays a central role in prime editing by specifically inserting the correction as DNA at the inserted nick using an RNA template provided by pegRNA. The correction of the complementary DNA strand then takes place via the natural cell repair mechanisms. This ensures an exact correction of the target sequence. We checked the reverse transcriptase to ensure it could perform precise genome editing without introducing unintended mutations. This was important to minimize the risk of off-target effects that could lead to unexpected or harmful consequences.
</p>
@@ -48,12 +74,12 @@ export const Safety: React.FC = () =>{
This prime-editing complex thus represents a precise and efficient method for gene editing. By combining these components, genetic modifications can be performed with minimal side effects
</p>
- <H4 text="Checkin for Cloning"></H4>
+ <H4 text="Check-in for Cloning"></H4>
<p>
For our cloning experiments and the development of our prime editing complexes, we have amplified various plasmids in <i>E. coli</i> K-12 strains (DH5α,10-Beta) When working with microbial strains such as <i>E. coli</i> K-12 strains, a it's important to consider potential risks associated with their use, even though they are generally regarded as safe in laboratory settings. All experiments were performed under strict S1 conditions, following all relevant safety protocols. Below you will find an overview of the <i>E. coli</i> K-12 strains for our cloning experiments, submitted by us as a checkin and the specific safety measures:
</p>
<p>
- <strong><i>E. coli K-12</i> strains (DH5α,10-Beta):</strong> Although these strains are non-pathogenic and have been modified to minimize the risk of spreading antibiotic resistance, there remains a low risk of horizontal gene transfer, where genetic material could be transferred to other microorganisms, potentially leading to the spread of resistance genes or other traits. If accidentally released into the environment, <i>E. coli</i> K-12 strains could potentially interact with native microbial communities. While they are typically outcompeted in natural environments, there's a remote possibility of ecological disruption, particularly in microenvironments where they could find a niche.While these strains are non-virulent, they still pose a minimal risk to humans, particularly immunocompromised individuals, through accidental ingestion or inhalation in a laboratory setting.
+ <strong><i>E. coli K-12</i> strains (DH5α, 10-Beta):</strong> Although these strains are non-pathogenic and have been modified to minimize the risk of spreading antibiotic resistance, there remains a low risk of horizontal gene transfer, where genetic material could be transferred to other microorganisms, potentially leading to the spread of resistance genes or other traits. If accidentally released into the environment, <i>E. coli</i> K-12 strains could potentially interact with native microbial communities. While they are typically outcompeted in natural environments, there's a remote possibility of ecological disruption, particularly in microenvironments where they could find a niche.While these strains are non-virulent, they still pose a minimal risk to humans, particularly immunocompromised individuals, through accidental ingestion or inhalation in a laboratory setting.
</p>
<p>
We submitted the yeast strain <i>Pichia pastoris</i> (SMD1163) for the protein expression of Fanzor.
@@ -62,7 +88,7 @@ export const Safety: React.FC = () =>{
<strong><i>Pichia pastoris</i> (SMD1163):</strong> <i>Pichia pastoris</i> (SMD1163) is a widely used yeast strain for the expression of recombinant proteins. It is characterized by a methanol-inducible expression system (AOX1 promoter) and high cell growth rates, which makes it ideal for industrial applications. The strain can be easily genetically manipulated and can perform post-translational modifications, which supports correct protein production.
When working with <i>Pichia pastoris</i> (SMD1163), various safety-relevant aspects must be observed. Although the organism is considered non-pathogenic and biologically safe (S1), skin contact and aerosol formation should be avoided to minimize the risk of infection or allergic reactions. When using genetically modified strains, it is important to follow the relevant GMO guidelines to prevent uncontrolled release. In addition, handling chemicals such as methanol requires special precautions as they are toxic and highly flammable. The disposal of cell cultures and waste must also be carried out in accordance with biosafety regulations, especially in the case of genetically modified organisms.
</p>
- <H4 text="Checkin for Testing in cell lines "></H4>
+ <H4 text="Check-in for Testing in cell lines "></H4>
<p>
In our project, we paid attention to safety at every step, especially when working with specific cell lines [link Zellinien]. All experiments were performed under strict S1 conditions, following all relevant safety protocols. Given the sensitivity of the human cell lines we used, we placed great emphasis on controlled and well-designed workflows. All transfections were performed in our own transfection laboratory to ensure a high level of safety and compliance. Below you will find an overview of the cell lines submitted by us as a checkin and the specific safety measures:
HEK293T-3HA-CFTR.
@@ -89,10 +115,26 @@ export const Safety: React.FC = () =>{
</div>
</Section>
<Section title="Our Lab" id="Our Lab">
- <LoremMedium/>
+ <p>
+ As part of our laboratory activities for our PreCyse project, we worked in various laboratories. For general lab work and cloning experiments, you can find some pictures of our laboratories below:
+ </p>
+ <H4 text="Our Cloning Lab"></H4>
+ <p>
+ Our Cloning-laboratory is divided into different work areas to ensure that the experiments run smoothly and efficiently. These include the gel station, the PCR station, the transformation section and the measurement area. Each area is specially equipped for the respective method, and the corresponding experiments were carried out exclusively in the designated stations. In this way, we ensure that our work is carried out under optimal conditions and with the greatest possible precision.
+ </p>
+ <H4 text="Our Cell Culture Lab "></H4>
+ <p>
+ In our cell culture laboratory, we work under sterile conditions to ensure optimal growth conditions for human cell lines. Among other things, we carry out transfections in order to introduce genetic material into cells and investigate their behavior. Strict protocols and state-of-the-art technology ensure the precision and reproducibility of our experiments.
+ </p>
+ <p>
+ In our S2 laboratory, the harvested nasal epithelial cells that serve as primary cultures undergo a comprehensive HHH test (link zu primär Kulturen) to ensure their safety and suitability for further experiments. This test is crucial to ensure that we can subsequently work safely with these cells in the S1 range without the risk of contamination or unwanted release of biological material.
+ </p>
+ <div className="col">
+ <img src="https://static.igem.wiki/teams/5247/photos/biosafety/s2/s2-lab.jpeg" width="50%" height="50%"/>
+ </div>
</Section>
<Section title="Biosafety" id="Biosafety">
- <Subesction title="Mechanism" id="Biosafety1">
+ <Subesction title="Safety aspects of our PrimeGuide" id="Biosafety1">
<p>
The biosafety of our Prime Editing complex has been a top priority throughout the entire development process. We have therefore tried to optimise all parts that influence the biosecurity of our system as much as possible. To ensure maximum biosecurity, we have created and tested many designs, as well as extensively researched alternatives and/or additional elements that contribute to biosecurity.
</p>
@@ -112,16 +154,18 @@ export const Safety: React.FC = () =>{
addition, our research steered us in a different direction, particularly with regard to the alternative mechanism involving the XBP1 intron to regulate the prime editing system. This alternative seemed more promising and was based on an established regulatory mechanism that is triggered by cellular stress and specifically responds to misfolding processes.
</p>
<H4 text="XBP1 Intron"></H4>
- <p>After extensive research, we discovered a regulatory system in eukaryotic cells, the XBP1 mechanism. The activation of XBP1 is an important mechanism that occurs as part of the Unfolded Protein Response (UPR), a cellular stress response triggered by the accumulation of misfolded proteins in the endoplasmic reticulum (ER). The ER is a key cellular component responsible for protein folding and transport. When many misfolded proteins accumulate in the ER, a specific regulatory mechanism is activated to reduce the stress on the ER. XBP1 activation is controlled by a protein called IRE1α, which is embedded in the ER membrane. IRE1α acts as a sensor for protein misfolding stress in the ER. Once IRE1α detects misfolded proteins, it dimerizes and becomes activated through autophosphorylation. This activation switches on the endoribonuclease activity of IRE1α, which is a crucial step in the activation of XBP1. The mRNA for XBP1 is continuously transcribed in the nucleus and transported to the cytoplasm, where it contains an intron that is not normally spliced out. This intron contains a stop codon, preventing the translation of a functional XBP1 protein. However, when ER stress activates IRE1α, the endoribonuclease domain of IRE1α splices this intron out of the XBP1 mRNA. This is an unconventional splicing event, as it occurs in the cytoplasm rather than in the nucleus. Once the intron is removed, the spliced XBP1 mRNA can be translated into a functional XBP1 protein. This activated XBP1 acts as a transcription factor, turning on genes that increase the protein-folding capacity of the ER and promote the degradation of misfolded proteins. In this way, XBP1 helps the cell cope with ER stress and restore balance in the protein-folding process. Thus, this mechanism originally functions within the cell in the context of ER stress to maintain ER function when protein folding is disrupted. [5] [6] Our idea was therefore to integrate this intron into the mRNA encoding our prime-editing complex and thus use this mechanism to ensure that a functional prime editor is only synthesized when there is a high accumulation of misfolded proteins in the cell (similar to F508del). This would therefore represent an optimal safety aspect, as our fusion protein, which is essential for prime editing, cannot be fully synthesised as long as the genetic defect is not present in the cell. Accordingly, this provides the security that no healthy cells, as well as correctly edited cells, cannot be edited, which is an enormous contribution to biosafety. However, there was too much uncertainty about the extent to which other factors, such as misfolded proteins that are not associated with the CFTR protein, play a role in this mechanism. And since we could not and did not want to take the risk of such factors initiating the system, we decided against using it. To clarify this unknown correlation, we have considered a future experiment in which we want to switch this intron in front of a fluorescent marker and express it in cells with defective CFTR in order to confirm/investigate the dependence of intron splicing and the presence of CFTR F508del.</p>
+ <p>
+ After extensive research, we discovered a regulatory system in eukaryotic cells, the XBP1 mechanism. The activation of XBP1 is an important mechanism that occurs as part of the Unfolded Protein Response (UPR), a cellular stress response triggered by the accumulation of misfolded proteins in the endoplasmic reticulum (ER). The ER is a key cellular component responsible for protein folding and transport. When many misfolded proteins accumulate in the ER, a specific regulatory mechanism is activated to reduce the stress on the ER. XBP1 activation is controlled by a protein called IRE1α, which is embedded in the ER membrane. IRE1α acts as a sensor for protein misfolding stress in the ER. Once IRE1α detects misfolded proteins, it dimerizes and becomes activated through autophosphorylation. This activation switches on the endoribonuclease activity of IRE1α, which is a crucial step in the activation of XBP1. The mRNA for XBP1 is continuously transcribed in the nucleus and transported to the cytoplasm, where it contains an intron that is not normally spliced out. This intron contains a stop codon, preventing the translation of a functional XBP1 protein. However, when ER stress activates IRE1α, the endoribonuclease domain of IRE1α splices this intron out of the XBP1 mRNA. This is an unconventional splicing event, as it occurs in the cytoplasm rather than in the nucleus. Once the intron is removed, the spliced XBP1 mRNA can be translated into a functional XBP1 protein. This activated XBP1 acts as a transcription factor, turning on genes that increase the protein-folding capacity of the ER and promote the degradation of misfolded proteins. In this way, XBP1 helps the cell cope with ER stress and restore balance in the protein-folding process. Thus, this mechanism originally functions within the cell in the context of ER stress to maintain ER function when protein folding is disrupted. [5] [6] Our idea was therefore to integrate this intron into the mRNA encoding our prime-editing complex and thus use this mechanism to ensure that a functional prime editor is only synthesized when there is a high accumulation of misfolded proteins in the cell (similar to F508del). This would therefore represent an optimal safety aspect, as our fusion protein, which is essential for prime editing, cannot be fully synthesised as long as the genetic defect is not present in the cell. Accordingly, this provides the security that no healthy cells, as well as correctly edited cells, cannot be edited, which is an enormous contribution to biosafety. However, there was too much uncertainty about the extent to which other factors, such as misfolded proteins that are not associated with the CFTR protein, play a role in this mechanism. And since we could not and did not want to take the risk of such factors initiating the system, we decided against using it. To clarify this unknown correlation, we have considered a future experiment in which we want to switch this intron in front of a fluorescent marker and express it in cells with defective CFTR in order to confirm/investigate the dependence of intron splicing and the presence of CFTR F508del.
+ </p>
</Subesction>
<Subesction title="Safety aspects of our Airbuddy" id="Biosafety2">
<H4 text="SORT LNP and Cytotoxicity"></H4>
<p>
- We have carefully considered the biosafety aspects of our delivery system, starting with the decision between Adeno-associated viruses (AAV) or lipid nanoparticles (LNPs) as delivery systems. Our comparison revealed that the biocompatibility and safety of LNPs are paramount for our approach. That is why we chose selective organ-targeting (SORT) lipid nanoparticles (LNPs) [1] in the context of targeted pulmonary mRNA delivery. One of our primary concerns with the LNP was the potential cytotoxicity of polyethylene glycol (PEG), a common stabilizing agent in LNP formulations. Aware of the immune responses PEG can trigger, potentially leading to cytotoxicity [2], we aimed at optimizing its concentration in our SORT LNPs to minimize such reactions while maintaining therapeutic efficacy. By the use of low molecular weight PEG, we addressed this problem. To test weather our approach succeeded, we conducted MTT and proliferation assays to ensure that our LNP posed no cytotoxicity risks.
+ We have carefully considered the biosafety aspects of our delivery system, starting with the decision between Adeno-associated viruses (AAV) or LNPs as delivery systems. Our comparison revealed that the biocompatibility and safety of LNPs are paramount for our approach. That is why we chose selective organ-targeting (SORT) lipid nanoparticles (LNPs) [7] in the context of targeted pulmonary mRNA delivery. One of our primary concerns with the LNP was the potential cytotoxicity of polyethylene glycol (PEG), a common stabilizing agent in LNP formulations. Aware of the immune responses PEG can trigger, potentially leading to cytotoxicity [8], we aimed at optimizing its concentration in our SORT LNPs to minimize such reactions while maintaining therapeutic efficacy. By the use of low molecular weight PEG, we addressed this problem. To test weather our approach succeeded, we conducted MTT and proliferation assays to ensure that our LNP posed no cytotoxicity risks.
</p>
<H4 text="Precision of our SORT LNP"></H4>
<p>
- To further improve safety, we focused on reducing off-target effects. By incorporating specific SORT molecules, such as permanently cationic lipids like DOTAP, we ensured that the nanoparticles are systematically directed to the lungs. This precise targeting is particularly beneficial for respiratory diseases, as it enhances therapeutic effectiveness while limiting the impact on non-target organs. Our outlook of antibody conjugation as surface modification of our LNP for cell type-specific delivery, more exactly club cells [3] and ionocytes [4] as CFTR-expressing lung epithelial cells, would round off this aspect.
+ To further improve safety, we focused on reducing off-target effects. By incorporating specific SORT molecules, such as permanently cationic lipids like DOTAP, we ensured that the nanoparticles are systematically directed to the lungs. This precise targeting is particularly beneficial for respiratory diseases, as it enhances therapeutic effectiveness while limiting the impact on non-target organs. Our outlook of antibody conjugation as surface modification of our LNP for cell type-specific delivery, more exactly club cells [9] and ionocytes [10] as CFTR-expressing lung epithelial cells, would round off this aspect.
</p>
<p>
In summary, our design strategy emphasizes both safety and efficacy. The careful optimization of components like PEG 2000 and the use of targeted delivery molecules allow SORT LNPs to deliver therapeutic agents directly to the lungs, reducing systemic exposure and minimizing side effects. This targeted approach ensures more effective treatments, especially for conditions requiring localized intervention.
@@ -129,26 +173,117 @@ export const Safety: React.FC = () =>{
</Subesction>
</Section>
<Section title="Biosecurity" id="Biosecurity">
- <Subesction title="Our Project" id="Biosecurity1">
- <LoremMedium/>
+ <Subesction title="About Our Project" id="Biosecurity1">
+ <p>
+ Our project focuses on the genetic disease cystic fibrosis, specifically targeting the Delta-508 mutation. The aim is to correct this mutation using Prime Editing, a precise genome-editing technique. We have explored different strategies to optimize the Prime Editing complex for this specific application.
+ </p>
+ <p>
+ The Prime Editing complex consists of a nickase, a reverse transcriptase, a pegRNA. The pegRNA guides the editing process by directing the complex to the target DNA sequence, allowing for precise genetic modifications. For targeted delivery, we selected LNPs to introduce the mRNA encoding the Prime Editing components specifically into lung epithelial cells, where the CFTR protein is highly expressed. Additionally, we investigated alternatives to the conventional Cas9 nickase, such as the smaller CasX and Fanzor, aiming to reduce the overall size of the Prime Editing complex. In our optimization efforts, we also explored smaller reverse transcriptases to enhance the efficiency of the system in human cells.
+ </p>
+ <p>
+ Furthermore, we have developed a modular plasmid that contains the backbone of our Prime Editing complex. The individual components can be cloned individually into the backbone. This plasmid allows us to either deliver the construct directly into target cells or transcribe the plasmid into RNA, enabling the delivery of the Prime Editing complex in the form of mRNA. The modularity of the plasmid is a key feature; specific restriction sites are included to facilitate the easy exchange of the complex's components. This design makes it straightforward to adapt the Prime Editing complex for various use cases and therapeutic requirements.
+ </p>
+ <p>
+ We have investigated safety mechanisms to control the prime-editing complex, including a riboswitch that responds to sodium ion concentrations, but have discarded it due to suspected insufficient sensitivity. We are currently investigating the use of the ER stress response to activate the prime editing complex only in cells with high ER stress, as is typical for cystic fibrosis. Further details can be found in the Biosafety section.
+ </p>
</Subesction>
- <Subesction title="Risk Assesment" id="Biosecurity2">
- <LoremMedium/>
+ <Subesction title="Assessing Project Risks" id="Biosecurity2">
+ <p>
+ Given the sensitive nature of genome editing, our project presents specific biosecurity concerns that need to be assessed and mitigated.
+ </p>
+ <p>
+ <strong>Dual-Use Potential:</strong> One of the main biosecurity risks is the potential for dual-use of the Prime Editing technology. The system we are developing, while intended for therapeutic use, could be misused to target other genes or genomes for malicious purposes.[11] This includes the possibility of weaponizing the technology to induce harmful genetic changes in crops, animals, or even humans. The modular design of our plasmid system, although intended to facilitate optimization, could be exploited to exchange components for harmful applications, thereby increasing the risk of misuse.
+ </p>
+ <p>
+ <strong>Unintendend Dissemination:</strong> Since our approach uses mRNA delivered via LNPs, there is a risk of unintended dissemination into the environment. If the LNPs are not adequately contained or disposed of, there is a possibility that they could be absorbed by non-target organisms, potentially leading to off-target genetic modifications.[12] In addition, the mRNA itself could theoretically be transferred between cells, especially if taken up by unintended hosts, raising concerns about unintentional spread in the environment.
+ </p>
+ <p>
+ <strong>Unauthorized Access:</strong> The genetic constructs and the detailed methodology of our Prime Editing system must be securely stored and protected.[13] If unauthorized individuals were to gain access to the plasmids, LNP formulations, or editing protocols, there is a risk of the technology being replicated or adapted for unintended, potentially harmful uses. This highlights the importance of proper biosecurity protocols in both physical and digital storage of our project materials.
+ </p>
+ <p>
+ <strong>Synthetic Biology and information Sharing:</strong> The ease of synthesizing genetic material means that our project information could potentially be used to order similar constructs from commercial synthesis providers.[14] While these providers follow biosecurity guidelines, the increasing accessibility of synthetic biology raises the concern of our Prime Editing system being reproduced or modified without our knowledge. This includes potential attempts to bypass safety mechanisms or create variants that evade current regulatory frameworks.
+ </p>
+ <p>
+ <strong>Public Perception and Miscommunication:</strong> There is a biosecurity risk in how our project's technology is communicated to the public.[15] Miscommunication or misunderstanding of the project’s intent and capabilities could lead to misinformation, fear, or even attempts to replicate the technology outside of controlled and regulated environments. This could undermine public trust in legitimate therapeutic uses of genome-editing technologies and potentially facilitate misuse.
+ </p>
</Subesction>
<Subesction title="Managing Risks" id="Biosecurity3">
- <LoremMedium/>
+ <H5 text="Dual-Use Potential"></H5>
+ <p>
+ To mitigate the risk of dual-use, where our Prime Editing technology could be exploited for unintended and potentially harmful purposes, we have implemented several strategies.
+ </p>
+ <p>
+ Firstly, we strictly control access to all our project data, including genetic sequences, plasmid designs, and protocols. Access is limited to authorized team members and collaborators who follow strict biosecurity guidelines. Further elaboration on these access controls will be provided in the "Unauthorized Access" section.
+ </p>
+ <p>
+ Secondly, we intend to incorporate a safety mechanism into our Prime Editing complex that significantly limits its potential misuse. By utilizing the ER stress response pathway, we would design our therapeutic mRNA to undergo unconventional splicing only in cells experiencing high levels of protein stress. Only this unconventional splicing would convert the mRNA into a form that can be translated into the final PE complex. This mechanism ensures that the Prime Editing complex becomes active primarily in cells under such stress conditions. While this does not exclusively limit the complex to cystic fibrosis-affected cells, it considerably narrows the range of cells where activation can occur, thus preventing arbitrary application of the editing system and reducing the risk of targeting unintended cells.
+ </p>
+ <p>
+ Together, these measures provide a layer of protection against dual-use risks, making it more difficult for the technology to be employed outside of its intended therapeutic context.
+ </p>
+ <p>
+ <H5 text="Unitended Dissemination"></H5>
+ </p>
+ <p>
+ To minimize the risk of our construct being inadvertently released into the environment, we adhere to strict standard operating procedures (SOPs) in the laboratory. These SOPs are designed to ensure that all safety standards are maintained, particularly when handling LNPs) and genetic materials. This includes rigorous protocols for storage, disposal, and decontamination, reducing the chance of accidental dissemination of the materials we work with.
+ </p>
+ <p>
+ In addition to our laboratory practices, we have formulated our LNPs with specific chemical components that enable them to selectively fuse with lung epithelial cells, such as ionocytes and club cells, which express CFTR. This selective fusion ensures that even if the LNPs were to accidentally enter the environment, they would only interact with the intended cells. This approach significantly enhances the specificity of the LNPs and provides an additional layer of containment, thereby reducing the risk of unintended dissemination or environmental contamination.
+ </p>
+ <p>
+ Looking ahead, we plan to further enhance the specificity of our LNPs by incorporating antibodies on their surface. These antibodies would be engineered to bind exclusively to surface proteins present on CFTR-expressing lung epithelial cells, adding an extra layer of control. While this antibody-based targeting has not yet been implemented, it represents a crucial next step in our development process, reinforcing our commitment to biosecurity by limiting the potential for unintended dissemination.
+ </p>
+ <p>
+ Together, these practices and design strategies help to ensure that the risk of our constructs inadvertently affecting non-target organisms or environments is minimized.
+ </p>
+ <p>
+ <H5 text="Unauthorized Access"></H5>
+ </p>
+ <p>
+ To prevent unauthorized access to our genetic sequences, plasmid constructs, and other sensitive information, we have implemented strict internal biosecurity policies. These policies ensure that we carefully manage which materials exist in physical form and their exact storage locations.
+ </p>
+ <p>
+ In terms of digital security, we strictly regulate access to our data storage systems through a combination of measures. We use a secure, password-protected cloud system, ensuring only authorized team members can access sensitive project information. Access to the lab is limited to team members with internal keys, and our server security includes stringent access rights management, allowing only approved individuals to view, modify, or share the data. These safeguards ensure that project information remains protected against unauthorized access.
+ </p>
+ <p>
+ Furthermore, we ensure that any sensitive data generated during our project is only published in the supplementary materials section, which is accessible exclusively to those with an official iGEM account. By taking this approach, we can limit the availability of sensitive information and reduce the risk of it being misused.
+ </p>
+ <p>
+ <H5 text="Synthetic Biology and Information Sharing"></H5>
+ </p>
+ <p>
+ Managing the risks associated with synthetic biology and information sharing is a complex challenge. Many of the strategies we use to address other risks, such as "Unauthorized Access" and "Dual-Use Potential," are equally relevant in this context. For instance, our strict control over access to sensitive information and our safety mechanisms both help mitigate the risks posed by the accessibility of synthetic biology tools.
+ </p>
+ <p>
+ However, it is important to acknowledge that this risk is inherent to the field of synthetic biology. The ease of obtaining information and, with the right expertise, combining various components to create powerful and potentially hazardous tools is a fundamental concern.
+ </p>
+ <p>
+ To address this, we adhere strictly to all policies and regulations set forth by iGEM, our university, the German government, and the European Union. By aligning our practices with existing regulations on synthetic biology, we aim to conduct our work responsibly and reduce the risks associated with the field.
+ </p>
+ <p>
+ <H5 text="Public Perception and Miscommunication"></H5>
+ </p>
+ <p>
+ One of the challenges in scientific research, especially in fields like synthetic biology, is that advancements can often outpace public understanding and discourse. This can lead to confusion, fear, or mistrust if the research is not communicated effectively. To address this issue, we believe that scientific progress should occur in constant dialogue with the public.
+ </p>
+ <p>
+ We have adopted a strong Human Practices approach to ensure transparency and foster public engagement. Our efforts include initiatives like "MUKOmoove" and "Teuto ruft," where we have worked directly with students, educational institutions, and public organizations. Through these initiatives, we aim to explain our project, discuss its implications, and answer any questions, thus maintaining an open line of communication. By collaborating with a variety of public entities, including patient associations, educational programs, and community groups, we ensure that our research remains accessible and understandable to a broader audience.
+ </p>
+ <p>
+ This proactive approach helps us address potential concerns, demystify our research, and contribute to a more informed public perception of synthetic biology.
+ </p>
</Subesction>
</Section>
<Section title="Bioethics" id="Bioethics">
<div>
<p>
- Bioethics is an interdisciplinary field of research that addresses ethical issues pertaining to the life sciences and medical research. It plays a pivotal role in contemporary research, particularly in projects that employ human samples or data. This is due to the fact that in these cases, the protection of the rights and dignity of the people involved is of the utmost importance <SupScrollLink label="1"/> (Chadwick_2012_Thiele_2001a). In order to ascertain the necessity for an ethics application, an interview was conducted with Eva-Maria Berens, the scientific director of the office of the Ethics Committee at Bielefeld University, as part of the current research project. Following a comprehensive review, it was concluded that an ethics application was not necessary for the specific research project. Nevertheless, a comprehensive patient consent form was developed in conjunction with Eva-Maria Berens to guarantee that the donors of their samples are adequately informed and provide their consent of their own volition. The document guarantees that all pertinent information regarding sample collection, utilisation and storage is provided in an intelligible format. Furthermore, an interview was conducted with Dr. Timm Weber, a representative of the biobank, to discuss the topic of bioethics in greater depth. During the course of the interviews, the ethical aspects of sample storage and utilisation within the biobank were discussed in detail. Particular attention was paid to the responsible handling and protection of the rights of the test subjects. The discussion of bioethics in both interviews emphasises the relevance of ethical principles for research and ensures that it is conducted in accordance with the highest ethical standards.
+ Bioethics is an interdisciplinary field of research that addresses ethical issues pertaining to the life sciences and medical research. It plays a pivotal role in contemporary research, particularly in projects that employ human samples or data. This is due to the fact that in these cases, the protection of the rights and dignity of the people involved is of the utmost importance <SupScrollLink label="1"/> [16]. In order to ascertain the necessity for an ethics application, an interview was conducted with Eva-Maria Berens, the scientific director of the office of the Ethics Committee at Bielefeld University, as part of the current research project. Following a comprehensive review, it was concluded that an ethics application was not necessary for the specific research project. Nevertheless, a comprehensive patient consent form was developed in conjunction with Eva-Maria Berens to guarantee that the donors of their samples are adequately informed and provide their consent of their own volition. The document guarantees that all pertinent information regarding sample collection, utilisation and storage is provided in an intelligible format. Furthermore, an interview was conducted with Dr. Timm Weber, a representative of the biobank, to discuss the topic of bioethics in greater depth. During the course of the interviews, the ethical aspects of sample storage and utilisation within the biobank were discussed in detail. Particular attention was paid to the responsible handling and protection of the rights of the test subjects. The discussion of bioethics in both interviews emphasises the relevance of ethical principles for research and ensures that it is conducted in accordance with the highest ethical standards.
</p>
</div>
<Subesction title="Gene Therapy" id="Bioethics1">
<div>
<p>
- The potential of gene therapy to treat genetic diseases is promising, but it is also associated with significant ethical issues. One of the principal challenges is ensuring the safety of the procedure and the potential for unforeseen long-term consequences. Such consequences may only become apparent years after the genetic intervention has taken place. The modification of the germline, which affects not only the individual but also future generations, is a particularly sensitive issue. This gives rise to the question of the extent to which the decisions made today will influence future generations without their consent, thereby jeopardising intergenerational justice <SupScrollLink label="2"/> (Rubeis_Steger_2018). Another ethical issue is the potential for misuse for eugenic purposes. While the current focus is on combating disease, future applications could be aimed at 'optimising' human traits, which could result in a worsening of social inequalities. Access to gene therapy is also a significant issue. High costs could limit access to wealthy population groups, which would reinforce existing inequalities <SupScrollLink label="3"/> (Ansah_2022_Cornetta_Patel_Wanjiku_Busakhala_2018). The issue of informed consent is also a key aspect. Many patients do not have the necessary knowledge to fully understand the complex risks, which raises ethical questions about their decision-making capacity. Overall, the debate around gene therapy highlights that ethical considerations such as safety, justice and patient rights need to be considered alongside scientific progress <SupScrollLink label="4"/> (Pugh_2020).
+ The potential of gene therapy to treat genetic diseases is promising, but it is also associated with significant ethical issues. One of the principal challenges is ensuring the safety of the procedure and the potential for unforeseen long-term consequences. Such consequences may only become apparent years after the genetic intervention has taken place. The modification of the germline, which affects not only the individual but also future generations, is a particularly sensitive issue. This gives rise to the question of the extent to which the decisions made today will influence future generations without their consent, thereby jeopardising intergenerational justice <SupScrollLink label="2"/> [17]. Another ethical issue is the potential for misuse for eugenic purposes. While the current focus is on combating disease, future applications could be aimed at 'optimising' human traits, which could result in a worsening of social inequalities. Access to gene therapy is also a significant issue. High costs could limit access to wealthy population groups, which would reinforce existing inequalities <SupScrollLink label="3"/> [18]. The issue of informed consent is also a key aspect. Many patients do not have the necessary knowledge to fully understand the complex risks, which raises ethical questions about their decision-making capacity. Overall, the debate around gene therapy highlights that ethical considerations such as safety, justice and patient rights need to be considered alongside scientific progress <SupScrollLink label="4"/> [19].
</p>
</div>
</Subesction>
@@ -156,11 +291,11 @@ export const Safety: React.FC = () =>{
<div>
<H4 text="Introduction of primary cultures"></H4>
<p>
- A primary culture is defined as a cell culture that is isolated directly from the tissue of an organism. In our case, the organism is human. The cells are then cultivated in a controlled environment, namely an S2 laboratory <SupScrollLink label="5"/> (Gstraunthaler_Lindl_2013). Primary cultures are a fundamental biomedical research tool, widely regarded as indispensable due to their capacity for realistic modelling of complex cell interactions. Primary cells are derived directly from the tissue of an organism and, as a consequence, they essentially retain their original properties. Consequently, they mirror the authentic conditions of the target tissue, which is vital for accurately assessing the impact of a therapeutic agent. In contrast, HEK cells represent transformed cell lines that exhibit physiological properties distinct from those of target cells in the human body. The effect of a therapeutic agent is typically limited to a specific cell type. The investigation of cell-specific effects and reactions of an active substance is feasible with the use of primary cells, as these possess the functional characteristics inherent to the cell type under consideration. Although HEK cells are relatively straightforward to cultivate, they are less representative of a number of tissue types and may activate other signalling pathways. The authenticity of the receptors and signalling pathways is guaranteed, as primary cells show the natural expression of receptors, ion channels and other cellular mechanisms. HEK cells are often genetically modified to express specific receptors, which can be useful for simple test systems. However, this does not reflect the complex environment of a real tissue. Given the sensitivity of primary cultures to environmental influences, thus resulting in higher risk of a contamination, it is imperative that researchers employ special safety measures to ensure the safety of themselves and the integrity of the cells. Primary cultures are employed extensively in the development of vaccines, cancer research and the investigation of basic cell processes.
+ A primary culture is defined as a cell culture that is isolated directly from the tissue of an organism. In our case, the organism is human. The cells are then cultivated in a controlled environment, namely an S2 laboratory <SupScrollLink label="5"/> [20]. Primary cultures are a fundamental biomedical research tool, widely regarded as indispensable due to their capacity for realistic modelling of complex cell interactions. Primary cells are derived directly from the tissue of an organism and, as a consequence, they essentially retain their original properties. Consequently, they mirror the authentic conditions of the target tissue, which is vital for accurately assessing the impact of a therapeutic agent. In contrast, HEK cells represent transformed cell lines that exhibit physiological properties distinct from those of target cells in the human body. The effect of a therapeutic agent is typically limited to a specific cell type. The investigation of cell-specific effects and reactions of an active substance is feasible with the use of primary cells, as these possess the functional characteristics inherent to the cell type under consideration. Although HEK cells are relatively straightforward to cultivate, they are less representative of a number of tissue types and may activate other signalling pathways. The authenticity of the receptors and signalling pathways is guaranteed, as primary cells show the natural expression of receptors, ion channels and other cellular mechanisms. HEK cells are often genetically modified to express specific receptors, which can be useful for simple test systems. However, this does not reflect the complex environment of a real tissue. Given the sensitivity of primary cultures to environmental influences, thus resulting in higher risk of a contamination, it is imperative that researchers employ special safety measures to ensure the safety of themselves and the integrity of the cells. Primary cultures are employed extensively in the development of vaccines, cancer research and the investigation of basic cell processes.
</p>
<H4 text="Ethics in work with primary cultures"></H4>
<p>
- The term 'ethics' is used to describe the examination of moral principles that determine the behaviour of individuals or groups <SupScrollLink label="6"/> (Thiele_2001b). In a scientific context, the term 'ethics' encompasses the examination of the moral justifiability of actions and decisions, particularly with regard to the welfare of living beings and the responsible use of resources <SupScrollLink label="7"/> (Gethmann_2001). The isolation of primary cells from living organisms raises ethical questions, particularly in the case of human or animal tissue. In the context of research with animal primary cells, careful consideration must be given to the need for animal suffering and the potential benefits of the research <SupScrollLink label="8"/> (Kiani_Pheby_Henehan_Brown_Sieving_Sykora_Marks_Falsini_Capodicasa_Miertus_et al._2022). An ethical dilemma frequently arises from the fact that primary cells offer the most meaningful data from a biological standpoint, yet their production is associated with challenges. In this context, the necessity of primary cell cultures is called into question, and the promotion of alternative methods, such as artificially produced tissues or organoids, is advocated where feasible. It is of crucial importance to emphasize the necessity of ethical responsibility in the collection of primary cultures. It is of the utmost importance that the procedure is carried out with consideration for the rights, and particularly the well-being of the donor. The removal of cells or tissue must be medically justifiable and, moreover, ethically justifiable in every case. To this end, the potential for research use and the possible risks and burdens for the donor must be weighed against each other to ensure careful consideration. However, it is also particularly important to ensure that the donor is involved in the entire process and is able to make an informed decision. The purpose of the research, the use of the cells and possible consequences must also be made transparent at all times.
+ The term 'ethics' is used to describe the examination of moral principles that determine the behaviour of individuals or groups <SupScrollLink label="6"/> [21]. In a scientific context, the term 'ethics' encompasses the examination of the moral justifiability of actions and decisions, particularly with regard to the welfare of living beings and the responsible use of resources <SupScrollLink label="7"/> [22]. The isolation of primary cells from living organisms raises ethical questions, particularly in the case of human or animal tissue. In the context of research with animal primary cells, careful consideration must be given to the need for animal suffering and the potential benefits of the research <SupScrollLink label="8"/> [23]. An ethical dilemma frequently arises from the fact that primary cells offer the most meaningful data from a biological standpoint, yet their production is associated with challenges. In this context, the necessity of primary cell cultures is called into question, and the promotion of alternative methods, such as artificially produced tissues or organoids, is advocated where feasible. It is of crucial importance to emphasize the necessity of ethical responsibility in the collection of primary cultures. It is of the utmost importance that the procedure is carried out with consideration for the rights, and particularly the well-being of the donor. The removal of cells or tissue must be medically justifiable and, moreover, ethically justifiable in every case. To this end, the potential for research use and the possible risks and burdens for the donor must be weighed against each other to ensure careful consideration. However, it is also particularly important to ensure that the donor is involved in the entire process and is able to make an informed decision. The purpose of the research, the use of the cells and possible consequences must also be made transparent at all times.
The obtaining of informed consent represents a fundamental aspect of ethical practice in the collection of primary cells. This process must encompass not only a formal consent procedure, but also the provision of comprehensive information to donors regarding the collection, utilisation and prospective future applications of the cells. The act of consent must be given freely and without undue influence, and donors must be fully aware of the consequences of their participation. Furthermore, donors must be granted the right to revoke their consent at any time without consequence. Prior to the collection of cells, a comprehensive discussion is held with the donor, during which all pertinent details are elucidated and any queries or concerns they may have, are addressed. This guarantees that the donor is adequately informed and is thus able to make an autonomous decision based on a comprehensive understanding of the procedure.
The protection of privacy and confidentiality is of paramount importance when working with primary cultures. Given that primary cultures are predominantly human tissue, they contain genetic information and other personal data that is sensitive and deserving of protection. It is therefore of great importance that the data is anonymized and kept strictly confidential in order to protect the identity of the donor.
Every person who has access to the data or samples must be obliged to comply with confidentiality standards. It must be ensured that all legal requirements for data protection are met, including compliance with data protection laws such as the GDPR in the EU.
@@ -182,139 +317,400 @@ export const Safety: React.FC = () =>{
</Subesction>
</Section>
<Section title="References" id="References">
- <ol>
- {/* <!-- Citation num 1--> */}
- <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
- <span property="schema:author" typeof="schema:Person">
- <span property="schema:Name">Scotet, V.</span>,
- <span property="schema:Name">Gutierrez, H.</span>,
- <span property="schema:Name">Farrell, P. </span>
- </span>
- <span property="schema:name">Newborn Screening for CF across the Globe—Where Is It Worthwhile? </span>
- <i property="schema:publisher" typeof="schema:Organization">Int J Neonatal Screen </i>
- <b property="issueNumber" typeof="PublicationIssue">6</b>,
- (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
- <a className="doi" href="https://doi.org/10.3390/ijn6010018"> doi: 10.3390/ijn6010018</a>
- </li>
- {/* <!-- Citation num 2--> */}
- <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
- <span property="schema:author" typeof="schema:Person">
- <span property="schema:Name">Scotet, V.</span>,
- <span property="schema:Name">Gutierrez, H.</span>,
- <span property="schema:Name">Farrell, P. </span>
- </span>
- <span property="schema:name">Newborn Screening for CF across the Globe—Where Is It Worthwhile? </span>
- <i property="schema:publisher" typeof="schema:Organization">Int J Neonatal Screen </i>
- <b property="issueNumber" typeof="PublicationIssue">6</b>,
- (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
- <a className="doi" href="https://doi.org/10.3390/ijn6010018"> doi: 10.3390/ijn6010018</a>
- </li>
- {/* <!-- Citation num 3--> */}
- <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
- <span property="schema:author" typeof="schema:Person">
- <span property="schema:Name">Scotet, V.</span>,
- <span property="schema:Name">Gutierrez, H.</span>,
- <span property="schema:Name">Farrell, P. </span>
- </span>
- <span property="schema:name">Newborn Screening for CF across the Globe—Where Is It Worthwhile? </span>
- <i property="schema:publisher" typeof="schema:Organization">Int J Neonatal Screen </i>
- <b property="issueNumber" typeof="PublicationIssue">6</b>,
- (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
- <a className="doi" href="https://doi.org/10.3390/ijn6010018"> doi: 10.3390/ijn6010018</a>
- </li>
- {/* <!-- Citation num 4--> */}
- <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
- <span property="schema:author" typeof="schema:Person">
- <span property="schema:Name">Scotet, V.</span>,
- <span property="schema:Name">Gutierrez, H.</span>,
- <span property="schema:Name">Farrell, P. </span>
- </span>
- <span property="schema:name">Newborn Screening for CF across the Globe—Where Is It Worthwhile? </span>
- <i property="schema:publisher" typeof="schema:Organization">Int J Neonatal Screen </i>
- <b property="issueNumber" typeof="PublicationIssue">6</b>,
- (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
- <a className="doi" href="https://doi.org/10.3390/ijn6010018"> doi: 10.3390/ijn6010018</a>
- </li>
- {/* <!-- Citation num 5--> */}
- <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
- <span property="schema:author" typeof="schema:Person">
- <span property="schema:Name">Scotet, V.</span>,
- <span property="schema:Name">Gutierrez, H.</span>,
- <span property="schema:Name">Farrell, P. </span>
- </span>
- <span property="schema:name">Newborn Screening for CF across the Globe—Where Is It Worthwhile? </span>
- <i property="schema:publisher" typeof="schema:Organization">Int J Neonatal Screen </i>
- <b property="issueNumber" typeof="PublicationIssue">6</b>,
- (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
- <a className="doi" href="https://doi.org/10.3390/ijn6010018"> doi: 10.3390/ijn6010018</a>
- </li>
- {/* <!-- Citation num 6--> */}
- <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
- <span property="schema:author" typeof="schema:Person">
- <span property="schema:Name">Scotet, V.</span>,
- <span property="schema:Name">Gutierrez, H.</span>,
- <span property="schema:Name">Farrell, P. </span>
- </span>
- <span property="schema:name">Newborn Screening for CF across the Globe—Where Is It Worthwhile? </span>
- <i property="schema:publisher" typeof="schema:Organization">Int J Neonatal Screen </i>
- <b property="issueNumber" typeof="PublicationIssue">6</b>,
- (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
- <a className="doi" href="https://doi.org/10.3390/ijn6010018"> doi: 10.3390/ijn6010018</a>
- </li>
- {/* <!-- Citation num 7--> */}
- <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
- <span property="schema:author" typeof="schema:Person">
- <span property="schema:Name">Scotet, V.</span>,
- <span property="schema:Name">Gutierrez, H.</span>,
- <span property="schema:Name">Farrell, P. </span>
- </span>
- <span property="schema:name">Newborn Screening for CF across the Globe—Where Is It Worthwhile? </span>
- <i property="schema:publisher" typeof="schema:Organization">Int J Neonatal Screen </i>
- <b property="issueNumber" typeof="PublicationIssue">6</b>,
- (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
- <a className="doi" href="https://doi.org/10.3390/ijn6010018"> doi: 10.3390/ijn6010018</a>
- </li>
- {/* <!-- Citation num 8--> */}
- <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
- <span property="schema:author" typeof="schema:Person">
- <span property="schema:Name">Scotet, V.</span>,
- <span property="schema:Name">Gutierrez, H.</span>,
- <span property="schema:Name">Farrell, P. </span>
- </span>
- <span property="schema:name">Newborn Screening for CF across the Globe—Where Is It Worthwhile? </span>
- <i property="schema:publisher" typeof="schema:Organization">Int J Neonatal Screen </i>
- <b property="issueNumber" typeof="PublicationIssue">6</b>,
- (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
- <a className="doi" href="https://doi.org/10.3390/ijn6010018"> doi: 10.3390/ijn6010018</a>
- </li>
- {/* <!-- Citation num 9--> */}
- <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
- <span property="schema:author" typeof="schema:Person">
- <span property="schema:Name">Scotet, V.</span>,
- <span property="schema:Name">Gutierrez, H.</span>,
- <span property="schema:Name">Farrell, P. </span>
- </span>
- <span property="schema:name">Newborn Screening for CF across the Globe—Where Is It Worthwhile? </span>
- <i property="schema:publisher" typeof="schema:Organization">Int J Neonatal Screen </i>
- <b property="issueNumber" typeof="PublicationIssue">6</b>,
- (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
- <a className="doi" href="https://doi.org/10.3390/ijn6010018"> doi: 10.3390/ijn6010018</a>
- </li>
- {/* <!-- Citation num 10--> */}
- <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
- <span property="schema:author" typeof="schema:Person">
- <span property="schema:Name">Scotet, V.</span>,
- <span property="schema:Name">Gutierrez, H.</span>,
- <span property="schema:Name">Farrell, P. </span>
- </span>
- <span property="schema:name">Newborn Screening for CF across the Globe—Where Is It Worthwhile? </span>
- <i property="schema:publisher" typeof="schema:Organization">Int J Neonatal Screen </i>
- <b property="issueNumber" typeof="PublicationIssue">6</b>,
- (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
- <a className="doi" href="https://doi.org/10.3390/ijn6010018"> doi: 10.3390/ijn6010018</a>
- </li>
- </ol>
- </Section>
+ <ol>{/*<!-- Citation num 1--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Cloarec-Ung, F.</span>
+ <span property="schema:Name"> Beaulieu, J.</span>
+ <span property="schema:Name"> Suthananthan, A.</span>
+ <span property="schema:Name"> Lehnertz, B.</span>
+ <span property="schema:Name"> Sauvageau, G.</span>
+ <span property="schema:Name"> Sheppard, H. M.</span>
+ <span property="schema:Name"> Knapp, D. J. H. F.</span>
+ </span>
+ <span property="schema:name">
+Near-perfect precise on-target editing of human hematopoietic stem and
+progenitor cells
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> eLife</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 12,</b>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2024">2024</time>).
+ <a className="doi" href="https://doi.org/10.7554/eLife.91288"> doi: 10.7554/eLife.91288</a>
+</li>
+
+{/*<!-- Citation num 2--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-2">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Nelson, J. W.</span>
+ <span property="schema:Name"> Randolph, P. B.</span>
+ <span property="schema:Name"> Shen, S. P.</span>
+ <span property="schema:Name"> Everette, K. A.</span>
+ <span property="schema:Name"> Chen, P. J.</span>
+ <span property="schema:Name"> Anzalone, A. V.</span>
+ <span property="schema:Name"> An, M.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name"> Engineered pegRNAs improve prime editing efficiency</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Nature Biotechnology</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 40</b>
+ , <span property="schema:pageBegin"> 402</span>-<span property="schema:pageEnd">410</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2022">2022</time>).
+ <a className="doi" href="https://doi.org/10.1038/s41587-021-01039-7"> doi: 10.1038/s41587-021-01039-7</a>
+</li>
+
+{/*<!-- Citation num 3--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-3">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Doench, J. G.</span>
+ <span property="schema:Name"> Fusi, N.</span>
+ <span property="schema:Name"> Sullender, M.</span>
+ <span property="schema:Name"> Hegde, M.</span>
+ <span property="schema:Name"> Vaimberg, E. W.</span>
+ <span property="schema:Name"> Donovan, K. F.</span>
+ <span property="schema:Name"> Smith, I.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name">
+Optimized sgRNA design to maximize activity and minimize off-target effects
+of CRISPR-Cas9
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Nature Biotechnology</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 34</b>
+ , <span property="schema:pageBegin"> 184</span>-<span property="schema:pageEnd">191</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2016">2016</time>).
+ <a className="doi" href="https://doi.org/10.1038/nbt.3437"> doi: 10.1038/nbt.3437</a>
+</li>
+
+{/*<!-- Citation num 4--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-4">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> White, N.</span>
+ <span property="schema:Name"> Sadeeshkumar, H.</span>
+ <span property="schema:Name"> Sun, A.</span>
+ <span property="schema:Name"> Sudarsan, N.</span>
+ <span property="schema:Name"> Breaker, R. R.</span>
+ </span>
+ <span property="schema:name">
+Na+ riboswitches regulate genes for diverse physiological processes in
+bacteria
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Nature Chemical Biology</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 18</b>
+ , <span property="schema:pageBegin"> 878</span>-<span property="schema:pageEnd">885</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2022">2022</time>).
+ <a className="doi" href="https://doi.org/10.1038/s41589-022-01086-4"> doi: 10.1038/s41589-022-01086-4</a>
+</li>
+
+{/*<!-- Citation num 5--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-5">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Iwawaki, T.</span>
+ <span property="schema:Name"> Akai, R.</span>
+ </span>
+ <span property="schema:name">
+Analysis of the XBP1 splicing mechanism using endoplasmic reticulum
+stress-indicators
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Biochemical and Biophysical Research Communications</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 350</b>
+ , <span property="schema:pageBegin"> 709</span>-<span property="schema:pageEnd">715</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2006">2006</time>).
+ <a className="doi" href="https://doi.org/10.1016/j.bbrc.2006.09.100"> doi: 10.1016/j.bbrc.2006.09.100</a>
+</li>
+
+{/*<!-- Citation num 6--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-6">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Zhang, Y.</span>
+ <span property="schema:Name"> Lin, S.</span>
+ <span property="schema:Name"> Yao, J.</span>
+ <span property="schema:Name"> Cai, W.</span>
+ <span property="schema:Name"> Chen, H.</span>
+ <span property="schema:Name"> Aierken, A.</span>
+ <span property="schema:Name"> Wang, Z.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name">
+XBP1 splicing contributes to endoplasmic reticulum stress-induced human islet
+amyloid polypeptide up-regulation
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Genes & Diseases</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 11</b>
+ <span property="schema:pageBegin">101148</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2023">2023</time>).
+ <a className="doi" href="https://doi.org/10.1016/j.gendis.2023.101148"> doi: 10.1016/j.gendis.2023.101148</a>
+</li>
+
+{/*<!-- Citation num 7--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-7">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Wei, T.</span>
+ <span property="schema:Name"> Sun, Y.</span>
+ <span property="schema:Name"> Cheng, Q.</span>
+ <span property="schema:Name"> Chatterjee, S.</span>
+ <span property="schema:Name"> Traylor, Z.</span>
+ <span property="schema:Name"> Johnson, L. T.</span>
+ <span property="schema:Name"> Coquelin, M. L.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name">
+Lung SORT LNPs enable precise homology-directed repair mediated
+CRISPR/Cas genome correction in cystic fibrosis models
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Nature Communications</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 14,</b>
+ <span property="schema:pageBegin"> 7322</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2023">2023</time>).
+ <a className="doi" href="https://doi.org/10.1038/s41467-023-42948-2"> doi: 10.1038/s41467-023-42948-2</a>
+</li>
+
+{/*<!-- Citation num 8--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-8">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Ibrahim, M.</span>
+ <span property="schema:Name"> Ramadan, E.</span>
+ <span property="schema:Name"> Elsadek, N. E.</span>
+ <span property="schema:Name"> Emam, S. E.</span>
+ <span property="schema:Name"> Shimizu, T.</span>
+ <span property="schema:Name"> Ando, H.</span>
+ <span property="schema:Name"> Ishima, Y.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name">
+Polyethylene glycol (PEG): The nature, immunogenicity, and role in the
+hypersensitivity of PEGylated products
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Journal of Controlled Release</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 351</b>
+ , <span property="schema:pageBegin"> 215</span>-<span property="schema:pageEnd">230</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2022">2022</time>).
+ <a className="doi" href="https://doi.org/https://doi.org/10.1016/j.jconrel.2022.09.031"> doi: https://doi.org/10.1016/j.jconrel.2022.09.031</a>
+</li>
+
+{/*<!-- Citation num 9--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-9">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Jiang, A. Y.</span>
+ <span property="schema:Name"> Witten, J.</span>
+ <span property="schema:Name"> Raji, I. O.</span>
+ <span property="schema:Name"> Eweje, F.</span>
+ <span property="schema:Name"> MacIsaac, C.</span>
+ <span property="schema:Name"> Meng, S.</span>
+ <span property="schema:Name"> Oladimeji, F. A.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name">
+Combinatorial development of nebulized mRNA delivery formulations for the
+lungs
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Nature Nanotechnology</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 19</b>
+ , <span property="schema:pageBegin"> 364</span>-<span property="schema:pageEnd">375</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2024">2024</time>).
+ <a className="doi" href="https://doi.org/10.1038/s41565-023-01548-3"> doi: 10.1038/s41565-023-01548-3</a>
+</li>
+
+{/*<!-- Citation num 10--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-10">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Vilà -González, M.</span>
+ <span property="schema:Name"> Pinte, L.</span>
+ <span property="schema:Name"> Fradique, R.</span>
+ <span property="schema:Name"> Causa, E.</span>
+ <span property="schema:Name"> Kool, H.</span>
+ <span property="schema:Name"> Rodrat, M.</span>
+ <span property="schema:Name"> Morell, C. M.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name">
+In vitro platform to model the function of ionocytes in the human airway
+epithelium
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Respiratory Research</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 25</b>
+ <span property="schema:pageBegin"> 180</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2024">2024</time>).
+ <a className="doi" href="https://doi.org/10.1186/s12931-024-02800-7"> doi: 10.1186/s12931-024-02800-7</a>
+</li>
+
+{/*<!-- Citation num 11--> */}
+<li typeof="schema:Book" role="doc-biblioentry" property="schema:citation" id="desc-11">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Paris, K.</span>
+ </span>
+ <span property="schema:name"> Genome Editing and Biological Weapons: Assessing the Risk of Misuse.</span>
+ <i property="schema:publisher" typeof="schema:Organization"> Springer Nature Switzerland AG</i>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2023">2023</time>).
+</li>
+
+{/*<!-- Citation num 12--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-12">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Wickiser, J. K.</span>
+ </span>
+ <span property="schema:name">
+The democratization of biology: how CRISPR and synthetic biology usher in new
+biosecurity threats
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Defense Horizons</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 85</b>
+ , <span property="schema:pageBegin"> 1</span>-<span property="schema:pageEnd">16</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2020">2020</time>).
+</li>
+
+{/*<!-- Citation num 13--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-13">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Cohen, J.</span>
+ <span property="schema:Name"> Desai, T.</span>
+ </span>
+ <span property="schema:name">
+Security implications of CRISPR-enabled genome editing: New weapons of mass
+disruption?
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Journal of Bioethical Inquiry</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 16</b>
+ , <span property="schema:pageBegin"> 219</span>-<span property="schema:pageEnd">228</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2019">2019</time>).
+ <a className="doi" href="https://doi.org/10.1007/s11673-019-09914-5"> doi: 10.1007/s11673-019-09914-5</a>
+</li>
+
+{/*<!-- Citation num 14--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-14">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Doudna, J. A.</span>
+ <span property="schema:Name"> Charpentier, E.</span>
+ </span>
+ <span property="schema:name">
+The rise of synthetic biology: New biosecurity risks and regulatory
+challenges
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Nature Reviews Genetics</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 21</b>
+ , <span property="schema:pageBegin"> 144</span>-<span property="schema:pageEnd">156</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2020">2020</time>).
+ <a className="doi" href="https://doi.org/10.1038/s41576-019-0182-7"> doi: 10.1038/s41576-019-0182-7</a>
+</li>
+
+{/*<!-- Citation num 15--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-15">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Shwartz, M.</span>
+ <span property="schema:Name"> Conklin, B.</span>
+ </span>
+ <span property="schema:name">
+Public perception of CRISPR and genome editing: Misconceptions and media
+portrayal
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Journal of Science Communication</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 18,</b>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2019">2019</time>).
+ <a className="doi" href="https://doi.org/10.22323/2.18040202"> doi: 10.22323/2.18040202</a>
+</li>
+
+{/*<!-- Citation num 16--> */}
+<li typeof="schema:Book" role="doc-biblioentry" property="schema:citation" id="desc-16">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Chadwick, R. F.</span>
+ </span>
+ <span property="schema:name"> Encyclopedia of applied ethics.</span>
+ <i property="schema:publisher" typeof="schema:Organization"> Academic Press</i>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2012">2012</time>).
+</li>
+
+{/*<!-- Citation num 17--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-17">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Rubeis, G.</span>
+ <span property="schema:Name"> Steger, F.</span>
+ </span>
+ <span property="schema:name"> Risks and benefits of human germline genome editing: An ethical analysis</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Asian Bioethics Review</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 10</b>
+ , <span property="schema:pageBegin"> 133</span>-<span property="schema:pageEnd">141</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2018">2018</time>).
+ <a className="doi" href="https://doi.org/10.1007/s41649-018-0056-x"> doi: 10.1007/s41649-018-0056-x</a>
+</li>
+
+{/*<!-- Citation num 18--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-18">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Ansah, E. O.</span>
+ </span>
+ <span property="schema:name">
+Ethical Challenges and Controversies in the Practice and Advancement of Gene
+Therapy
+</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Advances in Cell and Gene Therapy</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 2022</b>
+ , <span property="schema:pageBegin"> 1</span>-<span property="schema:pageEnd">5</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2022">2022</time>).
+ <a className="doi" href="https://doi.org/10.1155/2022/1015996"> doi: 10.1155/2022/1015996</a>
+</li>
+
+{/*<!-- Citation num 19--> */}
+<li typeof="schema:Book" role="doc-biblioentry" property="schema:citation" id="desc-19">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Pugh, J.</span>
+ </span>
+ <span property="schema:name"> Autonomy, Rationality, and Contemporary Bioethics.</span>
+ <i property="schema:publisher" typeof="schema:Organization"> Oxford University PressOxford</i>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2020">2020</time>).
+</li>
+
+{/*<!-- Citation num 20--> */}
+<li typeof="schema:Book" role="doc-biblioentry" property="schema:citation" id="desc-20">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Gstraunthaler, G.</span>
+ <span property="schema:Name"> Lindl, T.</span>
+ </span>
+ <span property="schema:name"> Allgemeine Aspekte der Primärkultur.</span>
+ <i property="schema:publisher" typeof="schema:Organization"> Springer</i>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2013">2013</time>).
+</li>
+
+{/*<!-- Citation num 21--> */}
+<li typeof="schema:Book" role="doc-biblioentry" property="schema:citation" id="desc-21">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Thiele, F.</span>
+ </span>
+ <span property="schema:name"> International Encyclopedia of the Social & Behavioral Sciences.</span>
+ <i property="schema:publisher" typeof="schema:Organization"> Elsevier</i>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2001">2001</time>).
+</li>
+
+{/*<!-- Citation num 22--> */}
+<li typeof="schema:Book" role="doc-biblioentry" property="schema:citation" id="desc-22">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Gethmann, C.</span>
+ </span>
+ <span property="schema:name"> Research: Ethical Aspects of Long-term Responsibilities.</span>
+ <i property="schema:publisher" typeof="schema:Organization"> Elsevier</i>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime="2001">2001</time>).
+</li>
+
+{/*<!-- Citation num 23--> */}
+<li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-23">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Kiani, A. K.</span>
+ <span property="schema:Name"> Pheby, D.</span>
+ <span property="schema:Name"> Henehan, G.</span>
+ <span property="schema:Name"> Brown, R.</span>
+ <span property="schema:Name"> Sieving, P.</span>
+ <span property="schema:Name"> Sykora, P.</span>
+ <span property="schema:Name"> Marks, R.</span>
+ <span property="schema:Name"> et al.</span>
+ </span>
+ <span property="schema:name"> Ethical considerations regarding animal experimentation</span>.
+ <i property="schema:publisher" typeof="schema:Organization"> Journal of Preventive Medicine and Hygiene</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 63</b>
+ , <span property="schema:pageBegin"> E255</span>-<span property="schema:pageEnd">E266</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2022">2022</time>).
+ <a className="doi" href="https://doi.org/10.15167/2421-4248/jpmh2022.63.2S3.2768"> doi: 10.15167/2421-4248/jpmh2022.63.2S3.2768</a>
+</li>
+
+</ol>
+ </Section>
</>
);
}
diff --git a/src/data/drug-data.tsx b/src/data/drug-data.tsx
index 3e15d263a6e2eceb5b9e9167ff33757407427d21..f0dd967c94b6ed9477c3db9b0e301831f08349fc 100644
--- a/src/data/drug-data.tsx
+++ b/src/data/drug-data.tsx
@@ -5,89 +5,95 @@ export interface DrugDatensatz {
introduction: string;
examples: Array<example>;
+
}
+
interface example{
title: string,
- text: Array<string>;
+ text: Array<string> | Array<React.ReactNode>;
}
-
+
export const drugdata: (Array<DrugDatensatz>) = [
- {
- name: "About",
- picture: "...",
- introduction: "",
- examples: [
- {
- title: "",
- text: [""]
- },
- {
- title: "",
- text: ["string"]
- },
- ]
- },
+// {
+// name: "About",
+// picture: "...",
+// introduction: "",
+// examples: [
+// {
+// title: "",
+// text: [""]
+// },
+// {
+// title: "",
+// text: ["string"]
+// },
+// ]
+// },
{
//gibt 4 Modulator Beispiele
name: "Modulators",
- picture: "...",
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/modulators.svg",
introduction: "CFTR modulators represent a significant advancement in CF treatment since they are small molecules improving the function of the defective CFTR protein in a mutation-specific way, which helps restore chloride ion transport across cell membranes. Notable pharmaceutical agents include Trikafta®, Symdeko®, Orkambi® and Kalydeco® [1]. These medications have been demonstrated to significantly improve lung function and reduce pulmonary exacerbations. However, they are expensive and may cause side effects such as liver enzyme elevations and cataracts in pediatric patients [2]. Furthermore, they are not suitable for all CF patients since only mutations which produce a CFTR channel can be supported by CFTR modulators, not those mutations which lead to a missing CFTR channel (knock out) [1], e.g. stop-mutations including p.Arg553Ter or p.Gly542Ter [3]. ",
examples: [
{
- title: "Trikafta",
- text: ["Active ingredient(s): Combination of elexacaftor/tezacaftor/ivacaftor","Indications: For CF patients aged 2 years and older with at least one F508del mutation à 85 % of CF patients","Mechanism: Elexacaftor and tezacaftor act as correctors on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5].","Administration: Oral tablets","Approval: Approved by the EMA in 2020 "]
+ title: "Trikafta", //quelle 4
+ text: ["Active ingredient(s): Combination of elexacaftor/tezacaftor/ivacaftor","Indications: For CF patients aged 2 years and older with at least one F508del mutation = 85 % of CF patients","Mechanism: Elexacaftor and tezacaftor act as correctors on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5]","Administration: Oral tablets","Approval: Approved by the EMA in 2020 "]
},
{
- title: "Symdeko",
+ title: "Symdeko", //quelle 1
text: ["Active ingredient(s): Combination of tezacaftor and ivacaftor","Indications: For CF patients aged 6 years and older with specific mutations in combination with F508del or with two copies of F508del mutation", "Mechanism: Tezacaftor acts as a corrector on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5]", "Administration: Oral tablets", "Approval: Approved by the EMA in 2018"]
},
{
- title: "Orkambi",
+ title: "Orkambi", //quelle 6
text: ["Active ingredient(s): Combination of lumacaftor and ivacaftor", "Indications: For CF patients aged 1 year and older with two copies of the F508del mutation","Mechanism: Lumacaftor acts as a corrector on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator act on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5]","Administration: Oral tablets","Approval: Approved by the EMA in 2015"]
},
{
- title: "Kalydeco",
+ title: "Kalydeco", //quelle 7
text: ["Active ingredient(s): Ivacaftor","Indications: For CF patients aged 4 months and older with a gating mutation in the CFTR gene (excluding F508del)","Mechanism: Ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5]","Administration: Oral tablets","Approval: Approved by the EMA in July 2012"]
},
]
},
{
- name: "Mucolytics & inhalation",
- picture: "...",
- introduction: "",
+ name: "Mucolytics and inhalation", //gibt 2 Inhalation Beispiele
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/mucolytics.svg",
+ introduction: "Mucolytics help thin and loosen the mucus in the lungs, making it easier to cough up and clear the airways. These therapies are typically administered via wet or dry inhalation, providing direct delivery to the lungs. In the case of wet inhalation, the medication is inhaled as an aqueous solution and nebulized, while in the case of dry inhalation, the medication is inhaled as a powder. [1] Key Therapies include mannitol, Pulmozyme® and hypertonic saline.",
examples: [
{
- title: "",
- text: ["test"]
+ title: "Pulmozyme", //quelle 8
+ text: ["Active ingredient(s): Dornase alfa as mucolytic enzyme","Indications: For CF patients aged 5 years and older","Mechanism: breaks up and thins mucus via DNase activity","Administration: Inhalation via nebulizer, once or twice daily","Approval: Approved by the FDA in 1993 [9]"]
},
{
- title: "",
- text: ["test2"]
- },
- {
- title: "",
- text: ["test2"]
+ title: "Hypertonic saline",//quelle 10
+ text: ["Active ingredient(s): Osmotic agent sodium chloride (3%, 3.5%, 7%)","Indications: For CF patients aged 6 years and older","Mechanism: Draws water into the airways, hydrating the mucus and improving clearance","Administration: Inhalation via nebulizer, used twice daily","Approval: no official approval by EMA or FDA available, but widely used for several decades [11]","Price: low-cost [11]"]
},
]
},
{
- name: "Modulators",
- picture: "...",
- introduction: "",
+ name: "Antibiotics", //gibt 2 AB Beispiele
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/antibiotics.svg",
+ introduction: "Antibiotics are crucial for treating bacterial infections in CF patients since the mucus serves as an optimal environment for pathogens. A huge variety of antibiotics can be inhaled, oral, or intravenous, depending on the severity and kind of the infection [12]. Commercially available medications include TOBI® and CAYSTON®. A major problem associated with the application of antibiotics is the fact that long-term use can lead to antibiotic resistance and potential side effects like kidney damage and hearing loss [12].",
examples: [
{
- title: "",
- text: ["test"]
+ title: "TOBI", //quelle 13 + Pseudo muss kursiv
+ text: ["Active ingredient(s): Tobramycin",<>Indications: For CF patients aged 6 years and older with <i> Pseudomonas aeruginosa </i> infections </>,"Mechanism: Aminoglycoside antibiotic disrupts bacterial protein synthesis, leading to the death of the pathogen","Administration: Inhalation of antibiotic via nebulizer, typically taken twice daily in 28-day cycles","Approval: Approved by the EMA in 2011 [14]"]
},
{
- title: "",
- text: ["test2"]
+ title: "CAYSTON", //quelle 15 + Pseudo muss kursiv
+ text: ["Active ingredient(s): Aztreonam",<>Indications: For CF patients aged 6 years and older with <i> Pseudomonas aeruginosa </i> infections </>,"Mechanism: Beta-Lactam antibiotic disrupts bacterial cell wall synthesis, leading to the death of the pathogen","Administration: Inhalation via nebulizer, taken three times daily in 28-day cycles","Approval: Approved by the EMA in 2009"]
},
+ ]
+ },
+ {
+ name: "Digestive enzymes and diet", //ein beispiel
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/diet.svg",
+ introduction: "The digestive process is impaired in 80% of patients with cystic fibrosis (CF), as a result of pancreatic insufficiency, which in turn leads to difficulties in digesting food and absorbing nutrients. Enzyme supplements like Creon® are therefore essential [16]. Moreover CF patients are also advised to eat a balanced and energy-rich diet, as the increased work of breathing and increased coughing, as well as infections, fever and diarrhoea, consume more energy than a healthy person. [1] It is also an option for patients to use nutritional supplements. Electrolyte preparations are also used in this context to compensate for the increased need for fluids and the required salts.",
+ examples: [
{
- title: "",
- text: ["test2"]
+ title: "Creon", //quelle 17
+ text: ["Active ingredient(s): pancreatic enzymes (lipase, amylase, protease) for enzyme replacement therapy","Indications: For CF patients with exocrine pancreatic insufficiency","Mechanism: Provides digestive enzymes (lipase, protease, amylase) to aid digestion","Administration: Oral capsules, taken with meals","Approval: Approved by the FDA in 2009"]
},
+
]
}
]
\ No newline at end of file
diff --git a/src/data/hptimelinedata.tsx b/src/data/hptimelinedata.tsx
index 2eacaa651b7862e3798818589029665fc754d96a..e1ee5a8ed45fa2ce48ceed8f98a3db3e9690598d 100644
--- a/src/data/hptimelinedata.tsx
+++ b/src/data/hptimelinedata.tsx
@@ -1,4 +1,5 @@
import { QaBox } from "../components/Boxes";
+import { TabScrollLink } from "../components/Link";
import { ScrollLinkWithChild } from "../components/ScrollLink";
export interface TimelineDatenpunkt {
@@ -27,11 +28,15 @@ export interface TimelineDatenpunkt {
more_pictures?: Array<string> ;
references?: Array<React.ReactNode>; /* Muss HTML Code sein - Liliana erstellt den aus Bib dateien */
interview?: React.ReactNode;
+ text?: string | Array<string> | Array<React.ReactNode>; /* Extra Text */
}
+
type StakeholderTag = 'Industry' | 'Academia' | 'Patient' | 'Medical Professional' | 'Milestone' | 'Other';
-type TypeTag = 'meta' ;
+type TypeTag = 'meta' | 'kaya' ;
type Language = 'en' | 'de';
+
+
const pics: { [key: string]: string } = {
placeholder: "https://static.igem.wiki/teams/5247/placeholders/placehilderperson.jpeg",
max: "https://static.igem.wiki/teams/5247/photos/hp/hp-max-portrait.jpg",
@@ -46,6 +51,7 @@ const pics: { [key: string]: string } = {
draeger: "https://static.igem.wiki/teams/5247/photos/hp/oliver-draeger-patch-clamp.jpeg",
winkeljann: "https://static.igem.wiki/teams/5247/photos/hp/rnhale-winkeljann.jpg",
kuehnel: "https://static.igem.wiki/teams/5247/photos/hp/hp-philippk-hnel.jpeg ",
+ wischmeyer: "https://static.igem.wiki/teams/5247/photos/hp/wischmeyer-erhard.webp",
};
/* {
@@ -68,7 +74,7 @@ const pics: { [key: string]: string } = {
Fehlende Infos einfach leer lassen und keine Dummy-Texte einfügen!
*/
-export const timelinedata: Array<TimelineDatenpunkt> = [
+export const timelinedata: Array<TimelineDatenpunkt> = [
{
vorname: "Building the team",
nachnname: "",
@@ -138,26 +144,25 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
heading: "Gathering valuable insights from the patient’s perspective",
interviewtabid: "maxfirst",
cardtext: "",
- quoteNachname: "Mundt",
- quoteVorname: "Philip",
language: "de",
- quote: "The statement that left the biggest impression for me was when Max was telling about a friend of his and fellow cystic fibrosis patient who caught a fungi infection which he now cannot get rid of anymore, showing how fast a seemingly little infection can change the life of a cystic fibrosis patient for the worse without any kind of warning.",
+ quote: "A friend of mine with cystic fibrosis recently got a fungal infection that he can't get rid of. His situation really struck me; it showed how quickly a seemingly minor issue can worsen a person's life, especially for someone like us. It’s a strong reminder of how fragile our health is and how fast things can change without warning.",
aimofcontact: [<p>When cystic fibrosis came up as a possible topic, we reached out to a teammate's friend Max in the hopes of getting insights into the needs of CF patients and current treatments to verify the need for further treatment options.
Since he was much more enthusiastic and open for discussion than we dared to hope, we extended our exchanges into the realms of the reality of life for CF patients, possible progressions, organizations and doctors in our area and his personal perspectives and values.
The interest in meeting him grew in the whole team and we invited him to one of our meetings. </p>],
- insights: [ <><p>His honest and open answers to us, mostly nothing more than strangers to him, were touching and let the seriousness of cystic fibrosis set in. Learning about the challenges he faced felt heavy, besides him being relatively healthy and having a good life quality as a CF patient.
+ insights: [ <><p>His honest and open answers to us, mostly nothing more than strangers to him, were touching and let the seriousness of cystic fibrosis set in.
+ Learning about the challenges he faced felt heavy, besides him being in relatively good health and having a good life quality for a CF patient.
</p>
<p>Additional to the interpersonal effects of our discussion, Max gave us the reasons to continue with gene therapy approach while focusing on the lung:
- Modulators do not erase all symptoms
- There is a keen interest for new treatments in the CF community
- The lung function is most affected for most patients
- The immense impact of treatments on the life quality </p>
+ Modulators do not erase all symptoms.
+ There is a keen interest for new treatments in the CF community.
+ The the decreasing lung functionality it the most limiting.
+ The immense impact of treatments on the life quality. </p>
<p>We learned a lot of new things that we did not consider before about cystic fibrosis such as:
- The need for a calorie rich diet and digestive problems
- The frequency of checkups needed
- How vastly different the progressions can be
- The increased need for hygiene
- The high price of medicines and induvial therapeutics </p>
+ The need for a calorie rich diet and digestive problems.
+ The frequency of checkups needed.
+ How vastly different the progressions can be.
+ The increased need for hygiene to prevent infections.
+ The high price of medicines and induvial therapeutics. </p>
<p>Afterwards, we reflected on the discussion and asked our team members what stuck with them:
“How much attention has to be paid to everything in everyday life, I hadn't even thought about problems at the hairdresser.â€
“Simply that he was there and reported everything in such detail. From minute 1, I had permanent goosebumps because I was so moved by this story. I think it's great how he stands his ground in life, does what he wants to do and what defines him as a person. It didn't seem as if his life was determined by CF. I somehow expected it to be different, even if that sounds a bit silly.â€
@@ -299,13 +304,13 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
nachnname: "Gerhards",
job: "Student",
affiliation: "Intern at Harvard/ Boston Childrens Hospital",
- pictureurl: pics['placeholder'],
+ pictureurl: "https://static.igem.wiki/teams/5247/photos/hp/hp-jpgerhards-potrats.webp",
tag: "Academia",
heading: "Discussion on optimizing our pegRNA Design to improve precision in prime editing",
interviewtabid: "JPpegRNA",
cardtext: "",
language: "de",
- quoteNachname:"Lenger",
+ quoteNachname:"Lenger, Teammember",
quoteVorname:"Malte",
quote: "The interview proved invaluable in gaining an initial understanding of the principles of pegRNA design and optimisation, particularly in the context of silent edits.",
aimofcontact: "The aim of the contact was to engage in a discussion about prime editing and pegRNAs, as the Jan-Phillip Gerhards had used these technologies in his internship. We sought to exchange ideas, gather insights, and explore potential improvements or strategies for our project, leveraging his experience with prime editing tools. His practical knowledge in this field was very valuable for refining our approach and ensuring we were aligned with the latest advancements and methodologies in prime editing. ",
@@ -373,26 +378,24 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<li>Psychological support is crucial.</li>
<li>A well-functioning treatment team is essential.</li>
</ol>,
- <p>We have jointly weighed up the extent to which an early diagnosis is always an advantage, as some parents perceive an early diagnosis as an additional burden and would prefer to experience the first years of their child's life without constant medical intervention. Especially when there are cases in which patients only show a clear clinical picture at an advanced age. The psychological burden also lies with the children, who often experience medical trauma because they are involved in such intensive medical care from birth. Additionally, the treatment of cystic fibrosis is very expensive, and the costs are covered by health insurance companies to varying degrees. In some countries, such as the USA, Ukraine or Developing countries, many families cannot afford the necessary treatments. Dr Olariu drew our attention to another problem in the treatment of cystic fibrosis. Infections, especially with bacteria such as Pseudomonas spcc., are difficult to treat and often lead to long hospital stays. Max, our patients’ representative, who knows Dr. Olariu through his treatment, talked about his infections with Pseudomonas spcc., illustrating the reality of an invisible danger that determines a patient's everyday life. Strict hygiene measures are required to prevent infections, such as wearing face masks in hospital and careful handling of potential sources of infection. The clinics where cystic fibrosis patients are treated work closely with a multidisciplinary team of doctors, psychologists, physiotherapists and nutritionists to ensure that patients receive holistic care. At the same time, research is constantly being carried out and new therapeutic approaches developed, such as the use of nanoparticles to improve drug delivery. Former patients are also involved in research and provide valuable insights and advances. </p>
- ,<ol>
- <li>Pros of Early Diagnosis and Treatment</li>
+ <p>We have jointly weighed up the extent to which an early diagnosis is always an advantage, as some parents perceive an early diagnosis as an additional burden and would prefer to experience the first years of their child's life without constant medical intervention. Especially when there are cases in which patients only show a clear clinical picture at an advanced age. The psychological burden also lies with the children, who often experience medical trauma because they are involved in such intensive medical care from birth. Additionally, the treatment of cystic fibrosis is very expensive, and the costs are covered by health insurance companies to varying degrees. In some countries, such as the USA, Ukraine or Developing countries, many families cannot afford the necessary treatments. Dr Olariu drew our attention to another problem in the treatment of cystic fibrosis. Infections, especially with bacteria such as Pseudomonas spcc., are difficult to treat and often lead to long hospital stays. Max, our patients’ representative, who knows Dr. Olariu through his treatment, talked about his infections with Pseudomonas spcc., illustrating the reality of an invisible danger that determines a patient's everyday life. Strict hygiene measures are required to prevent infections, such as wearing face masks in hospital and careful handling of potential sources of infection. The clinics where cystic fibrosis patients are treated work closely with a multidisciplinary team of doctors, psychologists, physiotherapists and nutritionists to ensure that patients receive holistic care. At the same time, research is constantly being carried out and new therapeutic approaches developed, such as the use of nanoparticles to improve drug delivery. Former patients are also involved in research and provide valuable insights and advances. </p>,
+ <ol>
+ <li>Pros of Early Diagnosis and Treatment</li> </ol>,
<ol>
<li>Timely Intervention: Prevents severe organ damage and improves long-term outcomes.</li>
<li>Holistic Care: Involves a multidisciplinary team for comprehensive patient support.</li>
<li>Access to Innovations: Allows patients to benefit from advancements like nanoparticle drug delivery.</li>
<li>Family Support: Provides education and resources for effective management from the start.</li>
- </ol>
- </ol>,
+ </ol>,
<ol>
- <li>Cons of Early Diagnosis and Treatment</li>
+ <li>Cons of Early Diagnosis and Treatment</li></ol>,
<ol>
<li>Psychological Burden: May cause stress for parents and children due to constant medical interventions.</li>
<li>Cost Implications: Treatments can be expensive, with varying insurance coverage, leaving many families unable to afford care.</li>
<li>Infection Risks: Patients still face risks from infections like Pseudomonas spp., leading to potential hospitalizations.</li>
<li>Over-medicalization: Continuous focus on treatment can overwhelm families, affecting the quality of early childhood experiences.</li>
- </ol>
- </ol>
+ </ol>,
],
implementation: "In summary, our project greatly benefited from the conversation with Dr. Olariu. His insights into the complexities of cystic fibrosis treatment, particularly the significance of early diagnosis, were invaluable. Max’s personal experiences added a crucial human perspective, illustrating the medical and psychological challenges he faces, including infections with Pseudomonas spp. Dr. Olariu emphasized the importance of a multidisciplinary approach, involving not just medical professionals but also psychologists, physiotherapists, and nutritionists for holistic care. This discussion helped us appreciate the balance between timely interventions and the emotional burden on patients and their families, guiding us to develop a more empathetic understanding of living with cystic fibrosis. ",
interview: <>
@@ -412,7 +415,10 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="What do you think about support groups or health retreats for CF patients?" a="Support groups are extremely important. Although we are a good medical team, advice from peers often resonates more with patients. We’ve organized two parents' evenings recently, where parents can exchange experiences and support each other. Unfortunately, we can’t invite the children themselves due to the risk of infection, but in rehabilitation settings, they can meet in germ-specific groups and benefit from shared experiences." />
<QaBox q="Is there a risk of antibiotic resistance with repeated treatments?" a="Yes, resistance is a concern, especially with repeated antibiotic treatments. However, there’s often a discrepancy between what we see in lab tests and the clinical outcomes. Even if a germ shows resistance on paper, many patients still respond well to treatment. We base our decisions more on clinical outcomes than lab results, changing antibiotics only if the patient’s condition doesn’t improve." />
<QaBox q="Are there any side effects to the medications?" a="Yes, all medications have potential side effects, though many of them are minor, like rashes or stomachaches. One serious side effect of some antibiotics is hearing damage, which can lead to lifelong hearing loss. This is why we closely monitor patients in the hospital when starting treatments. The newer therapies, like modulators, can cause liver stress, so we regularly check liver enzymes in the blood. However, severe side effects are rare, and the drugs are generally well tolerated." />
- </>
+ </>,
+ pictureurl_aim: "https://static.igem.wiki/teams/5247/photos/hp/interview-olariu.svg",
+ pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/hp/olario-abbildung1.svg",
+
},
{
vorname: "Mattijs",
@@ -425,15 +431,77 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
interviewtabid: "mattijsinv",
cardtext: "",
language: "en",
- quote: "I believe the challenge lies in the process when your cell has to repair the new DNA strand",
- aimofcontact: "Shortly after we decided to use prime editing as the gene editing method for our cystic fibrosis therapy, Mattijs Bulcaen from the Laboratory of Molecular Virology and Gene Therapy at KU Leuven and his colleagues published a paper directly related to our research1. In contrast to our approach, Bulcaen et al. 2024 targeted other, less common but drug-refractory CFTR-specific mutations (L227R- and N1303K). ",
- insights: "The insights gained from this interview proved invaluable in shaping our subsequent mechanistic approaches. Besides his comprehensive perspective of the significant advancements in the field of prime editing, Mattijs engaged us in a constructive dialogue, offering a critical assessment of our own ideas and approaches. ",
- implementation: "Mattijs explained why he did not try to target F508del. Of all the possible applications of Prime Editing in gene therapy, he told us, the CFTR F508del mutation is the most obvious target, but no substantial editing efficiency could be achieved at this target yet. He further elaborated that this might be due to DNA packaging, low cutting efficiencies at that locus, the AT rich region surrounding F508del and also possible intramolecular binding of the pegRNA, but we do not really understand the mechanistic reason yet. Additionally, he mentioned a talk given by David Liu,[Link] the principal investigator behind prime editing that helped us to consider further novel advancements in F508del-specific CFTR-treatment and include them into our project. Beside the clinical context, we discussed different methods of testing edited cells for CFTR reconstitution, such as measurements using the Ussing chamber, organoid swelling assays and halide sensitive eYFP fluorescence assays. Additionally, we discussed the use of stem loops for protection of the pegRNA, which we then included into our own pegRNA design. Lastly, we officially cooperated with the research group and the university: Mattijs was willing to share two different HEK293T cell lines [Link] stably overexpressing the CFTR wild-type and F508del proteins. We also visited Mattijs in his laboratory in Leuven to discuss this further. During our visit we discussed different downstream applications on proteomic, genomic and electrophysiological levels. Besides antibody staining of the CFTR-3HA protein, we asked for his insights on patch clamp measurements and DNA sequencing as well as the advantages and disadvantages of different delivery systems for prime editors. Additionally, Mattijs provided more details into the CFTR overexpressing cell lines, and we received guidance on handling of these kinds of cells. Until the end of the project, we maintained communication with Mattijs Bulcaen via email for further questions and gave updates concerning our project to implement the feedback loop according to our integrated Human Practice Framework.",
- /* references:
- <ol>
- /*<!-- Citation num 1--> */
+ quote: "[…] Prime Editing system is more complex than the canonical CRISPR systems, with more variables that can influence success or failure.",
+ aimofcontact: [<p>Shortly after we decided to use prime editing as the gene editing method for our cystic fibrosis therapy, Mattijs Bulcaen from the Laboratory of Molecular Virology and Gene Therapy at KU Leuven and his colleagues published a paper directly related to our research <TabScrollLink tab="mattijsinv" scrollId="desc-1" num="1" />. In contrast to our approach, Bulcaen et al. 2024 targeted other, less common but drug-refractory CFTR-specific mutations (L227R- and N1303K).  </p>],
+ insights: "The interview with Mattijs was valuable for us in a lot of ways. At that point in the project we were starting to design the components of our prime editor, but we were lacking a broader overview over the state of the field. Mattijs gave us this insight, mentioning techniques like PE3b systems, dsgRNAs and a talk given by David Liu,[Link] the principal investigator behind prime editing that helped us to consider further novel advancements in in Prime Editing and include them into our project. He discussed with us the difficulties that might await us when targeting the CFTR F508del deletion and mentioned that insertions of all the edits possible with prime editing are the hardest to make, the recognition of edits in the region might attract mismatch repair systems and the chromatin organization might negatively impact prime editing efficiency. Also, we learned a lot about how to design our pegRNAs, with important inputs being the 3’ stem loop motif trevopreQ1 used by Mattijs in his publication and the suggestion to use prediction tools to evaluate sgRNA spacer cutting efficiency. We reviewed our approach of testing pegRNAs using the PEAR reporter system and Mattjis recommended to use HEK cell lines for screening because of their easy handling and naturally impaired mismatch repair system. ",
+ implementation: "The inputs given by Mattijs directly impacted our design choices for multiple parts of the project. For the pegRNA design, we decided to use the same 3’ motif as Mattijs had used and also, like he suggested, checked our spacer candidates for predicted cleavage efficiency. Also we used HEK cells for screening our pegRNAs. We looked further into PE systems that influence cellular mismatch repair (such as PE4) and tried to include these into our design. ",
+ interview:<>
+ <QaBox q="You mentioned that it was quite challenging to target the F508 delta mutation. Could you provide more detailed reasons for why this is the case or explain why this mutation is particularly difficult to target compared to others?" a="Yes, that's the million-dollar question. First of all, let me clarify: our group has never directly worked on that mutation because we immediately focused on the drug-refractory mutations, such as nonsense mutations where the protein is not formed, indel mutations, or severe missense mutations that do not respond to modulator therapies. Of course, we know several groups in the field who either work on gene editing or focus on cystic fibrosis (CF). We've heard from some of them who attempted to target the F508 delta mutation. For example, some collaborators really tried to design different guides but were unable to find anything above the detection limit. F508del is probably one of the most logical mutations to try to correct, not just for CF but for the entire gene-editing field. If you look at the frequencies of mutations that cause genetic diseases, the F508 delta mutation is by far the most common deletion mutation causing a severe disease. This is because CF, along with sickle cell disease, is one of the most common deadly inherited diseases, and it's overrepresented within CF. So, it makes sense that they would have been trying to target it from the beginning. Interestingly, if you read the Prime Editing paper by Anzalone, F508 delta is mentioned in the introduction in connection with cystic fibrosis. So, it's somewhat surprising that after all this time—it's been almost five years now—they haven't published or released anything on F508 delta. However, last weekend, there was an online seminar where David Liu gave a talk, and he showed some unpublished data indicating that they managed to achieve quite good Prime Editing efficiency on F508 delta. It's worth noting that David Liu rarely presents unpublished data unless the publication is either accepted or very close to acceptance. So, we all kind of expect that the paper will be published soon, perhaps within the next week or at least within a month. From what I saw, it appears they leveraged many of the approaches available today to enhance Prime Editing. Now, regarding your question about why this mutation is so difficult to target with Prime Editing, I can't provide an exact answer. However, I can list some potential difficulties associated with the mutation, and it’s likely that F508 delta is challenging for several of these reasons. For instance, it could be related to the genomic region itself. Writing insertions can be more difficult; the easiest edits are single-point mutations, followed by deletions, and the most challenging are insertions. This difficulty arises because it involves writing a third strand and then relying on DNA damage repair mechanisms to fix it. It could also be that the region around the F508 delta mutation is challenging due to flap equilibration or that it attracts pathways such as mismatch repair that negatively impact Prime Editing. Additionally, the chromatin organization around that region could play a role. Over the past year, we’ve gathered clues that chromatin organization significantly affects Prime Editing capability, while this is much less of an issue for Cas9 and base editors. Studying this is not straightforward; you would need to conduct experiments like ATAC-seq to determine the chromatin organization around the mutation and how it might interfere. I also noticed on a slide that dsgRNAs were mentioned, though David Liu didn't discuss them in his talk. After looking them up online, I found that this technique, published a few years ago by other researchers, is specifically designed to open up chromatin. It seems they use different guides, without the three-prime extension, to open up the chromatin, which could be one way to overcome the limitations in Prime Editing efficiency. There could be other factors as well, and it’s often difficult to predict what will work and what won't. We have prediction tools for Prime Editing guides that work to some extent, but they are not as effective as the prediction tools available for regular CRISPR guide RNAs. This suggests that the Prime Editing system is more complex than the canonical CRISPR systems, with more variables that can influence success or failure. I hope this answers your question somewhat." />
+ <QaBox q="Perhaps we could quickly discuss which part of the prime editing complex you think plays the most significant role in making insertions much more challenging compared to deletions. Is it the reverse transcriptase or the RNA?" a="I don't think it's primarily the reverse transcriptase that's the issue. People have shown that longer insertions are definitely possible. I believe the challenge lies in the process when your cell has to repair the new DNA strand, which is generated and exists as a three-stranded intermediate. We don’t directly intervene in this process; it entirely depends on the cell and the DNA damage repair pathways active in those cells. Through expression of dominant negative DNA damage repair effectors, or by nicking the non-edited strand, the outcome can be steered to some extent. When you perform an insertion, the new strand must hybridize with the bottom strand, which remains intact. This creates a small loop that needs to be incorporated. At this point, the cell faces two options: it can either revert to the original state or incorporate the edit you’re trying to introduce. In certain circumstances, perhaps due to how the new DNA strand folds or the sequence context of the region of interest, the cell might heavily favor reverting to the original state, resulting in the absence of the intended edit. This process is extremely difficult to predict, but there are several indications pointing in this direction. For example, in the case of point mutations, it has been shown that it’s easier to convert a C to a G rather than the reverse, simply due to how these mismatches are recognized by the DNA damage repair mechanisms. This area is very complex, and I don’t think anyone fully understands it yet. It’s also difficult to study. I don't believe the rate of reverse transcription is the limiting factor here, although it could play a role for long or structured pegRNAs. You might have already come across this, but the PE6 generation of Prime Editors, which were released about half a year ago, involve engineered or evolved reverse transcriptases that are more processive and can more easily synthesize longer transcripts. Another factor that could play a role is the secondary structure of the guide RNA. Each prime editing guide RNA faces a common problem: it has a spacer that binds the bottom strand and a three-prime extension that binds the top strand. Since these two parts of the RNA bind complementary strands, they are also complementary to each other, meaning every prime editing guide has some tendency to bind itself. If the Gibbs free energy is too high, the guide RNA may fold in on itself, preventing it from binding to the prime editor, which then inhibits prime editing. Additionally, the three-prime extension itself can fold independently. I haven’t specifically examined this for the F508 delta guides, but it is something that can be predicted. There are tools available that can predict the secondary structure of an RNA sequence, and if there’s a significant hairpin structure, it might mean the three-prime extension remains closed, preventing the reverse transcriptase from using it as a template. The PE6 prime editors have been engineered to be more effective in such scenarios, being less affected by secondary structures and better able to read through them." />
+ <QaBox q="What would be the application? Would you administer the heat shock in vivo, or...?" a="I believe they used it to engineer zebrafish embryos or something along those lines. It’s quite specific, of course. If you plan to deliver your guide RNA through a viral vector or similar method for human therapy, the application would differ significantly. You obviously can't administer a heat shock to humans, so it really depends on the context of your application." />
+ <QaBox q="Given the time constraints, let's move on to the next question. Due to our limited resources, we are targeting a PE2 system, and we'd like to ask if you see any chances of success with this system. If so, how high do you think the chances of success are?" a="PE2 can work, but it really depends on your application and the methods you have to assess the editing efficiency. If you can use NGS (Next-Generation Sequencing) for everything, you'll be able to detect edits even with PE2 systems. However, I would generally expect the efficiency to be low. Whenever possible, I would always recommend trying the PE3 system. Could you share what your specific application is, or is that confidential?" />
+ <QaBox q="So our goal is to eventually use it in vivo, but for now, we're focusing on trying to correct the mutation first in regular cell cultures and then later in primary cells." a="Is your focus specifically on the F508 delta mutation? If so, we could potentially help you get you started, as we already have constructs and cells with that mutation. We would need to discuss the financial aspects, but we might be able to assist. However, are you fully committed to targeting F508, or are you also considering other diseases or mutations?" />
+ <QaBox q="The timeframe of the project, combined with the fact that we’re all studying on the side, limits us to a certain scope. Since this is our first time tackling a project like this, it makes sense to stick to something more manageable. So, we're somewhat committed to focusing on F508 due to these constraints." a="That's understandable. It can be really tough to juggle a project like this along with exams and studies, especially if you're also involved in competitions. But it's definitely worth the effort, even if you don't achieve huge results right away. The experience and learning, as well as the connections you make, are incredibly valuable. I'm a big supporter of such"/>
+ <QaBox q="We have one patient who is willing to provide us with cells, but we don't have them yet." a="It sounds like you're aware of the challenges, and I don't want to discourage you, but just to be realistic, working with primary cells and getting everything ready could be tricky, especially considering the competition is in October. Experiments in human cells can take time, especially if you need to do multiple iterations or clone constructs—it could easily take a week or more per experiment." />
+ <QaBox q="Regarding the cells we have, as mentioned in our paper, we screened all our guides on HEK cells with an integrated copy of the CFTR cDNA. HEK cells are easy to work with, but they don't naturally express CFTR, even though the gene is present in their genome. So, we introduced the mutation of interest into these cells, making it easier to screen." a="I'm not entirely sure if we can send over the cells due to ethical regulations, which can be complex and time-consuming to navigate. However, there's an alternative approach that might help you. Early on, we found that it's actually quite easy to screen guides using what we call a 'transient target.' In this method, you would transfect all your prime editing plasmids into HEK cells, along with a plasmid containing the CFTR cDNA with the mutation of interest." />
+ <QaBox q="While this approach isn’t as physiological as editing the chromosome directly, our side-by-side comparisons showed almost equal efficiencies between transient and chromosomal targets. It's much easier and faster than working with patient-derived cells. I can definitely send you the plasmid, which would save you a lot of time and effort. This method is much simpler and could be a practical solution for your project." a="Our initial plan is to work with a reporter plasmid that expresses eGFP, where we've removed a splice site, until we have patient cells or cell lines with CFTR mutations. This will allow us to screen easily without needing to sequence everything. Do you maybe have any suggestions or advice on this approach?" />
+ <QaBox q="Is that the PEAR system?" a="No, it’s a different one, but we also have a similar system. The advantage of this approach is that you can very easily see if it works, and it’s very sensitive—much easier than extracting and sequencing DNA. The downside, however, is that… actually, I’m not familiar with the 'flu PEAR system.'" />
+ <QaBox q="Actually, we use the exact same system in our lab. It’s very useful for optimizing delivery strategies because it’s easy to see results. The downside, of course, is that the guides you’re using for that system aren’t specific to the F508 delta mutation, right? So, these are scientific trade-offs. You could, for example, design a reporter that uses your F508 delta guide and also results in fluorescence, but you would need to design the reporter first. It’s challenging to prove that it works because you might not have a perfect guide for F508 delta." a="It really depends on what you want to achieve. If your goal is to first check if you can successfully perform prime editing, then using the reporter is definitely a good first step." />
+ <QaBox q="We will edit the plasmid, specifically the vector, so that we have almost the same pegRNA. The only difference will be downstream, behind the edit." a="Is this approach based on a paper from the Netherlands, or is it something you came up with yourself?" />
+ <QaBox q="Based on a paper." a="Yeah, that sounds like a very good way to start. Do you already have the reporter plasmid ready?" />
+ <QaBox q="Yeah, we bought the reporter, and now we’re making the necessary edits so we can use it." a="Okay, so do you also already have guides targeting F508 right now?" />
+ <QaBox q="We’ve designed some guides, but we haven’t tested them yet. That’s one of our next steps. So, at the moment, we’re just in the design phase, or we have already designed them, and..." a="Yeah, okay, cool. Good luck with that! And I suppose you’re starting off with HEK cells as well, right?" />
+ <QaBox q="We have HEK and HeLa cells, but we haven't decided yet which ones we'll use." a="I would start off in HEK cells because, by total accident or coincidence, they are much easier to achieve prime editing in. This is because the MLH1 gene, which negatively impacts prime editing outcomes, is naturally disabled in these cells—they don't produce the MLH1 protein. Of all cell lines available, HEK cells are the easiest to achieve editing with, so I would definitely recommend starting there." />
+ <QaBox q="In terms of transfection, HEK cells are also very easily transfected. If I can offer another piece of advice, always include GFP controls—plasmids that simply express GFP without requiring editing—and use them to determine your transfection efficiency. It's crucial to have a very high transfection efficiency because you'll be working with a three-component system: your reporter, your prime editor, and your guides. All three plasmids need to be present in the same cell for the editing to occur, so you should aim for at least 70% transfection efficiency, preferably 80% or higher." a="I don't know what transfection method you're planning to use, but we've always used Lipofectamine 3000. It’s expensive, but it works very well. However, if you're looking for more cost-effective options, we recently discovered two other transfection reagents, Jet Optimus and Jet Prime, which are much cheaper and also work quite well. That said, I would advise against starting with any of the cheaper transfection reagents; you really need to aim for high transfection efficiency." />
+ <QaBox q="Always make sure to measure and report transfection efficiency for every experiment because if it's low, the experiment might not yield useful results. If you have the funds or resources, I would also recommend designing P3 or even P3b guides, as they might offer better efficiency." a="When it comes to designing P3b guides, if you're primarily focused on P2 right now, there are some specific considerations to keep in mind. I'll provide you with a site that can help with this, and I'll give you the link in just a moment." />
+ <QaBox q="So, it's very advisable to check the Doench score. Do you know what it is?" a="No, not really." />
+ <QaBox q="There are papers by John Doench, an American researcher, from quite a while ago that, in my opinion, are some of the best around. He developed a comprehensive scoring matrix specifically for regular Cas9 that can evaluate the quality of the spacer in your guide RNA. This is important because Cas9 tends to prefer certain sequences over others. For instance, a good spacer should have an appropriate GC content and should avoid hairpins that might cause it to fold in on itself, which would prevent it from functioning properly. You can use this matrix to give a score for the quality of a guide RNA. I’m going to pull up an example here. The site from Synthego, a commercial provider of CRISPR reagents, allows you to check the quality of your guide. When you validate it, the site gives a score based on various factors, including off-target effects, although that might not be your primary concern at the moment. If you hover over a specific area, it will show you the Doench Score, which is crucial. Ideally, you want a guide with a good Doench Score. A good score starts at around 0.4, indicated by a green check mark for good efficiency. If the score is very low, it means that the guide likely has low CRISPR-Cas9 activity and may not be very efficient. When designing prime editing guides, RNA, we always check the spacer for a good Doench Score. If we are designing nicking guides for a PE3 or PE3b strategy, we also ensure that they have a good score. This is one of the easiest tools to check for that. Whenever possible, try using PE3. In some cases, PE3 performs better than PE2, though not always. PE3b might not always work either, but for many mutations, we have seen significant increases in editing efficiency by including the PE3 guide." a="Okay, yeah, that was quite clear from your results; the diagram illustrated that very well."/>
+ <QaBox q="Are there more off-target effects when using PE3 since you have to make another cut?" a="If you decide to use PE3, it's important to be aware that while it's not exactly an off-target issue, there is a risk of an undesired on-target outcome. The concern with regular PE3 is that both strands of DNA can be nicked simultaneously, which can lead to a staggered double-strand break. This can result in the formation of indels (insertions or deletions). In your case, this means that if the region around the F508 delta mutation is broken, the prime editor might not be able to repair it properly, leading to additional base pairs being removed or added, and thus, the sequence might be altered in an unintended way. The risk of on-target indels is definitely higher with PE3 compared to PE2. However, this risk is reduced when using PE3b, which employs sequential nicking. The PE3b nicking guides are designed to recognize the wild-type sequence, and they can only nick the opposite strand if the correction has already been made on the top strand. This sequential action helps to avoid the generation of indels. Introducing a second guide into the system also brings the possibility of off-target editing by that guide however, since only a Cas9 nickase is used, off-target indels should be limited."/>
+ <QaBox q="Yes, okay, thank you. Do you have time left, or are we out of time?" a="It's fine."/>
+ <QaBox q="We have more or less one last question. If it’s not possible, that’s completely fine. We just wanted to ask if you could possibly forward the contact details for the Ussing chamber setup in Paris that you mentioned in your email. Would that be possible?" a="You can certainly try to contact them, but I actually know that there are quite good labs in Germany that work on similar things."/>
+ <QaBox q="One major drawback for you might be the time it takes to differentiate cells. If you harvest stem cells or basal cells from patients, they will have the CFTR gene, but they don’t express it immediately. It takes about four weeks for them to differentiate and start producing the CFTR protein. Without this differentiation, you can't measure the currents, which could slow you down significantly. I'm not sure if you have that kind of time." a="If I can give you one piece of advice: it’s less physiological, but it’s still an accepted assay—try it on organoids. We could actually perform both assays here. If you find guides that work really well, we could consider doing those tests here. Someone could come over, or we could do the experiments if they’re not too expensive and have a good chance of working. I think we wouldn’t mind adding the F508 delta mutation to our list of editable mutations."/>
+ <QaBox q="There’s also the possibility that if the paper from the Liu Lab is published within the next month, you could just use the guide they provide, and you’d have a guide that is known to work." a="Yeah, so I think if our guides don’t work as well as we hope, this could be an opportunity. We still want to explore optimization of the prime editing system, such as trying different reverse transcriptases or other methods. For now, we’d like to try it on our own, but like you said, it’s good to have this opportunity in case it doesn’t work out."/>
+ <QaBox q="Yeah, I think working with patient cells is one thing, but just be aware that these models and assays typically take a lot of time—easily half a year, and that’s considered fast to get them up and running. Unless you're in a lab that already has experience with growing organoids, it could be very challenging to start from scratch." a="However, you can always try. The team in Paris that we know very well—they are incredibly kind, world-class experts in what they do, but they are also under a lot of pressure. They use these technologies not only for research but also to diagnose patients. What the French team has managed to do is show that if a patient’s cells respond to certain drugs, the government allows those drugs to be administered to the patient. You can imagine how important these experiments are, as they can directly impact patients' lives, which naturally takes the highest priority."/>
+ <QaBox q="Yeah, we recognized that too. We talked with the CF team at the University Clinic in Münster and asked about using their Ussing chamber, but they are really overworked with it. That’s why we reached out to you about it. But it’s completely fine, as we mentioned before." a="I'm going to put it bluntly: Ussing chamber experiments, while they are highly regarded and provide valuable data, are a real pain to perform. They are incredibly time-consuming and have a very low throughput. A typical setup has four chambers, so you always need to do repeats. In the best-case scenario, you can test two conditions at a time. If you have a very experienced person, they might be able to run eight samples, but they would have to stay with the machine for four to five hours, maintaining constant attention. With multiple technicians, as is the case in France, you might manage to run 16 samples a day."/>
+ <QaBox q="On top of that, the cells need to be differentiated properly, and you have to know how to handle them correctly. The medium required is very expensive, and working with these cells is almost more of an art than a science. You have to know when the cells look 'happy' or not because you don't want to waste time on cells that aren't in good condition. I've run quite a few of these assays myself, and while they are great for CF work and provide results that are relevant to patient outcomes, they are technically challenging and very demanding." a="If you want a functional output to show that the CFTR protein is working again, I would recommend starting with one of the easier models, like organoids. We also have in our lab 16HBE cells with a YFP sensor. I don't know if you've heard or read about that. These cells express YFP, which is sensitive to halide ions, including chloride and iodide. When you add a buffer containing these ions to the cells, the YFP intensity quenches. This is something we typically use in our experiments."/>
+ <QaBox q="For wild-type cells, you see a rapid and dramatic quenching because CFTR allows these ions to enter the cells. In cells with the mutation, there’s no quenching because the channel isn’t working. While it’s less relevant because these aren't patient cells, it’s closer to reality. The 16HBE cell line is an airway epithelial line, and the expression of CFTR is endogenous, so it’s not at the exaggerated levels you might see in more artificial models like HEK cells." a="Using the YFP assay could be a good alternative or a Plan B for getting a functional readout. This assay is medium to high throughput—you can run entire 96-well plates in about half an hour. All you need for this is the cells and a plate reader that can measure fluorescence and inject the buffer. If you don’t have a plate reader with an injection system, you can also manually add the buffer and quickly place the plate in the machine."/>
+ <QaBox q="Yes, that sounds quite good. I think we’ll definitely consider that as a method." a="If you have a little more time, I wanted to ask about the pegRNA. You stabilized it with a stem loop or some kind of motif in the paper, like the trevopreQ1. Did you test other motifs as well, or...?"/>
+ </>,
+ references: [<ol>{/*<!-- Citation num 1--> */}
+ <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Bulcaen, M.</span>;
+ <span property="schema:Name"> Kortleven, P.</span>;
+ <span property="schema:Name"> Liu, R.</span>;
+ <span property="schema:Name"> Maule, G.</span>;
+ <span property="schema:Name"> Dreano, E.</span>;
+ <span property="schema:Name"> Aubert, M.</span>;
+ <span property="schema:Name"> Ensinck, M.</span>;
+ <span property="schema:Name"> Thierie, S.</span>;
+ <span property="schema:Name"> Smits, M.</span>;
+ <span property="schema:Name"> Ciciani, M.</span>;
+ <span property="schema:Name"> Hatton, A.</span>;
+ <span property="schema:Name"> Chevalier, B.</span>;
+ <span property="schema:Name"> Ramalho, A.</span>;
+ <span property="schema:Name"> Casadevall i Solvas, X.</span>;
+ <span property="schema:Name"> Debyser, Z.</span>;
+ <span property="schema:Name"> Vermeulen, F.</span>;
+ <span property="schema:Name"> Gijsbers, R.</span>;
+ <span property="schema:Name"> Sermet-Gaudelus, I.</span>;
+ <span property="schema:Name"> Cereseto, A.</span>;
+ <span property="schema:Name"> Carlon, M.</span>
+ </span>
+ <span property="schema:name"> Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cells. </span>
+ <i property="schema:publisher" typeof="schema:Organization"> Cell Reports Medicine</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 5</b>,
+ <span property="schema:pageBegin">101544</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2024">2024</time>).
+ <a className="doi" href="https://doi.org/10.1016/j.xcrm.2024.101544"> doi: 10.1016/j.xcrm.2024.101544</a>
+ </li>
+
+ </ol>]
},
- {
+ {
vorname: "Nicole",
nachnname: "Friedlein",
job: "Research group on fundamental rights",
@@ -445,43 +513,87 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
cardtext: "",
language: "de",
quote: "",
- aimofcontact: "",
-
- insights: "",
- implementation: "",
+ aimofcontact: "The main objective of the contact was to learn from the discussion on issues related to cystic fibrosis (CF), gene therapy, health insurance processes and regulatory pathways. In particular, we wanted to understand the real-world challenges and technical aspects of gene editing, especially prime editing, as well as the complexities of approval and reimbursement of gene therapies for CF patients.",
+ insights: "The regulatory approval process, particularly by the European Medicines Agency (EMA) for advanced medical devices, has highlighted the bureaucratic hurdles that gene therapies must overcome. We learned that such therapies for cystic fibrosis have to navigate complex European and German regulatory systems. The discussion on the AMNOG process was crucial. We learnt that the additional benefit of a therapy is assessed for reimbursement by the statutory health insurance funds. We implemented this insight in our project by considering the long-term regulatory and economic effects as important milestones for therapy development. We also gained insight into how public and private health insurers may differ in their reimbursement of such therapies. Public insurers have stricter guidelines, while private insurers can be more flexible, but both require strict justification, especially for rare diseases such as cystic fibrosis. Information on newborn screening and genetic counselling covered by public health insurance was crucial to understanding how preventive measures for CF are managed. This underlines the importance of early intervention and diagnosis in our project. Atypical forms of CF, where health insurance companies do not cover treatment due to non-standardised test results, were identified as a key problem. This helped us to recognise the need for more adaptable insurance policies and clearer pathways for the treatment of atypical cases in our project plans. The debate about whether healthcare systems can afford the high costs of gene therapies highlighted an important issue in the current medical landscape. We have incorporated this insight into our project by discussing possible cost-effective alternatives and the need for thorough cost-benefit analysis in the development of treatments.",
+ implementation: "After the interview, we further tailored our project to focus on a simple delivery method. To gain an overview of the regulatory requirements and to better deliver the project, one of our team members attended a GxP course to ensure we met all the necessary standards. To deepen our knowledge of entrepreneurship, we conducted further interviews with start-ups and industrial companies, which gave us important insights into practical implementation. These steps ensure that our project is not only based on scientific research, but also takes into account the practical, regulatory and social aspects that are crucial to bringing new CF therapies to the market. We are currently developing strategies to successfully implement our ideas and the project in the future.",
},
{
vorname: "Katrin",
nachnname: "Westhoff",
job: "physiotherapist",
- affiliation: "",
+ affiliation: "Independent",
pictureurl: pics['westhoff'],
tag: "Medical Professional",
heading: "In-Depth Visit to Specialized Physiotherapist for CF Breathing Therapy",
interviewtabid: "westhoffvisit",
cardtext: "",
language: "de",
- quote: "",
- aimofcontact: "",
+ quote: "Children are the world's best “mucus hidersâ€.",
+ aimofcontact: "In the interview with Katrin Westhoff [Link], she invited us to join a few physiotherapy sessions – not just as spectators but as participants. We gladly accepted and visited her in her practice. Over a few hours, we took part in four sessions with different children – not all of them CF patients. ",
+ insights: "During the sessions, we could ask Katrin as well as the respective parents and children questions. We learned that breathing therapy is also useful for other illnesses and that you can easily do some of the exercises yourself. Despite having cystic fibrosis, the children were better at the breathing exercises than we and Katrin were! The sessions take 30 to 60 minutes and include both manual therapy and playful elements to help engage the children. Most older children range from mildly unhappy to enthusiastic, but babies often cry during the treatments as it feels uncomfortable. This is often hard on the parents even though the treatment brings good results. A lot of children tend to hide that they have mucus sitting in their lungs by suppressing coughs. Especially with young children, it is important to stay on top of it and do regular breathing therapy even if it seems like it is currently not necessary. We also learned about the various informational material aimed at children to help explain therapies and symptoms to them and what accessories for breathing therapy there are. For example, a flutter is to train breathing out forcefully by breathing against a small weight and a binder can be worn at night to promote deep breathing. ",
+ implementation: "The most important thing was that both Katrin and the parents agreed that the children were able to inhale at an early age and that there were generally no physical problems with inhalation in general. This reinforced our decision to work towards delivery by inhalation. It was very interesting to see the different ways children deal with their exercises and hear about the progress they made. ",
+ text: [<ol>
+ <li>
+ <strong>Robin (>10)</strong>
+ <p>Robin will soon start 4th grade and takes modulators. Since taking them, many problems have subsided. No regular pneumonia with long hospital stays and the mucus comes out easier. Nevertheless, Robin still goes to physiotherapy regularly to do manual breathing therapy to get the mucus out. Katrin tells us how the mucus changes color the longer it stays in the lungs. The new mucus is white, and the older mucus gets yellow first and then gets darker with time until it reaches a black color. Nowadays, Robin rarely has dark mucus or clumps, but we can still hear the rustling as Katrin starts the autogenous drainage (Autogene Drainage) by pressing on Robin's chest. The goal is to get out the mucus deep in the lungs. To do that, Robin must repeat the routine – breathing in deeply, holding, breathing out – multiple times and then cough and spit the mucus out. Sometimes it works, but other times the mucus does not come out easily. While according to Katrin the autogenous drainage is the gold standard, they do other useful exercises, too. For example, pressing the Vojta points (which the children call “the magic pointsâ€) on the chest to activate a deep breathing reflex and get air into parts of the lungs that may not have been used previously. Or physical activity such as climbing a few steps on a climbing ladder and hanging on it to stretch the thorax muscles.</p>
+ </li>
+ <li>
+ <strong>Sam (<10) & Alex (<10)</strong>
+ <p>Sam and Alex are siblings and do not have CF but another affliction that causes a persistent cough. They come together with a parent twice a week and do hanging exercises from the ceiling, nasal showers with needleless syringes, and the “magic points.†Katrin also checks their lungs for mucus in a similar manner to autogenous drainage. We, too, tried to do the nasal shower, and being a grown-up really does not guarantee being able to do that properly! This highlighted that the children know all their exercises by heart at a young age. On request, their parent told us that the physiotherapy made a big difference for both of them.</p>
+ </li>
+ <li>
+ <strong>Toni (<5)</strong>
+ <p>Toni has a light version of CF and has been doing physiotherapy with Katrin since shortly after birth. In contrast to most children we met or talked about, Toni refuses medication. Modulators are a possibility, but them and 'everything stinky' is a no-go, even though inhaling would be very beneficial due to the mucus buildup. Most exercises result in crying and screaming, which is very exhausting for the child. Due to the light nature of Toni's variant, they are not in danger, but a permanent therapy would be very beneficial.</p>
+ </li>
+ <li>
+ <strong>Chrissi (>10)</strong>
+ <p>Chrissi takes modulators and will soon take a trip to a water park with some friends. Katrin teaches us that when the children do not breathe out properly, air stays in the lungs and causes hyperinflation – with which it is actually harder to float in water! After the manual drainage, Katrin gets all of us glasses with water and dish soap and straws. Blowing bubbles is a playful way to train how to properly breathe out by either trying to blow bubbles as long as possible or trying to make an existing bubble as big as possible!</p>
+ </li>
+ </ol>,]
- insights: "",
- implementation: "",
},
{
- vorname: "Jukia",
+ vorname: "Julia",
nachnname: "XXX",
job: "parent",
- affiliation: "",
+ affiliation: "independent",
pictureurl: pics['julia'],
tag: "Patient",
heading: "Interview with a CF Parent About Their Experience and Treatment Needs",
interviewtabid: "julia",
cardtext: "",
language: "de",
- quote: "",
- aimofcontact: "",
- insights: "",
- implementation: "",
+ quote: "At first, our world fell apart. I still remember the conversation with the doctor. ",
+ aimofcontact: [ <p>We learned from our discussion with Max [Link Max] that cystic fibrosis (CF) has a profound impact on the whole family – not just the patient. In order to gain further insight into this subject, we sought to engage with the next of kin of CF patients.
+ We were able to make contact with Julia through the self-help group of Mukviszidose e.V. [Link https://www.muko.info/ ], of which Max is a member. She subsequently reached out to us following Max's request for potential candidates for an interview with a patient group.
+ She and her husband have a six-year-old daughter carrying the F508del mutation in the CFTR gene and a toddler without CF. </p>],
+ insights: [<p> The interview with Julia shifted our focus to a new group of stakeholders: The patient’s support systems. Most people do not get genetically tested before having children and due to that, many people could get in the position of having a loved one with CF.
+ We considered the societal impacts, such as the rising health care costs, which Nicole Friedlein emphasized during our interview. She explained how the long-term nature of treatment, frequent hospital visits, and the need for specialized medications place a significant
+ financial burden on both patients and the health care system. This insight shaped our understanding of the broader economic challenges faced by families and institutions involved in managing chronic illnesses. Meanwhile, Julia brought attention to the psychological impact,
+ stressing the emotional strain that accompanies not only the illness itself but also the financial pressures. She also showed us more perspectives on parenting of children with CF, than we heard before, and told us about the way from the first diagnosis to growing accustomed
+ to and living with a child with CF. Julia also confirmed that most children will have no issue using an inhalative therapy like we envision our gene therapy to be and shone light onto the comparatively very good situation for CF patients in Germany. </p>],
+ implementation: [<p> This interview helped us confirm the delivery method we planned to use as we were previously concerned how and if children would be able to use the inhalative therapy. Besides that, Julia gave us further insights into the emotional side of
+ dealing with CF and we were able to discuss the situation for patients in Germany in comparison to other countries better in later interviews [Link Joshua]. </p>],
+ interview: <>
+ <QaBox q="Can you tell us a bit about your family? How old are your children and yourselves?" a="I’m 37, my husband is 44, and our daughter is six, turning seven soon. We also have a son who’s about a year and a half." />
+ <QaBox q="Does your son also have cystic fibrosis?" a="No, he doesn’t." />
+ <QaBox q="When was your daughter diagnosed with cystic fibrosis?" a="Right after birth. She was transferred to a bigger hospital due to an intestinal blockage and had surgery. After about two to three weeks in intensive care, the cystic fibrosis diagnosis came through newborn screening. At that time, the results took longer to process than they do now." />
+ <QaBox q="That intestinal issue can happen for many reasons, right?" a="Yes, it was all new to us. The beginning was difficult, but things have gotten better since then, and we’re very grateful." />
+ <QaBox q="How did you feel when you first heard the diagnosis?" a="It felt like our world was falling apart. I still remember the moment—it was like being in a movie. We were told in a separate room, and it felt overwhelming. One doctor even suggested we go home to think about it in peace, but all I could think about was returning to my child. It was a lot to take in, especially thinking about how we’d tell our family." />
+ <QaBox q="That sounds incredibly hard. How did you handle it as time passed?" a="It was tough, but we were fortunate to have a doctor who really understood what we were going through, as he had a disabled child himself. He never scared us unnecessarily and guided us step by step, which made a big difference. We know many families who live in constant fear, but since those first months, we’ve learned to manage the situation without being overwhelmed by fear." />
+ <QaBox q="Did any particular support help your family adjust to the diagnosis?" a="Yes, the rehab program we attended was a huge help. It was a family-oriented program, so my husband could be there too, which was important since I manage most things day-to-day. It really helped our daughter realize she’s not alone—she met other kids with similar conditions, which was a huge comfort." />
+ <QaBox q="How did you explain the illness to your daughter?" a="We try to give it as little attention as possible in daily life. She’s been inhaling medication since she was eight weeks old, and it’s just part of her routine now. Thankfully, she doesn’t fight it or question it much, and her school and kindergarten haven’t made a big deal of it either, which is what we wanted." />
+ <QaBox q="Does she ever ask about her illness compared to her younger brother, who doesn’t have cystic fibrosis?" a="She does sometimes ask why she’s sick and he’s not, but she’s not upset by it. We’ve made sure not to give her any special treatment because of her illness, which can be hard at times, but we want her to understand that her illness doesn’t define her." />
+ <QaBox q="That sounds like a good balance. What about medications—did she start on any special treatments?" a="Yes, she started on Orkambi at around three years old but had to stop briefly due to high liver values. Now she’s on Kaftrio, which she started shortly before her sixth birthday, and it’s been going well." />
+ <QaBox q="Did you face any issues with the health insurance for covering these medications?" a="Fortunately, no. We have statutory health insurance, and they’ve covered everything without any issues. We’ve heard it can be more complicated for those with private insurance." />
+ <QaBox q="Have you ever had difficulties with access to medication?" a="Yes, there have been times when we’ve had to wait a few days for certain medications, like Kreon or antibiotics, especially in the winter. But we always plan ahead and keep a buffer, so we’ve never been without what we need." />
+ <QaBox q="What would you say has been the most affected area for your daughter?" a="Her intestines are the most affected. Before she started Kaftrio, she had fatty stools and frequent bowel movements, even with the right Kreon dosage. Since starting Kaftrio, this has improved significantly." />
+ <QaBox q="What kind of support would you have liked to receive earlier?" a="We wish we had been given more information about available services early on. We found out about Mukoviszidose e.V. from another family, not from our doctor. It would have been helpful to know about these resources right from the start." />
+ <QaBox q="How about psychosocial support?" a="Initially, we didn’t have any psychological support—our doctor took care of everything. Now, where we live, there are more resources, and we think it’s a good thing. The rehab helped a lot in coming to terms with everything. We wish we had known about such services sooner." />
+ <QaBox q="Does your daughter do physiotherapy?" a="Yes, once a week for about an hour. She’s been going since she was discharged from the hospital, and she has a close bond with her physiotherapist. They’ve been working together since she was a baby, and she goes by herself now." />
+ <QaBox q="Are there any restrictions for her in terms of physical activities?" a="No, not really. She does dancing once a week, physiotherapy, and she’s even done a swimming course without any problems." />
+ <QaBox q="How do you handle communicating about her illness?" a="We try not to make a big deal of it. When I looked for information, I found what we needed. There’s nothing we’ve really felt was missing." />
+ </>
},
{
vorname: "Joshua",
@@ -494,11 +606,135 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
interviewtabid: "joshua",
cardtext: "",
language: "en",
- quote: "",
- aimofcontact: "",
- insights: "",
- implementation: "",
- pictureurl_interview: ""
+ quote: "We’ve had to sit by and watch people die, knowing that better treatment exists but is inaccessible. ",
+ aimofcontact: [<p>We contacted the organization <a href="https://www.cfvww.org/">CF vests worldwide</a> with the aim to hear more diverse perspectives beyond Germany.
+ After the founder Rod connected us with Joshua, Joshua was so kind to conduct an interview with us not only about the perspectives and
+ stories he heard but also about his personal experiences with his daughter and living in a country where CF care is very hard to get. Joshua
+ (from the USA) and his family live in Thailand where he and his wife run a children’s home. Their daughter is the only child with CF.</p>,
+ <p>It is possible to learn more about Joshua and his family though the <a href="https://thebonnellfoundation.org/cf-vests-worldwide/">
+ podcast of the Bonnel foundation</a>.</p>],
+ insights: [<p> Joshua showed us just how dire the situation is for CF patients is in some regions. It was shocking to hear there is only one doctor
+ knowledgeable about CF in Thailand and that many doctors dismiss the possibility of CF due to racial bias and misinformation. Additionally, we confirmed how much the accessibility
+ of care depends on the healthcare system, as we already touched on during the interview with Nicole Friedlein [link]. On the parenting level, Joshua brought in many perspectives contrary to what we previously heard. In the interview with Max [Link], we learned he vehemently avoids ponding water while Joshua’s daughter is allowed to roam around with no such restrictions. Neither have chronic infections.</p>],
+ implementation: [<p>The interview with Josh made us realize we too needed to look at the reason why we chose F508del. Did we, too, fall for bias?
+ Despite a change of target not being feasible anymore, we looked into it and traced back our steps that led to our decision. We did not find as much
+ information about other mutations when first researching cystic fibrosis, especially in the context of prime editing. Mattijs Bulceans's paper on
+ targeting the mutations L227R and N1303K <TabScrollLink tab="joshua" scrollId="desc-1" num="1" /> was one of few papers. After explicitly searching for cystic fibrosis records for specific countries and
+ regions, we uncovered a moderate number of papers examining CF in Asia and other regions we previously did not know much about. The very first article
+ supported Joshua's hypotheses and painted a sad picture: Among other things, it describes the case of a four-month-old boy who was diagnosed with cystic
+ fibrosis. Nothing unusual in itself, but the circumstances are depressing. Two of the three siblings born before him died within months of birth and had
+ previously presented with symptoms of cystic fibrosis. He was the first to be diagnosed. A sweat test aimed at cystic fibrosis was not available at the
+ hospital, so one was improvised. Later on, a genetic test revealed the presence of 508del. <TabScrollLink tab="joshua" scrollId="desc-2" num="2" /> We found ourselves and our lack of knowledge in good
+ company as we found papers as new as from 2020 (14 years after the previously mentioned paper) containing statements such as “recent reports suggest
+ that CF does occur in Asia†<TabScrollLink tab="joshua" scrollId="desc-3" num="3" />. Fortunately, there is a rising number of cystic fibrosis experts for Asia and other previously overlooked regions
+ such as Africa. <TabScrollLink tab="joshua" scrollId="desc-4" num="4" /> We chose to not only look at the scientific data but also into anecdotal evidence. To find the latter, we searched official
+ and private websites and chatrooms for information and experiences of patients. In the end, we found narratives from most ethnic backgrounds
+ about being dismissed and often misdiagnosed. Of course, this is not an occurrence unique to cystic fibrosis. Our conclusion is that yes,
+ we did fall for bias. But regardless of ethnicity, 508del occurs and is overall the most prevalent mutation as was confirmed in our interview
+ with CF expert Sriram .... This experience was uncomfortable as we felt the pressure to be thorough and deliver a perfect project. What would
+ have been more devastating than realizing we made a wrong choice at the very core? We made the conscious decision to invest our resources into
+ figuring out if we indeed made a mistake and we want to encourage other teams to do the same. iGem stands for innovation – but also for growth.
+ Especially in the context of Integrated Human Practices, it is important to examine both the positive and the negative to create a project with a
+ future. </p>],
+ pictureurl_interview: "",
+ references: [<ol>{/*<!-- Citation num 1--> */}
+ <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Bulcaen, M.</span>;
+ <span property="schema:Name"> Kortleven, P.</span>;
+ <span property="schema:Name"> Liu, R.B.</span>;
+ <span property="schema:Name"> Maule, G.</span>;
+ <span property="schema:Name"> Dreano, E.</span>;
+ <span property="schema:Name"> Kelly, M.</span>;
+ <span property="schema:Name"> Ensinck, M.M.</span>;
+ <span property="schema:Name"> Thierie, S.</span>;
+ <span property="schema:Name"> Smits, M.</span>;
+ <span property="schema:Name"> Ciciani, M.</span>;
+ <span property="schema:Name"> Hatton, A.</span>;
+ <span property="schema:Name"> Chevalier, B.</span>;
+ <span property="schema:Name"> Ramalho, A.S.</span>;
+ <span property="schema:Name"> Solvas, X.</span>;
+ <span property="schema:Name"> Debyser, Z.</span>;
+ <span property="schema:Name"> Vermeulen, F.</span>;
+ <span property="schema:Name"> Gijsbers, R.</span>;
+ <span property="schema:Name"> Sermet-Gaudelus, I.</span>;
+ <span property="schema:Name"> Cereseto, A.</span>;
+ <span property="schema:Name"> Carlon, M.S.</span>
+ </span>
+ <span property="schema:name"> Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cells. </span>
+ <i property="schema:publisher" typeof="schema:Organization"> Cell Reports Medicine</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 5</b>,
+ <span property="schema:pageBegin">101544</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2024">2024</time>).
+ <a className="doi" href="https://doi.org/https://doi.org/10.1016/j.xcrm.2024.101544"> doi: https://doi.org/10.1016/j.xcrm.2024.101544</a>
+ </li>
+
+ {/*<!-- Citation num 2--> */}
+ <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-2">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Teeratakulpisarn, J.</span>;
+ <span property="schema:Name"> Kosuwon, P.</span>;
+ <span property="schema:Name"> Srinakarin, J.</span>;
+ <span property="schema:Name"> Panthongviriyakul, C.</span>;
+ <span property="schema:Name"> Sutra, S.</span>
+ </span>
+ <span property="schema:name"> Cystic fibrosis in three northeast Thai infants is CF really a rare disease in the Thai population?. </span>
+ <i property="schema:publisher" typeof="schema:Organization"> Journal of the Medical Association of Thailand = Chotmaihet thangphaet</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 89</b>,
+ <span property="schema:pageBegin"> 1756</span>-<span property="schema:pageEnd">61</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2006">2006</time>).
+ </li>
+
+ {/*<!-- Citation num 3--> */}
+ <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-3">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Ahmed, S.</span>;
+ <span property="schema:Name"> Cheok, G.</span>;
+ <span property="schema:Name"> Goh, A.</span>;
+ <span property="schema:Name"> Han, A.</span>;
+ <span property="schema:Name"> Hong, S.</span>;
+ <span property="schema:Name"> Indawati, W.</span>;
+ <span property="schema:Name"> Kabir, A.</span>;
+ <span property="schema:Name"> Kabra, S.</span>;
+ <span property="schema:Name"> Kamalaporn, H.</span>;
+ <span property="schema:Name"> Kim, H.</span>;
+ <span property="schema:Name"> Kunling, S.</span>;
+ <span property="schema:Name"> Lochindarat, S.</span>;
+ <span property="schema:Name"> Moslehi, M.</span>;
+ <span property="schema:Name"> Nathan, A.</span>;
+ <span property="schema:Name"> Ng, D.</span>;
+ <span property="schema:Name"> Phung, N.</span>;
+ <span property="schema:Name"> Singh, V.</span>;
+ <span property="schema:Name"> Takase, M.</span>;
+ <span property="schema:Name"> Triasih, R.</span>;
+ <span property="schema:Name"> Dai, Z.</span>
+ </span>
+ <span property="schema:name"> Cystic fibrosis in asia. </span>
+ <i property="schema:publisher" typeof="schema:Organization"> Pediatric Respirology and Critical Care Medicine</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 4</b>,
+ <span property="schema:pageBegin">8</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2020">2020</time>).
+ <a className="doi" href="https://doi.org/10.4103/prcm.prcm_5_20"> doi: 10.4103/prcm.prcm_5_20</a>
+ </li>
+
+ {/*<!-- Citation num 4--> */}
+ <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-4">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Bobbo, K.</span>;
+ <span property="schema:Name"> Ahmad, U.</span>;
+ <span property="schema:Name"> Chau, D.</span>;
+ <span property="schema:Name"> Nordin, N.</span>;
+ <span property="schema:Name"> Abdullah, S.</span>
+ </span>
+ <span property="schema:name"> A comprehensive review of Cystic Fibrosis in Africa and Asia. </span>
+ <i property="schema:publisher" typeof="schema:Organization"> Saudi Journal of Biological Sciences</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 30</b>,
+ <span property="schema:pageBegin">103685</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2023">2023</time>).
+ <a className="doi" href="https://doi.org/10.1016/j.sjbs.2023.103685"> doi: 10.1016/j.sjbs.2023.103685</a>
+ </li>
+
+ </ol>]
},
{
title: "Prof. Dr.",
@@ -506,7 +742,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
nachnname: "Wischmeyer",
job: "Research Group Cellular Neurophysiology",
affiliation: "Universität Bielefeld",
- pictureurl: pics['placeholder'],
+ pictureurl: pics['wischmeyer'],
tag: "Academia",
heading: "Discussion on Techniques for Measuring CFTR Channel Functionality",
interviewtabid: "patchclamp",
@@ -723,9 +959,9 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
this suggests a promising shelf-life for mRNA formulations under similar conditions. The spray drying process itself involves mixing an ethanol
phase containing lipids with an aqueous phase containing RNA. This mixture is then spray-dried, forming LNPs as tiny spherical particles.
Key parameters for this process include maintaining an internal drying temperature of around 100 °C and using excipients like lactose to
- preserve the nanoparticles' structure and function​ [1]. </p>,
+ preserve the nanoparticles' structure and function​ <TabScrollLink tab="rnhale" scrollId="desc-1" num="1" />. </p>,
<p>Ensuring the integrity and efficiency of the LNPs involves various methods, including gel electrophoresis, blotting, and functional readouts through transfection assays.
- After drying, the nanoparticles retain their spherical structure, which resembles that of "golf balls" under scanning electron microscopy (SEM)[1].
+ After drying, the nanoparticles retain their spherical structure, which resembles that of "golf balls" under scanning electron microscopy (SEM)<TabScrollLink tab="rnhale" scrollId="desc-1" num="1" />.
Moreover, RNhale employs artificial intelligence to optimize LNP formulations and predict the best drying conditions, reducing the need for
extensive wet lab work. This AI-driven approach enhances efficiency and reliability in developing therapeutic nanoparticles. </p>],
implementation: [
@@ -736,7 +972,32 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
pictureurl_aim: "https://static.igem.wiki/teams/5247/photos/hp/hp-rnhale-zoom.png",
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/for-wiki-texts/del-interview-rnhale/paper-overview.jpg",
pictureurl_implementation: "https://static.igem.wiki/teams/5247/photos/for-wiki-texts/del-interview-rnhale/paper-sem.jpg",
- references: [<div>noch einfügen</div>]
+ references: [<ol>{/*<!-- Citation num 1--> */}
+ <li typeof="schema:ScolarlyArticle" role="doc-biblioentry" property="schema:citation" id="desc-1">
+ <span property="schema:author" typeof="schema:Person">
+ <span property="schema:Name"> Zimmermann, C.M.</span>;
+ <span property="schema:Name"> Baldassi, D.</span>;
+ <span property="schema:Name"> Chan, K.</span>;
+ <span property="schema:Name"> Adams, N.B.</span>;
+ <span property="schema:Name"> Neumann, A.</span>;
+ <span property="schema:Name"> Porras-Gonzalez, D.L.</span>;
+ <span property="schema:Name"> Wei, X.</span>;
+ <span property="schema:Name"> Kneidinger, N.</span>;
+ <span property="schema:Name"> Stoleriu, M.G.</span>;
+ <span property="schema:Name"> Burgstaller, G.</span>;
+ <span property="schema:Name"> Witzigmann, D.</span>;
+ <span property="schema:Name"> Luciani, P.</span>;
+ <span property="schema:Name"> Merkel, O.M.</span>
+ </span>
+ <span property="schema:name"> Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery. </span>
+ <i property="schema:publisher" typeof="schema:Organization"> Journal of Controlled Release</i>
+ <b property="issueNumber" typeof="PublicationIssue"> 351</b>,
+ <span property="schema:pageBegin"> 137</span>-<span property="schema:pageEnd">150</span>
+ (<time property="schema:datePublished" datatype="xsd:gYear" dateTime=" 2022">2022</time>).
+ <a className="doi" href="https://doi.org/https://doi.org/10.1016/j.jconrel.2022.09.021"> doi: https://doi.org/10.1016/j.jconrel.2022.09.021</a>
+ </li>
+
+ </ol>]
},
{
title: "XXX",
@@ -760,7 +1021,7 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
job: "",
affiliation: "Corden Pharma",
pictureurl: pics['placeholder'],
- tag: "Academia",
+ tag: "Industry",
heading: "Corden",
interviewtabid: "corden",
cardtext: "",
diff --git a/src/data/parts.ts b/src/data/parts.ts
new file mode 100644
index 0000000000000000000000000000000000000000..464d9f13e0142f7f0baa0c93d67a5801377664a1
--- /dev/null
+++ b/src/data/parts.ts
@@ -0,0 +1,45 @@
+export interface Part{
+ partname: string,
+ registrycode: number,
+ description: string,
+ length: number,
+ type: PartType,
+ url: string
+}
+type PartType = "DNA" | "Protein";
+
+/*
+Vorlage:
+
+{
+ partname: "",
+ registrycode: ,
+ description: "",
+ length: ,
+ type: "",
+ url: ""
+ },
+
+*/
+
+export const BasicParts: Array<Part> = [
+ {
+ partname: "Beispiel",
+ registrycode: 0,
+ description: "Beispiel Description",
+ length: 0,
+ type: "DNA",
+ url: "....."
+ },
+]
+
+export const CompositeParts: Array<Part> = [
+ {
+ partname: "Beispiel",
+ registrycode: 0,
+ description: "Beispiel Description",
+ length: 0,
+ type: "DNA",
+ url: "....."
+ },
+]
\ No newline at end of file
diff --git a/src/data/symptom-data.tsx b/src/data/symptom-data.tsx
index cc46814c5485b0844ff35f09f686f6523c709830..5624a06c2d20626c0f29fc2e80697448a95f046e 100644
--- a/src/data/symptom-data.tsx
+++ b/src/data/symptom-data.tsx
@@ -2,134 +2,70 @@
export interface SymptomDatensatz {
name: string;
picture: string;
- introduction: string;
- subsections: Array<example>;
-
+ introduction: Array<string> | Array<React.ReactNode>;
}
-interface example{
- title: string,
- text: Array<string>;
-}
+//Bilder+Quellen müssen noch angepasst werden
+//da kommen jetzt folgende Organe: Pancreas, Intestines, Liver, Sexual glands, Lungs, Skeletal System, Skin, Nose, Brain/Mental Health
export const symptomdata: (Array<SymptomDatensatz>) = [
{
- name: "About",
- picture: "https://static.igem.wiki/teams/5247/scientific-figures/organs-together-normal.svg",
- introduction: "",
- subsections: [
- {
- title: "",
- text: ["string"]
- },
- {
- title: "",
- text: ["string"]
- },
- ]
+ name: "Pancreas",
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/pancreas.svg",
+ introduction: [<>Located behind the stomach in the back abdominal cavity [1]</>,<>Responsible for neutralizing stomach acid, production of hormones (like Insulin) and digestion enzymes [1]</>,<>Clogging caused by CF, so that products of the pancreatic gland can not be distributed [2]</>,<>Pancreatic insufficiency due to CF can lead to malnutrition [3], digestive problems and abdominal pain [4], CF-associated diabetes [5]</>,<>Treatment options include nutritional therapy and supplementation of pancreatic enzymes [6]</>]
+ },
+ {
+ name: "Intestines",
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/largeintestine.svg",
+ introduction: [<>Located in the abdominal cavity and extends from the stomach to the anus</>,<>Responsible for nutrient absorption, water reabsorption, and waste elimination [7]</>,<>CF can cause blocking of the intestines, preventing the normal movement of food and absorption of nutrients [8]</>,<>Intestinal blockage due to CF can lead to malabsorption of nutrients, and conditions like meconium ileus in newborns or distal intestinal obstruction syndrome (DIOS) in adults [8]</>,<>Treatment options include the use of laxatives, enzyme supplementation, feeding tubes, and in severe cases, surgical intervention or intestinal transplantation [8]</>]
},
{
- name: "Lung",
- picture: "https://static.igem.wiki/teams/5247/scientific-figures/lungs.svg",
- introduction: "",
- subsections: [
- {
- title: "",
- text: ["string"]
- },
- {
- title: "",
- text: ["string"]
- },
- ]
+ name: "Liver",
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/liver.svg",
+ introduction: [<>Located directly below the diaphragm near the pancreatic gland and stomach [9]</>,<>Responsible for detoxification, bile production for enhancement of digestion, protein synthesis for blood clotting and immune functions, nutrient processing and storage [9]</>,<>CF affects the normal secretion and function of bile- it becomes stickier [10]</>,<>Symptoms caused by CF include bruising, nose bleeds, Inflammation, more frequent chest infections, low body weight, liver cirrhosis, lethargy [10]</>,<>Treatment options include nutritional therapy, modulators, UDCA, liver transplantation [11]</>]
},
{
- name: "Pancreas",
- picture: "https://static.igem.wiki/teams/5247/scientific-figures/pancreas.svg",
- introduction: "",
- subsections: [
- {
- title: "",
- text: ["string"]
- },
- {
- title: "",
- text: ["string"]
- },
- ]
+ name: "Sexual glands",
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/glands.svg",
+ introduction: [<>Located in pelvic area [12]</>,<>Responsible for production of sperm (male)/ production of oocytes and as site for embryo development (female) [13]</>,<>CF causes thick mucus to block reproductive ducts (both), affects sperm transport (male) [14] and cervical mucus density (female) [15]</>,<>This can lead in context of CF to reduced fertility or even infertility [14][15]</>,<> <i> In vitro </i> fertilization can be an option for CF patients [16] </>]
},
{
- name: "liver",
- picture: "https://static.igem.wiki/teams/5247/scientific-figures/liver.svg",
- introduction: "",
- subsections: [
- {
- title: "",
- text: ["string"]
- },
- {
- title: "",
- text: ["string"]
- },
- ]
+ name: "Lungs",
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/lungs.svg",
+ introduction: [<>Located in the ribcage [17]</>,<>Responsible for breathing – aspiration of life-giving oxygen and deposition of carbondioxide [17]</>,<>CF causes the thickening of mucus on top of the respiratory epithelium, serving as nutrition ground as for pathogens and impairing the movement of cilia so that the mucus can not be cart away [18]</>,<>Symptoms caused by CF include shortness of breath, persistent cough [19], lung infections (mainly caused by <i> Pseudomonas aeruginosa </i>, <i> Staphylococcus aureus </i> and <i> Burkholderia cepacia </i>) [20], bronchiectasis [21] </>,<>Treatment options include respiratory physiotherapy (e.g. bronchiodilators), sports, inhalation, antibiotics against pathogens, lung transplantation [22]</>]
},
{
- name: "brain",
- picture: "https://static.igem.wiki/teams/5247/scientific-figures/brain.svg",
- introduction: "",
- subsections: [
- {
- title: "",
- text: ["string"]
- },
- {
- title: "",
- text: ["string"]
- },
- ]
+ name: "Skeletal System",
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/bones.svg",
+ introduction: [<>Located throughout the entire body</>,<>Responsible for structuration of the body, protection of organs, mineral storage, blood cell production [23]</>,<>CF affects the skeletal system by reducing bone mineral density [24]</>,<>This can lead in context of CF to osteoporosis, spinal fractures, kyphosis, scoliosis [24]</>,<>Treatment options include uptake of biophosphonates to increase bone density, vitamin D for maintenance of calcium levels needed for mineralization [24]</>]
},
{
- name: "Heart",
- picture: "https://static.igem.wiki/teams/5247/scientific-figures/heart.svg",
- introduction: "",
- subsections: [
- {
- title: "",
- text: ["string"]
- },
- {
- title: "",
- text: ["string"]
- },
- ]
+ name: "Skin",
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/skin.svg",
+ introduction: [<>Located on the surface of the entire body</>,<>Responsible for barrier function, immunological defense, regulation of homeostasis, sensory functions [25]</>,<>CF affects CFTR channels of sweat glands, which leads to salt deposits on the skin [26]</>,<>This can lead in context of CF to skin irritation (rash or dermatitis) [26]</>,<>Prevention via drinking a lot and a rather salty diet possible [27]</>]
},
{
- name: "guts",
- picture: "https://static.igem.wiki/teams/5247/scientific-figures/largeintestine.svg",
- introduction: "",
- subsections: [
- {
- title: "",
- text: ["string"]
- },
- {
- title: "",
- text: ["string"]
- },
- ]
+ name: "Nose",
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/nose.svg",
+ introduction: [<></>,<>Responsible for smell perception, breathing, filtration and cleaning, and serving as a resonance chamber for the voice [28]</>,<>CF affects thickness of nasal secretions, which cannot drain well [26]</>,<>This can lead in context of CF to nasal congestion, pressure headaches, sinusitis, inflammation of nasal polyps [26]</>,<>Therapy ranges from nasal sprays to surgical removal of nasal polyps [26]</>]
},
{
- name: "guts",
- picture: "https://static.igem.wiki/teams/5247/scientific-figures/pregnancy.svg",
- introduction: "",
- subsections: [
- {
- title: "",
- text: ["string"]
- },
- {
- title: "",
- text: ["string"]
- },
- ]
+ name: "Brain",
+ picture: "https://static.igem.wiki/teams/5247/scientific-figures/brain.svg",
+ introduction: [<>Located inside the skull</>,<>Responsible for cognitive functions, movement coordination, and control of vital functions [29]</>,<>CF affects mental health due to psychological stress and social isolation [30]</>,<>This can lead in context of CF to physical illnesses like depression and anxiety disorders [30]</>,<>Treatment options include psychotherapy, antidepressants, support groups and sports [31]</>]
}
+//
+// name: "guts",
+// picture: "https://static.igem.wiki/teams/5247/scientific-figures/pregnancy.svg",
+// introduction: "",
+// subsections: [
+// {
+// title: "",
+// text: ["string"]
+// },
+// {
+// title: "",
+// text: ["string"]
+// },
+// ]
+// }
]
\ No newline at end of file
diff --git a/src/sidebars/descS.tsx b/src/sidebars/descS.tsx
index 6b3ded063d67103d6de30c777084b757d627d056..01de44139f1a77af321b0726cf32dff917cbe55e 100644
--- a/src/sidebars/descS.tsx
+++ b/src/sidebars/descS.tsx
@@ -12,10 +12,9 @@ export function DescSidebar(){
const tabs = [
{ tab: "Abstract" },
- { tab: "Cystic Fibrosis", subtabs: ["Overview", "The CFTR Protein", "ΔF508", "Symptoms", "Diagnosis", "Treatment"]},
{tab: "Our Motivation"},
- {tab: "Approach"},
- {tab: "Delivery"},
+ { tab: "Cystic Fibrosis", subtabs: ["Overview", "The CFTR Protein", "ΔF508", "Symptoms", "Diagnosis", "Treatment"]},
+ {tab: "Approach", subtabs: ["Mechanism", "Delivery"]},
{tab: "Our Vision"},
{tab: "References"}
];
diff --git a/src/utils/openClass.ts b/src/utils/openClass.ts
new file mode 100644
index 0000000000000000000000000000000000000000..37060f09fc14a7e9aa3f5550d4fb5f3882c2dc93
--- /dev/null
+++ b/src/utils/openClass.ts
@@ -0,0 +1,16 @@
+export function openClasses({className, classtoHide}:{className: string, classtoHide: string}){
+ const showElementsByClass = (_event: React.MouseEvent<HTMLElement, MouseEvent>) => {
+ // Alle Elemente mit der angegebenen Klasse auswählen
+ const elements = document.getElementsByClassName(className);
+ const hide = document.getElementsByClassName(classtoHide);
+ for (let i = 0; i < hide.length; i++) {
+ hide[i].setAttribute('style', 'display: none;');
+ }
+ // Jedes Element durchgehen und den Display-Stil auf 'block' setzen
+ for (let i = 0; i < elements.length; i++) {
+ (elements[i] as HTMLElement).style.setProperty('display', 'block', 'important');
+ }
+
+ };
+ return showElementsByClass;
+}